Programme Book 05 – 08 June 2019

Glasgow · Scotland Scottish Event Campus (SEC)

www.espghancongress.org @ESPGHAN Society · #ESPGHAN19 ESPGHAN Annual Meeting

Table of Contents

ESPGHAN Annual Meeting Saturday, 08 June 2019 Make it YOUR meeting! 2 Programme Overview 64 Venue Map Scottish Event Campus (SEC) 4 Chronological Programme 66 Make it YOUR meeting! Welcome Letter 6 Congress APP – Q&A – Voting – Session Recording List of Invited Speakers, ESPGHAN Society Chairpersons and Tutors 72 Congress APP Congress Talks & Speakers ESPGHAN Council & Committees 8 Poster Exhibition • Venue information • Session recordings, eposters, Society Meetings 9 • Scientific programme speaker CV’s and abstracts ESPGHAN Annual General Meeting 10 Abstract Submission & Reviewing 76 • Abstracts • Annual Meetings 2016 – 2019 For Members Only 12 ePoster Presentations 78 • ePosters • Access through ESPGHAN Society & Membership 14 Posters selected for Poster Walk 88 • Faculty www.espghancongress.org Posters 96 • Sponsors and exhibitors • Create your own personal login Young ESPGHAN 16 • General information Awards & Grants 18 Abstract Reviewers 138 • Interactive modules: Q&A, voting, Session Recording networking • Available for all invited sessions* Scientific Programme Industry & General Information • Slides and audio available Education Partner Programme 144 Q&A Wednesday, 05 June 2019 • Online 2 hours after the end Congress Sponsors 146 • Join the discussions via the of the session Programme Overview 20 Endoscopy Learning Zone 148 Congress APP • Access via Congress Talks & Speakers Chronological Programme 22 • Submit your questions during Satellite Symposia 154 Young ESPGHAN Session 33 the session *Kindly note that the publication is based on Sponsors & Exhibitors List 164 • Chairs will choose interesting agreement of the speakers. Abstract sessions will not be recorded. Exhibition Plan 166 questions during discussion time Thursday, 06 June 2019 Exhibitor Directory Listing 169 Programme Overview 34 Voting Disclosure of Sponsorships 206 Chronological Programme 36 • Voting via the Congress APP • Participate in interactive sessions General Information 207 Friday, 07 June 2019 • Choose the session, start the voting Glasgow Map · Public Transport 214 feature and share your vote Programme Overview 46 Chronological Programme 48

2 ESPGHAN 52nd Annual Meeting Date of printing: 2 May 2019 – subject to change – www.espghancongress.org 3 Exhibition Centre Station

M8 TO CITY CENTRE REGISTRATION AREA Venue Map 1 Registration · Press · Scottish Event Campus (SEC) Cloakroom · Congress Bags 2 Speakers Ready Room STOBCROSS ROAD EXHIBITON AREA 3 Industry Exhibiton 4 ELZ Ground 7 6 5 4 5 Members Lounge Level 6 ESPGHAN Booth 7 ePoster Area 9

Walkway to station 8 Poster Area 9 Internet Corner 8 Hall 4 3 Hall 5 MEETING ROOMS Hall 3 1 10 Alsh I + II / Overflow 11 Etive / Silence Room 2 12 Fyne / Nursing Room 13 Boisdale I 14 Carron I + II Concourse 15 Dochart I + II

Main Entrance 16 ESPGHAN Meeting Room 1 10 17 ESPGHAN Meeting Room 2

Hall 2 11 SESSION HALLS Hall 1 Lomond Clyde Hall Hall 12 Lomond Hall 17 Concourse Hall 1 – 3 16 Mezzanine 13 14 Upper Clyde Hall Upper Level Level

15 to Clyde Hall Crowne Plaza Hotel

Walkway to City Centre

4 ESPGHAN 52nd Annual Meeting River Clyde River Clyde www.espghancongress.org 5 Welcome Letter ESPGHAN Annual Meeting

Dear Colleagues and Friends,

On behalf of ESPGHAN we are delighted to welcome you to the ESPGHAN 52nd Annual Meeting taking place in Glasgow, Scotland from 05 – 08 June 2019.

Each year the ESPGHAN Annual Meeting attracts key opinion leaders in the fields of Paediatric Gastroenterology, Hepatology and Nutrition from around the world to share knowledge and insights on the latest developments, findings and trends. With an attendance of over 4.600 from 100 countries in 2018, it is ESPGHAN Society the largest conference of its kind in the world.

This year over 1.000 abstracts were accepted. The authors will present their latest research results and the meeting will allow for an abundance of opportunities to meet colleagues in your related fields from across the globe. The scientific programme will once again include a wide range of sessions, symposia, a clinical track, postgraduate courses as well as the ever-popular hands-on Endoscopy Learning Zone as well as for the first time at ESPGHAN a live endoscopy session.

Scotland as well as Glasgow, is a popular destination for education and culture alike attracting tourists and businesspersons. Rich in history and tradition a friendly welcome is guaranteed wherever you go with some of the world’s oldest universities, with research including medical and life sciences. The city and country therefore is an ideal setting for ESPGHAN’s journey and provides an inspiring atmosphere for the ESPGHAN 52nd Annual Meeting.

We thank you very much for your participation and wish you a rewarding and enjoyable experience!

Prof. Raanan Shamir Prof. Richard Russell ESPGHAN President Chair Local Organizing Committee

6 ESPGHAN 52nd Annual Meeting www.espghancongress.org 7 ESPGHAN Council & Committees Society Meetings ESPGHAN Annual Meeting

ESPGHAN Council Wednesday, 05 June 2019 President Raanan Shamir, Israel Time Meeting Room Access 08:00 – 09:00 ESPGHAN Research Committee ESPGHAN Invite Only President Elect Sanja Kolaček, Croatia Meeting Meeting Room 1 General Secretary Jorge Amil Dias, Portugal Treasurer Annamaria Staiano, Italy Thursday, 06 June 2019 Education Secretary Iva Hojsak, Croatia Time Meeting Room Access Internat. Affairs Representative Almuthe Christina Hauer, Austria 12:15 – 14:15 ESPGHAN Nutrition Committee ESPGHAN Invite Only Scientific Secretary Matthias Zilbauer, United Kingdom Meeting Meeting Room 2 Gastroenterology Committee Nikhil Thapar, United Kingdom 12:30 – 13:30 ESPGHAN Ethics Committee ESPGHAN Invite Only Meeting Meeting Room 1 Hepatology Committee Henkjan Verkade, The Netherlands 13:30 – 15:00 ESPGHAN Public Affairs ESPGHAN Invite Only Nutrition Committee Magnus Domellöf, Sweden Committee Meeting Meeting Room 1 Allied Health Professionals Jackie Falconer, United Kingdom 16:30 – 17:30 ESPGHAN Publication Committee ESPGHAN Invite Only Meeting Meeting Room 1 YOUNG ESPGHAN Committee Nathalie Rock, Switzerland Chair of LOC Richard Russell, United Kingdom Friday, 07 June 2019 Time Meeting Room Access Scientific Programme Committee 07:00 – 08:45 ESPGHAN Gastroenterology ESPGHAN Invite Only President Raanan Shamir, Israel Committee Meeting Meeting Room 2 Scientific Secretary Matthias Zilbauer, United Kingdom 10:00 – 10:30 ESPGHAN Hepatology Committee ESPGHAN Invite Only Chair of LOC Richard Russell, United Kingdom Meeting Meeting Room 2 Gastroenterology Nikhil Thapar, United Kingdom 10:30 – 13:00 ESPGHAN AHP Committee ESPGHAN Invite Only Meeting Meeting Room 2 Hepatology Henkjan Verkade, The Netherlands 15:00 – 17:00 Young ESPGHAN Committee ESPGHAN Invite Only Nutrition Magnus Domellöf, Sweden Meeting Meeting Room 2 Allied Health Professionals Jackie Falconer, United Kingdom 17:30 – 19:45 ESPGHAN Annual General Lomond Hall Open to Meeting ESPGHAN Members Local Organising Committee UK Chair Richard Russell Saturday, 08 June 2019 Further members Andrew Barclay Time Meeting Room Access Elaine Buchanan 08:00 – 09:30 ESPGHAN National Societies ESPGHAN Invite Only Victoria Garrick Meeting Meeting Room 1 Richard Hansen 09:30 – 10:30 ESPGHAN Finance Committee ESPGHAN Invite Only Deirdre Kelly Meeting Meeting Room 2 David Wilson

8 ESPGHAN 52nd Annual Meeting www.espghancongress.org 9 17:30 – 19:45 Lomond Hall Time No. Topic Presenter ESPGHAN Annual Meeting Friday, 07 June 2019 19:15 10. Questions from the Members Chairs & on Committee and Activity Reports Representatives ESPGHAN Annual General Meeting 10.1 Gastroenterology Nikhil Thapar (Members Only) 10.2 Hepatology Henkjan Verkade 10.3 Nutrition Magnus Domellöf 10.4 Young ESPGHAN Natalie Rock Time No. Topic Presenter 10.5 Allied Health Professionals Jackie Falconer 17:30 1. President’s Welcome Raanan Shamir 10.6 Public Affairs Deirdre Kelly 2. Apologies for absence Raanan Shamir 10.7 Publication Bert Koletzko 3. Notification of other business Raanan Shamir 10.8 International Affairs Almuthe Christina 4. Approval of AGM Minutes – Geneva 2018 Raanan Shamir Hauer 17:40 5. President’s Report Raanan Shamir 10.9 Ethics Martin Burdelski

18:10 6. Finances 10.10 JPGN Hania Szajewska 6.1 Financial Report 2018 Annamaria Staiano 10.11 Education Iva Hojsak 6.2 Financial Report 2019 Annamaria Staiano 19:30 11. Any other Business Raanan Shamir

18:30 7. Proposed Changes to Constitution 19:40 12. Thanks to Outgoing Council Members Raanan Shamir

7.1 Updates to Constitution 2019 Jorge Amil Dias 19:45 13. Close of Meeting 7.2 Ongoing updates to Rules Jorge Amil Dias and Regulations

18:55 8. New Members and Elections 8.1 2019_01 – New Members Jorge Amil Dias 8.2 New Council Members Jorge Amil Dias

19:05 9. Future Meetings Next Meeting 9.1 ESPGHAN 2020 – Copenhagen Raanan Shamir AGM 2020 9.2 ESPGHAN 2021 – Vienna Raanan Shamir 05 June 2020 · 17:30 – 19:45 Copenhagen, Denmark 9.3 ESPGHAN 2022 – Milan Raanan Shamir 9.4 Voting on 2023 Destination AGM

10 ESPGHAN 52nd Annual Meeting www.espghancongress.org 11 For Members Only ESPGHAN Annual Meeting

ESPGHAN Members & Young ESPGHAN Lounge ESPGHAN Mentorship Reunion

Young ESPGHAN would like to invite all mentors and mentees participating Location Exhibition Hall (Hall 4) in the ESPGHAN Mentorship Programme, from all the three previous Date Open all day from Thursday, 06 June through editions to a Reunion Meeting on Wednesday, 05 June from 18:00 – 19:00 Saturday, 09 June 2019 (14:15) at the Mezzanine area of the SEC. Join our comfortable area for members in the exhibition hall next to the Here you can meet up with each other to catch up and make new plans ESPGHAN booth. while having a drink and a bite! The Members and Young ESPGHAN Lounge is combined to enhance communication between all members. All participants already active in the programme have received an invitation via the ESPGHAN office. Meet your friends and colleagues in a relaxed and comfortable atmosphere and enjoy some snacks and drinks throughout the day. Come in and start All persons interested in becoming a mentor and/or mentee can contact networking! YE committee during this reunion or by email.

Special activities at the Young ESPGHAN Lounge Members Evening Members of the Young ESPGHAN Committee will attend the lounge and are there to meet you and answer your questions about ongoing activities Location Argyle Street Arches (253 Argyle Street, Glasgow G2 8DL) and voluntary involvement. Date Friday, 07 June 2019, 20:15 50 € per person Thursday, 06 June 2019 Costs 12:45 – 13:45 (Lunch Break) Transfer 20:00 from SEC (after the end of the ESPGHAN AGM) Meet the President and the ESPGHAN Council: take the chance to Return transfer from 22:30 onwards interact with the President and board members of ESPGHAN, talk about Dress Code Casual your needs, concerns or just enjoy the informal friendly meeting. A buzzling downtown event location welcomes all ESPGHAN Members to 10:00 – 10:45 and 16:30 – 17:15 (Coffee Breaks) a Scottish night full of local experiences. Come and join your colleagues Meet the Young ESPGHAN: get to know the Young ESPGHAN Committee and friends for some delicious Scottish food and drinks and don’t miss the and let them know how they can help you. Discover the events dedicated to famous Ceilidh dance! Young ESPGHAN all year long: Educational events, Mentorship Programme, Image of the Month, Young investigator forum, Young ESPGHAN session Don’t forget to bring your ticket! Please note that this event needs to be registered in advance and is for members only. Friday, 07 June 2019 All members who pre-registered for a free ticket in combination with the attendance 10:30 – 11:15 (Coffee Break) of the Annual General Meeting, will receive a bracelet at the AGM. Meet the ESPGHAN Awardees: come and meet the young people who have been awarded an ESPGHAN prize and learn from their experience why and how you should apply. ESPGHAN Annual General Meeting Location Lomond Hall All ESPGHAN Members have access to the lounges – please present your badge at the entrance. Date Friday, 07 June 2019, 17:30 – 19:45 Registration and pre-session reception: from 17:00 onwards

12 ESPGHAN 52nd Annual Meeting www.espghancongress.org 13 European Society for Paediatric To promote the health of children Gastroenterology, Hepatology ESPGHAN

and Nutrition Annual Meeting

Society & Membership Key Activities enterology, Hepatology & Nutrition ESPGHAN has three standing in Europe, while the Young ESPGHAN committees focusing on Gastro­ Committee promotes and supports enterology, Hepatology and Nutrition. specialist training and guides trainees All aim to promote child health and towards full membership of ESPGHAN. increase understanding and treatment of disease states. ESPGHAN members ESPGHAN also promotes scientific are further involved in various working exchange amongst research groups in groups that concentrate on particular Europe and amongst trainees, young aspects of child care and / or disease doctors and scientists through Young states. The Allied Health Professional Investigator Forums, Monothematic Committee aims to enhance the Meetings, International Schools and multi­­disciplinary approach in Gastro­ Eastern European Schools.

ESPGHAN Booth ESPGHAN Office For any queries about ESPGHAN, European Society for membership or any other society Paediatric Gastroenterology, Become a Member letters, accesses to the member’s related matters, please contact Hepatology and Nutrition area of the ESPGHAN website and By becoming a member of ESPGHAN, a member of the ESPGHAN Office discounted registration fees for the [email protected] you will experience and gain access at the society booth. ESPGHAN Annual Meeting are among www.espghan.org to a range of benefits including an You can find us in the Exhibition the benefits of ESPGHAN members. international network of specialists Hall 4 next to the Members who promote and encourage colla­ According to your professional Lounge. boration and exchange of information status you can choose between within GI-, Hepatology-, Nutrition full, corres­ponding, trainee, allied- Committees, working groups and health pro­fessional and emeritus their outcomes. member­ship. You will find us in the Exhibition Hall Subscription to JPGN, the Journal Members must have an active interest next to the Members of Pediatric Gastroenterology and in paediatric gastroenterology and/or Lounge Nutrition, receipt of ESPGHAN news­ hepatology or nutrition (PGHN).

14 ESPGHAN 52nd Annual Meeting www.espghancongress.org 15 Young ESPGHAN Committee Nathalie Rock ESPGHAN Switzerland, Chair Annual Meeting Line Modin Denmark, Secretary Andreia Nita Romania, Committee Member Fiona Cameron United Kingdom, Committee Member Dimitrios Tapsas Young ESPGHAN Greece, Committee Member

Young ESPGHAN – consisting of trainees and young investigators – is the fastest growing members-group within ESPGHAN. The Young Young ESPGHAN at 52nd Annual Join ESPGHAN, become a Young ESPGHAN Committee represents their interests, shortlists trainees Meeting, Glasgow ESPGHAN Member! or young investigators for scientific committees and encourages them to participate in specific working groups. The YOUNG ESPGHAN Committee is The Young ESPGHAN membership organizing several events dedicated to addresses people less than 10 years active trainee ESPGHAN members. More details in the field of Paediatric Gastroenterology, in the section for members only. Hepatology and Nutrition (PGHN). 2018 in retrospective In 2017 the Young ESPGHAN Mentorship • Meet the President and the ESPGHAN Being a member gives you opportunities programme was launched aiming at Council such as: Young ESPGHAN has developed a relation­ creating a platform of interaction between • Meet the Young ESPGHAN Committee ship with UEG Young Talent group, having junior and senior ESPGHAN members. • Meet the ESPGHAN Awardees - Access to the biggest network in PGHN 2 meetings, first at UEG Week 2018 and Senior members can help junior members • Mentorship reunion in Europe the second at ECYG 2018 and is aiming by giving insight in the functioning of the • Young ESPGHAN session - Reduction in congress fees to strengthen it. Young ESPGHAN was society and opportunities within ESPGHAN (both members and non-members can - Eligibility for grants & research prizes represented by 4 Young ESPGHAN mem­ as well as helping them to develop their attend this session) - Participation in 2 educational events/ st career path. Participants in this programme, bers at the 1 European Conference of year: summer schools, masterclasses, both mentors and mentees, receive a Young Gastroentrologists which took young investigator forum professional mentorship training. There place in Zagreb, in December 2018. Also, - Becoming a Mentee in the Mentorship have been three very successful trainings Contact Young ESPGHAN Committee is working program in July 2017 in Glasgow, March 2018 in on establishing a connection with other For more information about Young - Attending the special events dedicated Brussels and March 2019 in Porto. international societies of interest and ESPGHAN membership and activities to Young ESPGHAN members during young representatives of national societies kindly contact us at [email protected], each Annual Meeting The Young ESPGHAN Committee has among European countries. or visit our website: updated its mission and rules statement Membership application is open twice www.espghan.org/home/join-us In 2018 the- Image of the Month- contest as well as the ESPGHAN training syllabus. a year! Please upload your application has been launched on the ESPGHAN Communication between the Young www.espghan.org/about-espghan/ on the ESPGHAN website before website. Its aim is to present a monthly ESPGHAN Committee and the trainees/young committees/young-espghan 30 September or 31 March. clinical image (radiology, endoscopy or investigators is assured by newsletters, Follow us on pathology) and case on the website of the social media and via the ESPGHAN website. ESPGHAN and on the social media. The best The Young ESPGHAN Committee has sent Twitter – @Young_ESPGHAN and image/case will win a prize. around surveys on PGHAN training and research opportunities during training and Linkedin – Young ESPGHAN has assisted the tran­s­ition to full members. to be the first to find out about Young ESPGHAN events and news. 16 ESPGHAN 52nd Annual Meeting www.espghancongress.org 17 Awards & Grants

ESPGHAN provides a number of awards and grants to members and non-members alike. These awards are wide ranging and are both project based and travel awards and grants.

Research Grant Initiative ...... up to 100,000 € Research and Networking Grants ...... 50,000 € Charlotte Anderson Travel Award (next awarded 2019) . . . . 5,000 € Scientific Programme ESPGHAN International Exchange Award ...... 3,000 € Young Investigator Awards (YIA) ...... up to 1,000 € ESPGHAN Conference Prizes ...... 2,500 € ESPGHAN / NASPGHAN Travel Award ...... 5,000 $/€ UEG Week YIA ...... up to 1,000 € WCPGHAN Young Investigator Award ...... up to 1,000 €

The Research and Networking Grants are available for ESPGHAN members to apply for funding for research and networking projects that involve cross border partnerships. The deadline for applications is 31 July 2019.

Conference Prizes The below prizes will be awarded with 2,500 € during the Closing Session for the best abstract presentations in Gastroenterology, Hepatology and Nutrition. The Annual John Harries Prize For the best presentation on Gastroenterology The Annual Alex Mowat Prize For the best presentation on Hepatology The Annual Jean Rey Prize For the best presentation on Nutrition For further information on the Young Investigator Awards Awards and Grants The purpose of the Young Investigator Awards is to please visit: support travel expenses of up to 1,000 € for Young www.espghan.org Investigators who have had their abstract accepted for presentation at the ESPGHAN Annual Meeting. The candidate must be the first author and/or presenter of the work being presented.

18 ESPGHAN 52nd Annual Meeting www.espghancongress.org 19 ESPGHAN 52nd Annual Meeting Programme Overview Wednesday, 05 June 2019

Alsh I + II Lomond Hall Hall 1 Boisdale I Carron I Carron II Dochart I Dochart II Etive Fyne

AHP Course Course in PGHaN IBD Course Working Groups Working Groups

08:00 Session 1: Session 1: Nutrition 05 June 2019 (combined session) The basics Wednesday 09:00 Endoscopy SIG 09:30 Coffee Break PreventCD Coffee Break Coffee Break Meeting 10:00 Session 2: Session 2: Session 2: Esophageal (Invite Only) Helicobacter Network for European Gastroenterology Hepatology Treatment Atresia WG Pylori WG Intestinal Reference Network (Invite Only) Rehabilitation and RARE LIVER Transplantation 11:00 Helicobacter in Europe (NITE) Educational Pylori WG Task Force 11:30 (Invite Only) 11:50 AHP Open Meeting 12:00 Neonatal Graft Injury Group Nutrition SIG WG (GIG) 12:30 Lunch Break Genius WG Lunch Break (Invite Only) 13:00 Session 3: Session 3: SIG-CD Cystic Fibrosis Special Interest Eosinophilic Gastroenterology IBD Specialist Steering and Pancreas WG Group on Gut Gastrointestinal 13:30 Session 3: I topics Committee Microbiota & Diseases (EGID) Abstracts (Invite Only) Modification (Invite Only) and innovative 14:00 practice Special Interest Group 14:30 Coffee Break on Coeliac Disease 15:00 Session 4: Session 3: Session 4: (Invite Only) Neurogastro, Eosinophilic Outcomes in International Joint Hepatology/ Gastroenterology Difficult cases Motility and Gastrointestinal Nutrition Trials WG Registry of GI session II Functional GI Diseases (EGID) (Invite Only) Congenital Disorders SIG/WG Porto-systemic 16:00 Special Outcomes in shunts Interest Group Nutrition Trials WG (IRCPSS) on Coeliac 16:30 Porto IBD Disease Clinical Polyposis Basic and SIG Malnutrition WG WG Translational­ 17:00 The best papers Young ESPGHAN Research and this year in JPGN Session Epigenetics in 17:30 see page 24 see page 33 Hepatology PGHN SIG Interest Group 18:00 see page 22 see page 25 see page 27 see page 29 see page 29

18:30 Welcome Reception · Exhibition Hall 18:30 Welcome Reception · Exhibition Hall

as of 2 May 2019 · subject to change IBD Course AHP Course Gastroenterology Nutrition Course in PGHaN Other Hepatology Young ESPGHAN 20 ESPGHAN 52nd Annual Meeting www.espghancongress.org 21 Wednesday, 05 June 2019 Chronological Programme

11:50 – 12:30 Alsh I + II AHP Course AHP Open Meeting

Chair Jackie Falconer, United Kingdom 08:00 – 09:30 Lomond Hall 05 June 2019 Session 1: Nutrition (combined session with Course in PGHaN) Wednesday 12:30 – 13:30 Lunch Break Chairs Jackie Falconer, United Kingdom · Heather Grant, United Kingdom

08:00 Blended diet and enteral feeding; the Sarah Durnan, perceived benefits, controversies and United Kingdom 13:30 – 14:30 Alsh I + II suggestions for clinical practice 08:30 Eosinophilic eosphagitis – medical and dietary Diana Flynn, Session 3: Abstracts and innovative practice treatment options United Kingdom · Chairs Paula Crespo-Escobar, Spain · Kathleen Ross, United Kingdom Tracey Cardigan, United Kingdom 13:30 N-O-001 What impact does gastro-intestinal surgery Hannah Duggan, 09:00 Old and new dietary treatments in Crohn‘s Rotem Sigall-Boneh, have on the growth of very low birth weight United Kingdom disease Israel preterm infants? 13:40 G-O-001 Long-term follow-up of gut-directed hypno­- Robyn Rexwinkel, therapy self-exercises at home using CD versus The Netherlands 09:30 – 10:00 Coffee Break individual therapy by qualified therapists in children with irritable bowel syndrome or functional abdominal pain syndrome 13:50 N-O-002 Characteristics of polymeric formula and Sara Sila, Croatia 10:00 – 11:50 Alsh I + II route of delivery of exclusive enteral nutrition have no effect on disease outcome and weight Session 2: Gastroenterology gain in children with Crohn‘s disease 14:00 G-O-002 Dietary therapies induce rapid response and Rotem Sigall-Boneh, Chairs Rut Anne Thomassen, Norway · Sarah MacDonald, United Kingdom remission in active paediatric Crohn‘s disease Israel

10:00 Motility – medical diagnosis, investigations Michiel P. van Wijk, 14:10 The Scottish transition model in IBD Victoria Garrick, and management The Netherlands United Kingdom 10:30 Nursing management of rectal irrigation Jenna Tarr, United Kingdom 10:50 Susan Protheroe, Ethical considerations in feeding the 14:30 – 15:00 Coffee Break neurological child with intestinal failure United Kingdom 11:10 Feeding the child with dysmotility Tracey Johnson, United Kingdom 11:30 Update of the new ESPGHAN PN guidelines Magnus Domellöf, Sweden

22 ESPGHAN 52nd Annual Meeting www.espghancongress.org 23 Wednesday, 05 June 2019 Chronological Programme

15:00 – 16:30 Alsh I + II Clinical Course in PGHaN Session 4: Joint Hepatology/GI session

Chairs Sara Mancell, United Kingdom · Tena Niseteo, Croatia 08:00 – 09:30 Lomond Hall 15:00 Nutritional management in Pancreatitis – Keith Lindley, latest guidelines (NICE and ESPGHAN) United Kingdom Session 1: Nutrition (combined session with AHP Course) 05 June 2019 Wednesday 15:20 PN use pre liver transplant Jonathan Hind, Chairs Jackie Falconer, United Kingdom · Heather Grant, United Kingdom United Kingdom 15:40 Transplant aquired food allergy Ruth De Bruyne, 08:00 Blended diet and enteral feeding; the Sarah Durnan, Belgium perceived benefits, controversies and United Kingdom suggestions for clinical practice 16:00 Panel – difficult case – short gut syndrome Paul Henderson, United Kingdom 08:30 Eosinophilic eosphagitis – medical and dietary Diana Flynn, Jonathan Hind, United Kingdom treatment options United Kingdom · Elaine Buchanan, United Kingdom Tracey Cardigan, David Hoole, United Kingdom United Kingdom Catherine Paxton, United Kingdom 09:00 Old and new dietary treatments in Crohn‘s Rotem Sigall-Boneh, disease Israel

17:00 – 18:00 Alsh I + II

The best papers this year in JPGN 09:30 – 10:00 Coffee Break

Chairs Hania Szajewska, Poland · Mel Heyman, USA

17:00 Welcome and opening remarks Hania Szajewska, 10:00 – 12:00 Lomond Hall Poland 17:02 The best gastroenterology papers Johanna Escher, Session 2: Hepatology The Netherlands Chairs Paul Henderson, United Kingdom · Rachel Taylor, Canada 17:10 The best nutrition papers Hans van Goudoever, 10:00 Acute and long term management of Ulrich Baumann, The Netherlands oesophageal varices – who, when and where? Germany 17:18 The best hepatology papers Piotr Socha, Poland 10:30 How to diagnose and treat acute liver failure Valérie McLin, Switzerland 17:26 The best pancreatology papers Michael Wilschanski, Israel 11:00 Surgical and medical treatment of infantile Suzanne Davison, cholestasis United Kingdom 17:34 ESPGHAN guidelines in JPGN. Novelties Lorenzo D‘Antiga, 11:30 Diagnosis and new treatment options for Giuseppe Indolfi, Italy hepatitis in children Italy 17:42 My first JPGN paper accepted Fiona Cameron, United Kingdom 17:50 JPGN 2014-2019: Where are we now? Hania Szajewska, 12:00 – 13:00 Lunch Break Where are we going? Poland 17:55 Informal discussion with the audience All JPGN Editors

24 ESPGHAN 52nd Annual Meeting www.espghancongress.org 25 Wednesday, 05 June 2019 Chronological Programme

13:00 – 14:30 Lomond Hall IBD Course Session 3: Gastroenterology I

Chairs Susan Protheroe, United Kingdom · Billy Bourke, United Kingdom 08:00 – 09:30 Hall 1 13:00 Biologics and biosimilars: what should I Amit Assa, Israel 05 June 2019 choose and when? Session 1: The basics Wednesday

13:30 Basic and advanced care of patients with Peter Gillett, Chairs Christos Tzivinikos, United Arab Emirates · Dan Turner, Israel coeliac disease in 2019 United Kingdom 14:00 Investigation of common and rare cause of Simon Murch, 08:00 Chairs‘ introduction Dan Turner, Israel · chronic diarrhea in children using case studies United Kingdom Christos Tzivinikos, United Arab Emirates 08:05 The clinical relevance of PIBD classification Sibylle Koletzko, Germany 14:30 – 15:00 Coffee Break 08:30 So many genes in VEOIBD – how to bring to Aleixo Muise, practice? Canada 09:00 From bench to our patients‘ mouth: Konstantinos 15:00 – 16:30 Lomond Hall nutritional therapy in Crohn‘s disease Gerasimidis, United Kingdom Session 4: Gastroenterology II

Chairs Jorge Amil Dias, Portugal · Nathalie Marie Rock, Switzerland 09:30 – 10:00 Coffee Break 15:00 Everything you need to know about Paraic McGrogan, aerodigestive disorders in children Qatar 15:30 Polyposis syndromes in children – recognition, Shlomi Cohen, 10:00 – 12:00 Hall 1 management and prognosis Israel Session 2: Treatment 16:00 Recognising common and obscure diagnoses Paolo Lionetti, at endoscopy – an interactive quiz Italy Chairs Richard Russell, United Kingdom · Amit Assa, Israel

10:00 Does the evidence support proactive Anne Griffiths, monitoring of anti-TNF levels? Canada 17:00 – 18:00 Lomond Hall 10:30 Unusual solutions for usual challenges in PIBD Arie Levine, Israel Young ESPGHAN Session 11:00 Who to choose for biologics at disease onset? Frank Ruemmele, > Details on page 33 France 11:30 Practicalities in prescribing vedolizumab, Lissy de Ridder, ustekinumab and tofacitinib in children The Netherlands

12:00 – 13:00 Lunch Break

26 ESPGHAN 52nd Annual Meeting www.espghancongress.org 27 Wednesday, 05 June 2019 Chronological Programme

13:00 – 14:30 Hall 1 Working Groups (Members Only) Session 3: IBD Specialist topics

Chairs Annamaria Staiano, Italy · Jorge Amil Dias, Portugal 09:00 – 10:00 Dochart II 13:00 A clinical approach to pancreatic disorders Michael Wilschanski,

Endoscopy SIG 05 June 2019 in IBD Israel Wednesday Chair Mike Thomson, United Kingdom 13:30 A tandem talk: stenotic Crohn‘s disease – when Gregor Walker, primary medical or surgical is appropriate? United Kingdom · David Wilson, 09:30 – 12:30 Carron I United Kingdom 14:00 Management of perianal Crohn‘s disease Paolo Lionetti, Italy PreventCD meeting (Invite Only) Chair Luisa Mearin, The Netherlands

14:30 – 15:00 Coffee Break 10:00 – 12:00 Boisdale I Esophageal Atresia WG 15:00 – 16:30 Hall 1 Chair Frédéric Gottrand, France Session 4: Difficult cases 10:00 – 11:00 Carron II Chairs Anne Griffiths, Canada · Gregor Walker, United Kindom · Dan Turner, Israel · David Wilson, United Kingdom Helicobacter Pylori (Invite Only) Chair Patrick Bontems, Belgium 15:00 Relapsing and refractory UC Iain Chalmers, United Kingdom 15:45 Managing the high risk Crohn‘s patient Marina Aloi, Italy 10:00 – 11:30 Dochart I Network for Intestinal Rehabilitation and Transplantation in Europe (NITE) Chair Jutta Koeglmeier, United Kingdom

10:00 – 11:30 Dochart II European Reference Network RARE LIVER Chair Ekkehard Sturm, Germany

28 ESPGHAN 52nd Annual Meeting www.espghancongress.org 29 Wednesday, 05 June 2019 Chronological Programme

11:00 – 12:30 Carron II 13:00 – 15:00 Dochart I Helicobacter Pylori Special Interest Group on Gut Microbiota & Modification Chair Patrick Bontems, Belgium Chairs Hania Szajewska, Poland · Zvi Weizman, Israel

11:00 – 13:00 Fyne 13:00 – 15:00 Dochart II 05 June 2019 Wednesday Educational Task Force (Invite Only) Eosinophilic Gastrointestinal Diseases (EGID) (Invite Only) Chair Iva Hojsak, Croatia Chair Alexandra Papadopoulou, Greece

12:00 – 13:00 Dochart I 14:00 – 16:00 Carron I Neonatal Nutrition SIG Special Interest Group on Coeliac Disease (Invite Only) Chair Hans van Goudoever, The Netherlands Chair Carmen Ribes Koninckx, Spain

12:00 – 15:00 Etive 15:00 – 17:30 Dochart I Graft Injury Group (GIG) (Invite Only) Neurogastro, Motility and Functional GI Disorders SIG/WG Chair Deirdre Kelly, United Kingdom Chair Silvia Salvatore, Italy

12:30 – 14:00 Boisdale I 15:00 – 16:00 Dochart II GENIUS WG Eosinophilic Gastrointestinal Diseases (EGID) Chair Frank Ruemmele, France Chair Alexandra Papadopoulou, Greece

13:00 – 14:00 Carron I 15:00 – 16:00 Etive Special Interest Group on Coeliac Disease Outcomes in Nutrition Trials WG (Invite Only) Steering Committee (Invite Only) Chair Merit Tabbers, The Netherlands Chair Carmen Ribes Koninckx, Spain 15:00 – 16:30 Fyne 13:00 – 14:30 Carron II International Registry of Congenital Porto-systemic Cystic Fibrosis and Pancreas WG shunts (IRCPSS) Chair Frank Bowedes, The Netherlands Chair Valérie McLin, Switzerland

30 ESPGHAN 52nd Annual Meeting www.espghancongress.org 31 Wednesday, 05 June 2019 · 17:00 – 18:00 · Lomond Hall Wednesday, 05 June 2019 Young ESPGHAN Session Everything we know about writing and publishing, work and life, 16:00 – 18:00 Carron I success and failure – a different Young ESPGHAN conversational Special Interest Group on Coeliac Disease (SIG-CD) session with contributions from her, me and you. Chair Carmen Ribes Koninckx, Spain

The presenter: The Content: 16:00 – 16:30 Etive

Come and join us for a unique session 05 June 2019 Wednesday Outcomes in Nutrition Trials WG organised by the Young ESPGHAN Committee! Chair Merit Tabbers, The Netherlands Over the past fifty years the study of literature has become a generally 16:30 – 18:00 Boisdale I accepted aspect of medical education. Porto IBD SIG Literature is highly suited to assist learners Helen McClory, PhD in questioning conventional thinking and Chair Dan Turner, Israel Author assumptions about various dimensions of work, life, professionalism, identity, and Helen has a PhD in literature and creative health. 16:30 – 18:00 Carron II writing from the University of Glasgow. Therefore, the seemingly separate Helen McClory lives in Edinburgh and Clinical Malnutrition WG universes of an author and a young doctor grew up between there and the isle of Chair Konstantinos Gerasimidis, United Kingdom are sewed together in a conversation Skye. Her first collection, On the Edges between Helen McClory and Line Modin, of Vision, was published by Queen‘s Ferry MD, PhD. who will interview Helen on Press in August 2015 and won the Saltire 16:30 – 18:30 Dochart II stage and invite you to ask questions along First Book of the Year 2015. Her second the way. Polyposis WG collection, Mayhem & Death, was written This interactive session will be a diverse Chairs Shlomi Cohen, Israel · Warren Hyer, United Kingdom for the lonely and published in March 2018. mix of literary performances, non medical and medical perspectives on writing and Mayhem & Death is the matured, darker 16:30 – 18:00 Fyne publishing, work and life and all the stuff companion to On the Edges of Vision and that lies in between. Basic and Translational Research and Epigenetics in shows McClory’s ever expanding ability to envelop and entrance her readers with We genuinely look forward to invite you Paediatric Gastroenterology, Hepatology and Nutrition SIG lyrical language of lore, stunning settings into a different session. Chair Andreas Jenke, Germany and curious characters. There is a moor and a cold sea in her heart. What to expect: 17:30 – 18:30 Dochart I Helen about herself: • Discussions on work life balance in an ‘Part islander, part denizen of the ‘city of unbalanced world. Perspectives from a Hepatology Interest Group Hume and Boswell’ (and Burke and Hare, Scottish author and by spirit, Jekyll and Hyde), I’ve lived in Chair Henkjan Verkade, The Netherlands • How to finish, how to publish – how to Sydney (for graduate studies) and in New prevent the paper from staying in the York City, though for the moment I’m back drawer ? in Edinburgh working on my next project and daydreaming of more travels.’ • The process of successful writing • How to fail (successfully) in writing

32 ESPGHAN 52nd Annual Meeting www.espghancongress.org 33 ESPGHAN 52nd Annual Meeting Programme Overview Thursday, 06 June 2019

Clyde Hall Lomond Hall Hall 1 Hall 2 Hall 3 Poster Exhibition 07:15 Breakfast Symposium Breakfast Symposium Breakfast Symposium Hall 4

see page 154 see page 157 see page 154 08:15

08:30 Opening Session see page 36

09:30 State of the Art see page 36 08:00 – 18:00

10:00 Coffee Break Coffee Break Thursday see page 86 06 June 2019 10:45 Plenary Session Highest Scoring Abstracts see page 37 ePoster Exhibition Hall 4 12:15 Keynote Lecture Hepatology see page 37 12:45 13:00 Lunchtime Symposium Lunchtime Symposium Lunch Break Lunchtime Symposium Lunch Break

see page 157 see page 158 see page 158

14:00 08:00 – 18:00

14:30 Parallel Symposium Parallel Symposium Parallel Symposium Parallel Symposium Live Endoscopy see page 78 Monitoring in Dysphagia The gut-liver axis Nutritional status – paediatric IBD monitoring see page 38 see page 39 see page 39 see page 40 see page 41 16:30 Coffee Break Coffee Break 17:15 Parallel Session Clinical Practice Parallel Session Parallel Session Parallel Symposium Gastroenterology 1 in Hepatology Gastroenterology 2 Nutrition 1 Specialised Endoscopy see page 42 see page 42 see page 43 see page 44 see page 45 18:15 18:30 Evening Symposium Evening Symposium Evening Symposium see page 161 see page 160 see page 160

as of 2 May 2019 Gastroenterology ESPGHAN subject to change Hepatology Industry Nutrition 34 ESPGHAN 52nd Annual Meeting www.espghancongress.org 35 Thursday, 06 June 2019 Chronological Programme

07:15 – 08:15 Lomond Hall 10:45 – 12:15 Clyde Hall Breakfast Symposium Plenary Session: Highest Scoring Abstracts Industry sponsored > Details on page 154 Chairs Richard Russell, United Kingdom · Matthias Zilbauer, United Kingdom

07:15 – 08:15 Hall 2 10:45 G-O-003 Human RIPK1 deficiency - molecular insights Daniel Kotlarz, from children with inflammatory bowel Germany Breakfast Symposium disease Industry sponsored > Details on page 157 10:55 G-O-004 Contractile segment impedance (CSI) for the Taher Omari, diagnosis of gastroesophageal reflux disease Australia during high resolution esophageal manometry: 07:15 – 08:15 Hall 3 a pediatric study Breakfast Symposium 11:05 H-O-001 First report of the international registry of Valérie McLin, Thursday

congenital porto-systemic shunts Switzerland 06 June 2019 Industry sponsored > Details on page 154 11:15 N-O-003 Gut microbiome and its metabolic activity in Esther Neelis, children with intestinal failure dependent on The Netherlands long-term parenteral nutrition 11:25 G-O-005 Technical outcomes in pediatric ERCP: David Troendle, 08:30 – 09:30 Clyde Hall experience with the multicenter pediatric ERCP USA database initiative (PEDI) Opening Session 11:35 H-O-002 Renal function after liver transplantation at C. J. van der Vlist, paediatric age: effects of long-term calcineurin The Netherlands inhibitor treatment 11:45 N-O-004 Neural pathways activated by formula Colin Prosser, consumption New Zealand 09:30 – 10:00 Clyde Hall 11:55 G-O-006 Risk factors for anastomotic strictures in the Madeleine Aumar, State of the Art Lecture first year after oesophageal atresia REPAIR: France data from a prospective multicentric cohort Chair Raanan Shamir, Israel

9:30 Immune mediated inflammatory diseases: Iain B. McInnes, what would Lister do next? United Kingdom 12:15 – 12:45 Clyde Hall Keynote Lecture: Hepatology

Chair Henkjan Verkade, The Netherlands 10:00 – 10:45 Coffee Break 12:15 Reversing liver fibrosis Detlef Schuppan, Germany

36 ESPGHAN 52nd Annual Meeting www.espghancongress.org 37 Thursday, 06 June 2019 Chronological Programme

13:00 – 14:00 Clyde Hall 14:30 – 16:30 Lomond Hall Lunchtime Symposium Parallel Symposium: Dysphagia Industry sponsored > Details on page 157 Chairs Annamaria Staiano, Italy · Marc Benninga, The Netherlands

13:00 – 14:00 Lomond Hall 14:30 Pharyngeal dysphagia Nathalie Rommel, Lunchtime Symposium Belgium 14:50 Achalasia Maartje Singendonk, Industry sponsored > Details on page 158 The Netherlands 15:10 G-O-010 Heller myotomy is more efficient than endoscopic­ Frédéric Gottrand, 13:00 – 14:00 Hall 2 dilatation for treating oesophageal achalasia in France Lunchtime Symposium children: a retrospective multicentre study 15:20 Eosinophilic oesophagitis Osvaldo Borrelli, Thursday

Industry sponsored > Details on page 158 06 June 2019 United Kingdom 15:40 Oesophageal atresia Frédéric Gottrand, 12:30 – 14:30 Lunch Break France 16:00 G-O-011 Clinical presentation of rumination syndrome Teresa Di Chio, in a tertiary/quaternary referral centre: the United Kingdom 14:30 – 16:30 Clyde Hall role of oesophageal high-resolution impedance manometry (HRIM) Parallel Symposium 16:10 GERD: dysphagia from complications and Michiel P. van Wijk, Monitoring in paediatric IBD treatment The Netherlands Chairs Patrick van Rheenen, The Netherlands · Sally Lawrence, Canada

14:30 – 16:30 Hall 1 14:30 Tight monitoring of disease activity of PIBD in Marina Aloi, clinical practice Italy Parallel Symposium: The gut-liver axis 14:55 G-O-007 Pharmacogenetics of anti-TNF therapy in Sara paediatric Crohns‘ disease and ulcerative colitis. Salvador-Martín, Chairs Girish Gupte, United Kingdom · Jörg Jahnel, Austria Comparison with adults Spain 14:30 Signaling pathways between liver and gut Frank Bodewes, 15:05 Capsule endoscopy or MRE for PIBD? Dan Turner, Israel The Netherlands 15:25 The new Crohn’s small and large bowel Capsule Salvatore Oliva, 15:03 H-O-003 Long-term follow-up of liver disease in children Line Modin, - new horizons Italy and young people with cystic fibrosis (CF) in the UK United Kingdom 15:45 G-O-008 Pan-enteric capsule endoscopy in paediatric Salvatore Oliva, 15:13 Management options for sclerosing Etienne Sokal, Crohn‘s Disease - the Ped-Pan study: preliminary Italy cholangitis Belgium results of a multicenter trial 15:46 H-O-004 Evaluation of defensins as markers of gut Aldona Wierzbicka- 15:55 G-O-009 A global prospective observational study in Martine A. Aardoom, microbiota disturbances in children with Rucińska, Poland paediatric-onset IBD: the PIBD-SETQuality The Netherlands obesity and non-alcoholic fatty liver disease inception cohort 15:56 Gut and hepatic encephalopathy Debbie L. Shawcross, 16:05 The clinical role of whole exome sequencing Aleixo Muise, United Kingdom outside of VEOIBD setup Canada

38 ESPGHAN 52nd Annual Meeting www.espghancongress.org 39 Thursday, 06 June 2019 Chronological Programme

14:30 – 16:30 Hall 2 14:30 – 16:30 Hall 3 Parallel Symposium: Nutritional status – monitoring Live Endoscopy

Chairs Koen Huysentruyt, Belgium · Konstantinos Gerasimidis, United Kingdom Glasgow Chairs Priya Narula (United Kingdom), Matjaž Homan (Slovenia) 14:30 An update of nutritional screening tools for Jessie Hulst, Sheffield Endoscopists Mike Thomson, Prithviraj Rao (United Kingdom) paediatric patients Canada Sheffield Surgeons Sean Marven, Richard Lindley (United Kingdom) 15:00 N-O-005 The interactive effect of prenatal iron Jie Shao, China Technical – Glasgow Richard Hansen (United Kingdom) deficiency and family economy education on Technical – Sheffield Natalia Nedelkopolou, Shishu Sharma and Arun Urs children´s motor development in China (United Kingdom) 15:10 N-O-006 Vitamin D in Brazilian paediatric population Marcia Cavichio, from North to South Brazil This is the first live endoscopy symposium in ESPGHAN history and something we 15:20 Pitfalls in nutritional assessment in sick or Konstantinos

hope will become a core component of future programmes. Thursday critically ill paediatric patients Gerasimidis, 06 June 2019 United Kingdom Due to the nature of live endoscopy, we cannot give a precise programme with specific 15:50 N-O-007 Comparison of Fenton intrauterine growth Susanta Kumar timings, however, we will be beaming live cases with commentary from two theatres in chart and INTERGROWTH-21 postnatal growth Badatya, India the International Academy for Paediatric Endoscopy Training, Sheffield Children‘s Hospital chart to assess growth restriction at birth and across the course of the afternoon. discharge in very low birth weight neonates We expect to show cases including: 16:00 Non-nutritional factors in determining Jarod Wong, nutritional status in chronic illness United Kingdom • Laparoscopically-assisted endoscopic jejunostomy • Endoscopic division of congenital duodenal congenital web • Multiple polypectomy from PTEN hamartoma tumour syndrome • Single stage percutaneous endoscopic gastrostomy button • Argon plasma coagulation for anastomotic ulceration • Over-the-scope clips and Hemospray for gastrointestinal bleeding (if case availability allows) This will help to showcase some of the GI-surgical interface and also the approaches that prevent the need for formal surgical intervention. An interactive debate on approaches with audience participation and an ongoing dialogue with the team performing the procedures is expected. We hope it will be instructive as well as stimulating and will be well attended, serving as a spring board for future years.

We advise interested delegates to attend early for this session, which we anticipate being busy.

16:30 – 17:15 Coffee Break

40 ESPGHAN 52nd Annual Meeting www.espghancongress.org 41 Thursday, 06 June 2019 Chronological Programme

17:15 – 18:15 Clyde Hall 17:15 – 18:15 Hall 1 Parallel Session: Gastroenterology 1 Parallel Session: Gastroenterology 2

Chairs Christos Tzivinikos, United Arab Emirates · Jochen Kammermeier, United Kingdom Chairs Osvaldo Borrelli, United Kingdom · Alexandra Papadopoulou, Greece

17:15 G-O-012 Accurate classification of paediatric colonic Jasbir Dhaliwal, 17:15 G-O-018 Automated stool consistency scoring for Thomas Ludwig, IBD subtype using random forest machine Canada non-toilet trained children by machine Singapore learning classifier learning algorithms 17:25 G-O-013 Delineating the phenotype of paediatric Amanda Ricciuto, 17:25 G-O-019 Plasma dosage of ghrelin and leptin related Letizia Zenzeri, PSC-IBD using longitudinal data analysis Canada to gastric emptying time and esophageal Italy pH-impedance parameters in obese children and 17:35 G-O-014 Nationwide incidence and prevalence of Christopher adolescents paediatric inflammatory bowel disease J. Burgess, in Scotland 2015-2017 demonstrates the United Kingdom 17:35 G-O-020 Protocol adherence and behavior-related Marin L. Leijdekkers, Thursday

highest paediatric prevalence rate recorded artefacts in paediatric high resolution The Netherlands 06 June 2019 worldwide manometry 17:45 G-O-015 The evolving role of biologic therapy in Eileen Crowley, 17:45 G-O-021 Evaluation of probiotic Lactobacillus Girish Deshpande, paediatric very early onset inflammatory bowel Canada reuteri (DSM17938) for treatment of Australia disease (VEO-IBD) gastro-oesophageal reflux in preterm neonates: a prospective observational study 17:55 G-O-016 Disease activity patterns during the first 5 years Marina Aloi, Italy after diagnosis in children with ulcerative colitis: 17:55 G-O-022 Fibrostenotic phenotype in patients with Diana Marcela a population-based study eosino­philic esophagitis, is not exclusive of adults Montoya Villa, Spain 18:05 G-O-017 Clock gene disruption may be a causative event Yael Weintraub, 18:05 G-O-023 The prevalence of lymphocytic oesophagitis and Aneta in inflammatory bowel disease flares and a Israel of eosinophilic oesophagitis in children: a 5-year Szalacha-Szczur, target for treatment observational study in a tertiary care pediatric Poland center

17:15 – 18:15 Lomond Hall Clinical Practice in Hepatology

Chairs Nedim Hadzic, United Kingdom · Karen Murray, USA

17:15 Abnormalities in liver ultrasound: Stéphanie 1. what the radiologist sees Franchi-Abella, France 17:30 Abnormalities in liver ultrasound: Piotr Czubkowski, 2. OK... and now what? Poland 17:45 Infections of the liver: a practical approach Giuseppe Indolfi, Italy

42 ESPGHAN 52nd Annual Meeting www.espghancongress.org 43 Thursday, 06 June 2019 Chronological Programme

17:15 – 18:15 Hall 2 17:15 – 18:15 Hall 3 Parallel Session: Nutrition 1 Parallel Symposium: Specialised Endoscopy

Chairs Alexandre Lapillonne, France · Nicholas Embleton, United Kingdom Chairs Prithviraj Rao, United Kingdom · Ilse Broekaert, Germany

17:15 N-O-008 Human milk oligosaccharide 2´-fucosyllactose Saskia Overbeek, 17:15 POEM Luigi Dall‘Oglio, more efficiently modulates immunogenicity The Netherlands Italy during maturation of human dendritic cells in 17:35 G-O-025 Polyp progression in paediatric patients with Anele Chukwuemek, the presence of scGOS/lcFOS prebiotics familial adenomatous polyposis syndrome – is United Kingdom 17:25 N-O-009 Modulation of 3‘SL level in pre-weaning milk Jonas Hauser, annual surveillance required – a single center impact attention, learning and memory in the Switzerland experience adult offspring 17:45 The place of ERCP and EUS in children – who Douglas Fishman, 17:35 N-O-010 Maternal secretor status is associated with Olga Sakwinska, should perform it and why? USA Thursday

reduced incidence of respiratory infections in Switzerland 06 June 2019 infants in the microbiota and health cohort 17:45 N-O-011 Combination of specific pre-and postbiotics in Mona Mischke, infant formula induces gut barrier maturation The Netherlands closer to mother‘s milk and supports gut 18:30 – 19:30 Lomond Hall functionality in mice Evening Symposium 17:55 N-O-012 Term infant formula supplemented with bovine Jian Yan, milk-derived oligosaccharides shifts stool Switzerland Industry sponsored > Details on page 161 microbiota closer to that of breastfed infants 18:05 N-O-013 Growth in infants with cow‘s milk protein allergy Yvan Vandenplas, 18:30 – 19:30 Hall 2 fed an amino acid-based formula Belgium Evening Symposium Industry sponsored > Details on page 160

18:30 – 19:30 Hall 3 Evening Symposium Industry sponsored > Details on page 160

44 ESPGHAN 52nd Annual Meeting www.espghancongress.org 45 ESPGHAN 52nd Annual Meeting Programme Overview Friday, 07 June 2019

Clyde Hall Lomond Hall Hall 1 Hall 2 Hall 3 Poster Session & 07:15 Breakfast Breakfast Breakfast Poster Walk Symposium Symposium Symposium Hall 4

see page 162 see page 161 see page 162

08:15

08:30 Plenary Session Plenary Session Plenary Session Gastroenterology 1 Nutrition Hepatology

see page 48 see page 49 see page 50 14:00 – 14:45 10:00 Keynote Lecture Nutrition see page 88

see page 51 ePoster Exhibition 10:30 Coffee Break Coffee Break Hall 4

11:15 Clinical Practice Parallel Session Parallel Session Parallel Session Parallel Session in Gastroenterology Nutrition 2 Gastroenterology 3 Hepatology 1 Gastroenterology 4 Friday 07 June 2019 see page 52 see page 53 see page 54 see page 55

12:15 08:00 – 18:00 12:30 Parallel Session Parallel Session Parallel Session Parallel Session Nutrition 3 Gastroenterology 5 Hepatology 2 Gastroenterology 6 see page 78 see page 51 see page 56 see page 57 see page 58 see page 59 Exhibition Area Lunch Break & Poster Walks (Poster only) Lunch Break & Poster Walks (Poster only) 13:30 Hall 4 15:15 Parallel Symposium Parallel Symposium Parallel Symposium Parallel Symposium Functional Contemporary Liver transplantation­ Donor human milk Endoscopy GI-disorders management of PIBD Learning Zone 1 ”Beginners“ see page 60 see page 61 see page 62 see page 63 (Ticket required) 11:00 – 13:30 17:15

17:30 ESPGHAN AGM Endoscopy (Members Only) Learning Zone 2 ”Advanced“ see page 10 (Ticket required) 15:15 – 17:45

as of 2 May 2019 see page 148 Gastroenterology ESPGHAN subject to change Hepatology ELZ Nutrition Industry 46 ESPGHAN 52nd Annual Meeting www.espghancongress.org 47 Friday, 07 June 2019 Chronological Programme

07:15 – 08:15 Lomond Hall 09:30 G-O-032 A phase I randomised, double-blind, placebo- Richard Hansen, controlled study to assess the safety and United Kingdom Breakfast Symposium tolerability of (Thetanix®) Bacteroides thetaiotaomicron in adolescents with stable Industry sponsored > Details on page 162 Crohn´s disease 09:40 G-O-033 Identification of serum protein biomarkers for Towia A. Libermann, 07:15 – 08:15 Hall 2 non-invasive diagnosis of pediatric IBD using USA SOMAscan Breakfast Symposium Industry sponsored > Details on page 161

07:15 – 08:15 Hall 3 08:30 – 10:00 Lomond Hall Breakfast Symposium Plenary Session: Nutrition

Industry sponsored > Details on page 162 Chairs Mary Fewtrell, United Kingdom · Magnus Domellöf, Sweden

08:30 N-O-014 Fecal metabolite profiles of mixed-fed Sharon Donovan, 08:30 – 10:00 Clyde Hall infants are more similar to formula-fed than USA breastfed infants Plenary Session: Gastroenterology 1 08:40 N-O-015 Annurca apple extracts in treatment of Michele di Toma, children‘s hypercholesterolemia: double blind Italy Chairs Rok Orel, Slovenia · Carmen Ribes Koninckx, Spain Friday

placebo controlled cross-over randomized study 07 June 2019 08:30 G-O-026 Maternal gluten and fibre intake during Ketil Størdal, 08:50 N-O-016 Milk-derived exosomes (MDE) have a different Shimon Reif, Israel pregnancy and risk of childhood celiac Norway biological effect on normal fetal epithelial disease: the Norwegian mother and child colonic cells compared to colonic tumor cells cohort study in a miRNA-dependent manner 08:40 G-O-027 Potential celiac disease patients fail to Valentina Discepolo, 09:00 N-O-017 Dietary choline-containing phospholipids Jian Yan, express activating NK receptors and epithelial USA are associated with cognitive performance in Switzerland stress markers even those who will evolve to school-aged children full-blown CD 09:10 N-O-018 Early intervention with hydrolysed formulas is Carla Patricia Harris, 08:50 G-O-028 Current treatment of Helicobacter pylori Thu Giang Le Thi, not protective against functional gastrointestinal­ Germany infected children and adolescents in Europe: Germany disorders in adolescence – the GINI Study interim results of the new EuroPedHp registry 09:20 N-O-019 Effects of infant formula enriched with milk Steven Wu, USA 09:00 G-O-029 Intestinal-specific Reg4 deficiency ameliorates Yongtao Xiao, fat globule membrane (MFGM) and lactoferrin intestinal inflammation China on the gastrointestinal microbiome and metabolome 09:10 G-O-030 Top-down Infliximab superior to step-up in Lissy de Ridder, children with moderate-to-severe Crohn‘s disease The Netherlands 09:30 N-O-020 Effect of long-chain polyunsaturated fatty Miguel Saenz de – a multicenter randomized controlled trial acid supplementation of preterm infants on Pipaon, Spain infection. A systematic review and meta-analysis 09:20 G-O-031 Alterations in T and B cell receptor repertoires Dror Shouval, patterns in patients with deleterious IL10/IL10 Israel 09:40 N-O-021 Maternal and child gluten intake and risk of Ketil Størdal, receptor mutations and history of infantile-onset type 1 diabetes: the Norwegian mother and Norway IBD child cohort study

48 ESPGHAN 52nd Annual Meeting www.espghancongress.org 49 Friday, 07 June 2019 Chronological Programme

08:30 – 10:00 Hall 2 10:00 – 10:30 Clyde Hall Plenary Session: Hepatology Keynote Lecture: Nutrition

Chairs Ulrich Baumann, Germany · Jian She Wang, China Chair Magnus Domellöf, Sweden

08:30 H-O-005 The contribution of variants in genes involved Teresa Brunetti, 10:00 The gut microbiome – maternal/fetal factors Lars Engstrand, in bile acid metabolism to the progression United Kingdom and health outcomes Sweden of Non-alcoholic fatty liver disease in a paediatric cohort 08:40 H-O-006 Effects of the ileal bile acid transport inhibitor Ulrich Baumann, A4250 on serum bile acids, pruritus and sleep in Germany patients with Alagille syndrome: phase 2 study 10:30 – 11:15 Coffee Break results 08:50 H-O-007 Factors associated with the natural course Daan van Wessel, of disease in patients with FIC1-deficiency: The Netherlands the NAPPED-consortium 11:15 – 13:30 Clyde Hall 09:00 H-O-008 Biallelic mutations in RINT1 – a new cause Dominic Lenz, of recurrent acute liver failure with onset in Germany Clinical Practice in Gastroenterology infancy and dysostosis multiplex Chairs Rok Orel, Slovenia · Andrew Barclay, United Kingdom 09:10 H-O-009 Functional rescue of an ABCB11 variant by Elodie Mareux,

ivacaftor: a new targeted pharmacotherapy France 11:15 Polyposis: topline from the guidelines Warren Hyer, Friday

approach in bsep deficiency United Kingdom 07 June 2019 09:20 H-O-010 Bile duct injury in a toxic model of biliary atresia Orith 11:50 Eosinophilic GI disease beyond the esophagus – Jorge Amil Dias, is mediated by genes in WNT and NOTCH Waisbourd-Zinman, to treat or not to treat? Portugal signaling pathways Israel 12:15 Paediatric functional GI disorders: if drugs Marc Benninga, 09:30 H-O-011 Biodegradable biliary stent placement as Javi Juampérez, don‘t work… what else? The Netherlands treatment of anastomotic biliary strictures in Spain 12:40 Fecal microbiota transplantation – beyond C Diff Richard paediatric patients with liver transplantation Kellermayer, USA 09:40 H-O-012 Impact of donor CYP3A5 genotype and Michele Pinon, 13:05 Gastrointestinal allergy: contemporary Sibylle Koletzko, graft size on tacrolimus pharmacokinetics in Italy approaches to diagnosis and management Germany paediatric liver transplant patients

50 ESPGHAN 52nd Annual Meeting www.espghancongress.org 51 Friday, 07 June 2019 Chronological Programme

11:15 – 12:15 Lomond Hall 11:15 – 12:15 Hall 1 Parallel Session: Nutrition 2 Parallel Session: Gastroenterology 3

Chairs Lorenzo Norsa, Italy · Jiri Bronsky, Czech Republic Chairs Paolo Lionetti, Italy · Javier Martín de Carpi, Spain

11:15 N-O-022 Results of a 24-week phase III study of Susan Protheroe, 11:15 G-O-34 CD-TREAT a novel dietary therapy of active Vaios Svolos, teduglutide in children with short bowel United Kingdom Crohn‘s disease using the exclusive enteral United Kingdom syndrome-associated intestinal failure (SBS-IF) nutrition paradigm 11:25 N-O-023 Low FODMAP diet is not effective in reducing Katarzyna 11:25 G-O-35 Crohn‘s disease exclusion diet is equally effective Arie Levine, Israel symptoms of functional abdominal pain in Mirosława Boradyn, but better tolerated than exclusive enteral children: a randomized, double-blind study Poland nutrition for induction of remission in mild to moderate active paediatric Crohn‘s disease: a 11:35 N-O-024 Effects of fish oil lipid emulsion compared Ying Wang, China prospective randomized controlled trial with MCT/LCT lipid emulsion on intestinal failure associated liver disease (IFALD) in 11:35 G-O-36 Exclusive enteral nutrition versus corticosteroid Thomas D. Walters, children induction therapy for new onset paediatric Canada Crohn‘s disease: comparison of 18 month 11:45 N-O-025 Third trimester maternal choline Richard L. Canfield, out­comes in a Canadian prospective multi- supplementation improves child memory, USA centre inception cohort attention, and problem-solving at age 7 years 11:45 G-O-37 Not so simple perianal Crohn‘s Disease! – Cher-Antonia 11:55 N-O-026 Serum bile acids perturbations induced by Ying Wang, China operative intervention for perianal fissuring Khedim, disturbed gut microbiota in a rat model of disease in South-East Scotland: an 18 year United Kingdom

parenteral nutrition-associated liver disease Friday population-based cohort study 07 June 2019 12:05 N-O-027 The overload gut syndrome Cecile Lambe, 11:55 G-O-38 Efficacy, pharmacokinetics and immunogenicity Karen van Hoeve, France is not affected by switching from Infliximab Belgium originator to a biosimilar in pediatric patients with inflammatory bowel disease 12:05 G-O-39 Thiopurine enhancement using Allopurinol Ali Hakizimana, in the short and medium term in paediatric United Kingdom inflammatory bowel disease (pIBD) – paediatric IBD Porto group of ESPGHAN

52 ESPGHAN 52nd Annual Meeting www.espghancongress.org 53 Friday, 07 June 2019 Chronological Programme

11:15 – 12:15 Hall 2 11:15 – 12:15 Hall 3 Parallel Session: Hepatology 1 Parallel Session: Gastroenterology 4

Chairs Saul Karpen, USA · Deirdre Kelly, United Kingdom Chairs Corina Pienar, Romania · Riccardo Troncone, Italy

11:15 H-O-013 Growth trajectories in Alagille syndrome from Koen Huysentruyt, 11:15 G-O-041 Prospective longitudinal gut metagenomic Francesco Valitutti, birth to early childhood: towards condition Belgium analysis suggests altered microbiome Italy specific growth charts composition and function in infants prior to coeliac disease onset 11:25 H-O-014 Cholestasis decreases hippocampal dendritic Laurianne spine density in an organotypic rat model Giovannoni, 11:25 G-O-042 Growth of children with coeliac disease is Renata Auricchio, Switzerland compromised before the onset of the disease Italy 11:35 H-O-015 ATP7B and copper homeostasis genes in Annamaria 11:35 G-O-043 Helicobacter pylori infection in children Burcu Volkan, Wilson‘s disease by targeted next-generation Sapuppo, Italy with concomitant coeliac disease and type 1 Turkey sequencing diabetes mellitus 11:45 H-O-016 Predicting long-term outcome after surgical Daan van Wessel, 11:45 G-O-044 Analysis of glycated hemoglobin values in Maria Bavastrelli, biliary diversion in BSEP-deficiency patients: The Netherlands coeliac patients, compared with those of Italy results from the NAPPED consortium general population: a possible marker of an increased health risk? 11:55 H-O-017 Hepatoadrenal syndrome in cirrhotic children: Moinak Sen Sarma, does it exist? India 11:55 G-O-045 A novel homozygous CARMIL2 variant causes Orly Eshach Adiv, infantile colitis and eosinophilic disease without Israel 12:05 H-O-018 Endoscopic variceal ligation as primary Maria Mercadal-

recurrent infections Friday prophylaxis for upper gastrointestinal bleeding Hally, Spain 07 June 2019 in children

54 ESPGHAN 52nd Annual Meeting www.espghancongress.org 55 Friday, 07 June 2019 Chronological Programme

12:30 – 13:30 Lomond Hall 12:30 – 13:30 Hall 1 Parallel Session: Nutrition 3 Parallel Session: Gastroenterology 5

Chairs Cristina Campoy, Spain · Elvira Verduci, Italy Chairs Jutta Koeglmeier, United Kingdom · Andreas Jenke, Germany

12:30 N-O-028 Frequency of gene variants of the leptin / Béatrice Dubern, 12:30 G-O-046 Early feeding in acute pancreatitis in children – Shlomi Cohen, melanocortin pathway in severe obesity France a prospective randomised controlled trial Israel 12:40 N-O-029 Validity of LATCH Score in predicting exclusive Mubashir Hassan 12:40 G-O-047 The way from abdominal pain to pediatric Dóra Mosztbacher, breast feeding and weight velocity at 6 weeks in Shah, India pancreatitis – the PINEAPPLE study Hungary healthy term Indian infants 12:50 G-O-048 The utility of ultrasound in cystic fibrosis Julie Dobbin, 12:50 N-O-030 Pre-pubertal amino acid and lipid metabolism Francois-Pierre related liver disease United Kingdom associates with glycaemic traits at adolescence Martin, Switzerland 13:00 G-O-049 An international multicentre validation study Amin J. Roberts, 13:00 N-O-031 Adiponectin agonist treatment during Antonio Gázquez, of the toronto listing criteria for pediatric New Zealand pregnancy improves glycaemia but not lipid Spain intestinal transplant profile in diabetic rats and their offspring 13:10 G-O-050 Developmental and cognitive profile of children Riikka Gunnar, 13:10 N-O-032 Effectiveness of individual vs. group-based Elvira Verduci, Italy with intestinal failure Finland lifestyle intervention on anthropometric and 13:20 G-O-051 Muscle mass after intestinal transplantation Kushila Rupasinghe, metabolic profile of obese children in children is greater than in those on home United Kingdom 13:20 N-O-033 Dietary patterns established early in life and Veronica Luque, parenteral nutrition their associations with cardiovascular risk Spain factors in late childhood Friday 07 June 2019

56 ESPGHAN 52nd Annual Meeting www.espghancongress.org 57 Friday, 07 June 2019 Chronological Programme

12:30 – 13:30 Hall 2 12:30 – 13:30 Hall 3 Parallel Session: Hepatology 2 Parallel Session: Gastroenterology 6

Chairs Mohammad Ali Shagrani, Saudi Arabia · Ekkehard Sturm, Germany Chairs Lissy de Ridder, The Netherlands · Rut Anne Thomassen, Norway

12:30 H-O-019 Shortened 8-weeks course of Sofosbuvir/ Daniele Serranti, 12:30 G-O-052 Treatment failure, safety, and immunogenicity Neil Chanchlani, Ledipasvir therapy in adolescents with chronic Italy of anti-TNF treatment in biologic-naïve United Kingdom Hepatitis C infection: a real-word experience children and adolescents with Crohn‘s disease: a subgroup analysis of the PANTS cohort 12:40 H-O-020 Development and Validation of a novel, Bikrant Biharilal dynamic, etiology specific prognostic model Raghuvanshi, India 12:40 G-O-053 Tolerability, safety, and efficacy of Carsten Posovszky, (Peds-HAV) in 100 children with Hepatitis A varicella-zoster-virus vaccination in Germany induced pediatric acute liver failure immunosuppressed children with inflammatory bowel disease or autoimmunhepatitis 12:50 H-O-021 A combined blood and MR imaging risk Kamil Janowski, score for monitoring liver inflammation in Poland 12:50 G-O-054 Nephrotoxicity of aminosalicylates in children Angeliki Pappa, paediatric AIH and adolescents with inflammatory bowel Germany disease (IBD)-data excerpt of CEDATA GPGE® 13:00 H-O-022 Cellular infiltrate and expression of IL-37 in Lucas Griessmair, pediatric AIH, PSC and ASC Germany 13:00 G-O-055 Neurological adverse events induced by tumour Valerie Bertrand, necrosis factor alpha inhibitors in paediatric France 13:10 H-O-023 Functional and immunometabolic analysis of Suz Warner, inflammatory bowel diseases: an analysis based liver derived MAIT cells in autoimmune liver United Kingdom on the French National Pharmacovigilance disease Database 13:20 H-O-024 Preventative strategies against cytomegalovirus Emanuele Nicastro, Friday 13:10 G-O-056 Final growth in paediatric Crohn´s Disease Amit Assa, Israel 07 June 2019 in paediatric liver transplantation: results Italy is impaired also in the era of biologics: from the European prospective multi-centre a population based analysis from the epiIIRN ChilSFree cohort study administrative cohort 13:20 G-O-057 An ongoing safety registry to identify rare and Martine A. Aardoom, severe complications in paediatric-onset IBD The Netherlands

13:30 – 15:15 Lunch Break & Poster Session incl. Poster Walks

58 ESPGHAN 52nd Annual Meeting www.espghancongress.org 59 Friday, 07 June 2019 Chronological Programme

15:15 – 17:15 Clyde Hall 15:15 – 17:15 Hall 1 Parallel Symposium: Functional GI-disorders Parallel Symposium: Contemporary management of PIBD Chairs Nikhil Thapar, United Kingdom · Silvia Salvatore, Italy Chairs David Wilson, United Kingdom · Dan Turner, Israel 15:15 Functional nausea, diagnosis and treatment Katja Kovacic, USA 15:40 G-O-058 Pediatric PPI use and fracture risk Nathan Fleishman, 15:15 Managing PIBD in low resource setup Almuthe Christina USA Hauer, Austria · Michael Lentze, 15:50 G-O-059 Genetic factors influence on the development Elżbieta Germany of functional constipation (FC) disease in Czkwianianc, children Poland 15:40 PIBD ahead: predicting disease course in IBD Anne Griffiths, and how to select children requiring biologics Canada 16:00 Pain modulation in functional abdominal pain Qasim Aziz, at disease onset disorders United Kingdom 16:05 Predicting response to anti-TNF in children Nicholas Kennedy, 16:25 The effect of placebo in FGIDs Arine Vlieger, United Kingdom Belgium 16:30 G-O-060 Vedolizumab is effective in real life paediatric Dan Turner, 16:50 Allergy and FGIDs a true association? Yvan Vandenplas, inflammatory bowel disease: report from the Israel The Netherlands prospective, multi-centre VEDOKIDS cohort study 16:40 G-O-061 Proactive adalimumab trough measurements Amit Assa, increase corticosteroid-free clinical remission Israel

in pediatric patients with Crohn‘s disease: Friday the pediatric Crohn‘s disease adalimumab 07 June 2019 level-based optimization treatment (PAILOT) randomized controlled trial 16:50 Will the new UC guidelines help me look after Javier Martín de my patients? Examples from practice Carpi, Spain

60 ESPGHAN 52nd Annual Meeting www.espghancongress.org 61 Friday, 07 June 2019 Chronological Programme

15:15 – 17:15 Hall 2 15:15 – 17:15 Hall 3 Parallel Symposium: Liver transplantation Parallel Symposium: Donor human milk

Chairs Françoise Smets, Belgium · Marianne Samyn, United Kingdom Chairs Judith Simpson, United Kingdom · Nicholas Embleton, United Kingdom

15:15 The late post-transplant liver biopsy: towards Stefan G. Hübscher, 15:15 What is the evidence base for the use of Nicholas Embleton, standardisation United Kingdom donor milk in preterm infants? United Kingdom 15:48 H-O-025 Evolution of liver transplantation for children Ulrich Baumann, 15:45 N-O-034 Postnatal longitudinal growth and reference Srinivas Murki, and adolescents in Europe – a report of the Germany growth charts for very preterm infants on India European liver transplant registry predominant human milk feeding 15:58 Late graft injury – natural history and Steffen Hartleif, 15:55 N-O-035 The preparation and storage of fortified Mandy Davies, mechanisms Germany expressed breast milk in neonatal units in United Kingdom England - a survey 16:31 H-O-026 Early emergence of de novo donor specific Come Tissandier, antibodies in pediatric liver recipients are Switzerland 16:05 Protection of functional components during Jean-Charles Picaud, associated with T cell mediated rejection donor milk pasteurization France 16:41 Noninvasive assessment of fibrosis after liver Jonathan 16:35 N-O-036 Effects of early use of donor human milk on Deepa Hariharan, transplantation: where do we stand? Fallowfield, United growth, development and neonatal morbidity India Kingdom in very low birth weight infants: comparison to mother´s own milk and preterm formula 16:45 Discussion: examples and challenges of national organisation of milk banking Friday 07 June 2019 Sertac Arslanoglu, Turkey Hans van Goudoever, The Netherlands Jean-Charles Picaud, France Magnus Domellöf, Sweden

17:30 – 19:45 Lomond Hall ESPGHAN Annual General Meeting (Members Only)

> Details on page 10

62 ESPGHAN 52nd Annual Meeting www.espghancongress.org 63 ESPGHAN 52nd Annual Meeting Programme Overview Saturday, 08 June 2019

Clyde Hall Lomond Hall Hall 1 Hall 2 ePoster Session Poster Exhibition Hall 4 Hall 4 08:30 Parallel Symposium Parallel Symposium Parallel Symposium Parallel Symposium Organoids: Cutting Probiotics for Novelties in Coeliac disease: edge translational infants Hepatology Diagnosis and screening research tools for everybody in paediatric Gastroenterology The ePosters will see page 66 see page 66 see page 67 see page 68 be presented at 10:40 – 11:30 10:30 Coffee Break & Coffee Break & 08:00 – 14:15 ePoster Session ePoster Session see page 78 see page 86 11:40 Keynote Lecture Gastroenterology Exhibition Area see page 68 Hall 4

12:10 Clinical Practice in Joint Symposium Endoscopy Nutrition: Nutrition and Learning Zone 3 12:15 Plenary Session Feeding disorders Gastroenterology ”Beginners“ Gastroenterology 2 (Ticket required) 12:25 Parallel Session: 08:00 – 10:30 Hepatology 3

see page 70 see page 69 see page 71 see page 69 Endoscopy Learning Zone 4 13:25 ”Advanced“ (Ticket required) Saturday 13:30 Closing & Awards 11:00 – 13:30 08 June 2019

see page 71 see page 148

as of 2 May 2019 Gastroenterology ESPGHAN subject to change Hepatology ELZ Nutrition 64 ESPGHAN 52nd Annual Meeting www.espghancongress.org 65 Saturday, 08 June 2019 Chronological Programme

08:30 – 10:30 Clyde Hall 09:20 N-O-038 Bifidobacterium with early feeding with Yuichiro Yamashiro, colostrums and human milk benefits weight Japan Parallel Symposium: gain and metabolic responses associated with Organoids: Cutting edge translational research microbiota establishment tools in paediatric Gastro 09:30 Safety and quality control of probiotics Sanja Kolaček, Croatia Chairs Holm Uhlig, United Kingdom · Andreas Jenke, Germany 09:50 N-O-039 Combination of prebiotic oligosaccharides and Dominique Turck, 08:30 Intestinal epithelial organoids in GI health Matthias Zilbauer, fermented infant formula (with Bifido­bacterium France and disease United Kingdom breve C50 and Streptococcus thermophilus O65) is safe and modulates the gut microbiota 08:55 Genetic engineering of intestinal organoids Bon-Kyoung Koo, towards a microbiota closer to that of breastfed Austria infants 09:20 G-O-062 Lin-28/Occludin axis: an aberrant signal Junkai Yan, 10:00 Probiotics for prevention of NEC Hans van leading to impaired intestinal barrier function China Goudoever, under total parenteral nutrition The Netherlands 09:30 Drug development and personalised medicine in Jeffrey M. cystic fibrosis using intestinal organoids Beekman, The Netherlands 09:55 Liver organoids as models to study human Alexander Ross, development and disease United Kingdom 08:30 – 10:30 Hall 1 Parallel Symposium: Novelties in Hepatology

Chairs Aglaia Zellos, Greece · Dominique Debray, France

08:30 Surgical developments in liver transplantation: Dieter Clemens 08:30 – 10:30 Lomond Hall what has changed and what is expected to Broering, Parallel Symposium: Probiotics for infants change shortly Saudi Arabia 09:03 H-O-027 USP53 mutation manifest as low-GGT Ye Yang, China Chairs Flavia Indrio, Italy · Iva Hojsak, Croatia intrahepatic cholestasis Saturday 08:30 The normal development of the infant gut Christopher 09:13 Liver directed gene therapy: current results Amit C. Nathwani, 08 June 2019 microbiota Stewart, United Kingdom United Kingdom 09:46 H-O-028 Mayo PSC risk score: a prognostication tool for Vandana Jain, 08:50 N-O-037 Daily administration of Lactobacillus plantarum Pierre Poinsot, Biliary Atresia outcomes in adulthood United Kingdom improves mouse juvenile growth kinetics by France 09:56 The liver and enzyme replacement therapy: Roshni Vara, sustaining somatotropic axis activity upon to give or not to give? United Kingdom undernutrition 09:00 Probiotics in infant formula – what is the Hania Szajewska, evidence? Poland

66 ESPGHAN 52nd Annual Meeting www.espghancongress.org 67 Saturday, 08 June 2019 Chronological Programme

08:30 – 10:30 Hall 2 12:10 – 13:25 Lomond Hall Parallel Symposium: Clinical Practice in Nutrition: Feeding disorders Coeliac disease: Diagnosis and screening for everybody? Chairs Jessie Hulst, Canada · Iva Hojsak, Croatia Chairs Luisa Mearin, The Netherlands · Daniel Agardh, Sweden 12:10 Feeding disorders: diagnosis, classification – Gillian Harris, 08:30 Population screening: pros and cons Carlo Catassi, Italy · a practical approach United Kingdom Kalle Kurppa, 12:40 Feeding disorders: treatment (and the utility Tena Niseteo, Finland of a feeding team) Croatia 09:20 The ethics of screening Martine de Vries, 13:05 N-O-040 ARFID is a common diagnosis at a paediatric Lotta Söderberg, The Netherlands eating observation clinic Sweden · 09:45 G-O-064 Value of anti-tTG IgA in screening of coeliac Ozlem Kalaycık Emma Gotthardsson, disease in asymptomatic children with high-risk Sengül, Turkey Sweden 09:55 G-O-065 How long children with a first-degree coeliac Ilma R. Korponay- 13:15 N-O-041 Improving swallowing function due to electrical Ewa Winnicka, relative should be followed by antibody Szabó, Hungary stimulation in group of children – preliminary Poland screening? results from an innovative method of treatment 10:05 The 2019 ESPGHAN guidelines for coeliac Steffen Husby, disease: consolidation of the no-biopsy Denmark approach 12:10 – 13:25 Hall 2 Joint Symposium: Nutrition and Gastroenterology

Chairs Erasmo Miele, Italy · Konstantinos Gerasimidis, United Kingdom

12:10 Food additives and food industrialisation in Arie Levine, 10:30 – 11:40 Coffee Break & ePoster Session the aetiology and progression of IBD Isreal 12:30 The epidemiology of the role of diet in the Andrew Hart, aetiology of IBD United Kingdom 12:50 G-O-073 Rapid reversion to baseline microbiome Michael Logan, Saturday 11:40 – 12:10 Clyde Hall during food reintroduction after successful United Kingdom 08 June 2019 course of exclusive enteral nutrition (EEN) in Keynote Lecture: Gastroenterology paediatric Crohn‘s disease (CD) 13:00 N-O-042 Dietary intake and adherence to mediterranean Caterina Chair Nikhil Thapar, United Kingdom diet in a cohort of pediatric patients with Strisciuglio, Inflammatory Bowel Diseases (IBD) Italy 11:40 The brain in the gut: master conductor of the Vassilis Pachnis, orchestra United Kingdom 13:10 Exclusion diets in the management of IBD: Vaios Svolos, how much and how good is the evidence? United Kingdom

68 ESPGHAN 52nd Annual Meeting www.espghancongress.org 69 Saturday, 08 June 2019 Chronological Programme

12:15 – 13:25 Clyde Hall 12:25 – 13:25 Hall 1 Plenary Session: Gastroenterology 2 Parallel Session: Hepatology 3

Chairs Jernej Dolinšek, Slovenia · Emmanuel Mas, France Chairs Nedim Hadzic, United Kingdom · Norman Junge, Germany

12:15 G-O-066 SOMAscan as a discovery platform to identify Tina Morhardt, 12:25 H-O-029 Characterisation of different sources of Teresa Brunetti, predictive serum proteomic biomarkers of USA stromal cells as support for primary human United Kingdom infliximab response in pediatric patients with hepatocytes to improve the outcome of Crohn‘s disease hepatocyte transplantation 12:25 G-O-067 Panallergens in natural history of EoE: Monica Malamisura, 12:35 H-O-030 How to infuse heterologous human adult Louise Coppin, are they predictive of diet failure? Italy liver-derived progenitor cells safely? Belgium 12:35 G-O-068 Standard dosing of Infliximab dosing not Maria Myrthe 12:45 H-O-031 Hepatopulmonary syndrome in children: Emanuele Nicastro, sufficient in young paediatric IBD patients – Jongsma, a two-decades experience at a single liver Italy a multicenter study The Netherlands transplantation referral centre 12:45 G-O-069 SERPINB12 as a possible marker of steroid Salvatore Oliva, 12:55 H-O-032 Biallelic complete loss-of-function ZFYVE19 Chen-Zhi Hao, dependency in children with Eosinophilic Italy mutations: congenital hepatic fibrosis, sclerosing China Esophagitis: A pilot study cholangiopathy, and high-GGT cholestasis 12:55 G-O-070 Correlation between antroduodenal manometry Atchariya 13:05 H-O-033 Magnetic resonance elastography in evaluation Duygu Demirtas and histopathology in paediatric intestinal Chanpong, of hepatic fibrosis in children with chronic liver Guner, Turkey pseudo-obstruction United Kingdom disease 13:05 G-O-071 Constitutive alterations of vesicular trafficking Maria Vittoria 13:15 H-O-034 Gallstone disease and heart rhythm disorders in Kseniya Yurchyk, predispose to innate immune response to Barone, Italy children Belarus gliadin in celiac disease 13:15 G-O-072 Characterization of Eosinophilic Esophagitis Salvatore Oliva, in a multicenter patient population from the Italy European Pediatric Eosinophilic Esophagitis Registry (pEEr) of ESPGHAN

13:30 – 14:15 Clyde Hall Saturday 08 June 2019 Closing Session and Award Ceremony

70 ESPGHAN 52nd Annual Meeting www.espghancongress.org 71 2019 List of Invited Speakers, Chairpersons and Tutors 2019

List of Invited Speakers, Chairpersons and Tutors

A Iain Chalmers, United Kingdom Douglas Fishman, USA Jessie Hulst, Canada Daniel Agardh, Sweden Atchariya Chanpong, United Kingdom Diana Flynn, United Kingdom SteffenHusby , Denmark Marina Aloi, Italy Shlomi Cohen, Israel Raoul Furlano, Switzerland Koen Huysentruyt, Belgium Jorge Amil Dias, Portugal Paula Crespo-Escobar, Spain Stéphanie Franchi-Abella, France Warren Hyer, United Kingdom Sertac Arslanoglu, Turkey Nicholas Croft, United Kingdom Amit Assa, Israel Piotr Czubkowski, Poland G I Marcus Auth, United Kingdom Diana García Tirado, Spain Giuseppe Indolfi, Italy Qasim Aziz, United Kingdom D Victoria Garrick, United Kingdom Flavia Indrio, Italy Luigi Dall‘Oglio, Italy Konstantinos Gerasimidis, B Giulia D‘Arcangelo, Italy United Kingdom J Andrew Barclay, United Kingdom Suzanne Davison, United Kingdom Peter Gillett, United Kingdom Jörg Jahnel, Austria Ulrich Baumann, Germany Ruth De Bruyne, Belgium Frédéric Gottrand, France Andreas Jenke, Germany JeffreyBeekman , The Netherlands Lissy de Ridder, Netherlands Tassos Grammatikopoulos, Tracey Johnson, United Kingdom Marc Benninga, The Netherlands Martine de Vries, The Netherlands United Kingdom Norman Junge, Germany Vishnu Biradar, India Dominique Debray, France Heather Grant, United Kingdom Frank Bodewes, The Netherlands Marco Deganello Saccomani, Itay Anne Griffiths, Canada K Patrick Bontems , Belgium Anil Dhawan, United Kingdom Girish Gupte, United Kingdom Jochen Kammermeier, United Kingdom Osvaldo Borrelli, United Kingdom Jernej Dolinšek, Slovenia Saul Karpen, USA Billy Bourke, Ireland Magnus Domellöf, Sweden H Richard Kellermayer, USA Ronald Bremner, United Kingdom Sarah Durnan, United Kingdom Nedim Hadzic, United Kingdom Deirdre Kelly, United Kingdom Ilse Broekaert, Germany Richard Hansen, United Kingdom Nicholas Kennedy, United Kingdom Dieter Clemens Broering, Saudi Arabia E Gillian Harris, United Kingdom Jutta Koeglmeier, United Kingdom Jiri Bronsky, Czech Republic Muftah Eltumi, United Kingdom Andrew Hart, United Kingdom Sanja Kolaček, Croatia Elaine Buchanan, United Kingdom Nicholas Embleton, United Kingdom SteffenHartleif , Germany Sibylle Koletzko, Germany Su Bunn, United Kingdom Lars Engstrand, Sweden Almuthe Christina Hauer, Austria Bon-Kyoung Koo, Austria Paul Henderson, United Kingdom Katja Kovacic, USA C F Jonathan Hind, United Kingdom Kalle Kurppa, Finland Samy Cadranel, Belgium Jackie Falconer, United Kingdom Iva Hojsak, Croatia Cristina Campoy, Spain Jonathan Fallowfield, United Kingdom Matjaž Homan, Slovenia L Tracey Cardigan, United Kingdom Simona Faraci, Italy David Hoole, United Kingdom Alexandre Lapillonne, France Carlo Catassi, Italy Mary Fewtrell, United Kingdom Stefan G. Hübscher, United Kingdom Sally Lawrence, Canada

72 ESPGHAN 52nd Annual Meeting www.espghancongress.org 73 2019 List of Invited Speakers, Chairpersons and Tutors 2019

Michael Lentze, Germany Lorenzo Norsa, Italy Isabelle Scheers, Belgium Vaidotas Urbonas, Lithuania Arie Levine, Isreal Jan Nowak, Poland Detlef Schuppan, Germany Arun Urs, United Kingdom Delphine Ley, France Daniele Serranti, Italy Keith Lindley, United Kingdom O Mohammad Ali Shagrani, Saudi Arabia V Paolo Lionetti, Italy Salvatore Oliva, Italy Raanan Shamir, Israel Wendy van der Woerd, The Netherlands Zuzana Londt, United Kingdom Rok Orel, Slovenia Shishu Sharma, United Kingdom Hans van Goudoever, The Netherlands Eberhard Lurz, Germany P Debbie L. Shawcross, United Kingdom Patrick van Rheenen, The Netherlands Vassilis Pachnis, United Kingdom Rotem Sigall Boneh, Israel Michiel P. van Wijk, The Netherlands M Alexandra Papadopoulou, Greece Ari Silbermintz, Israel Yvan Vandenplas, Belgium Sarah MacDonald, United Kingdom Catherine Paxton, United Kingdom Judith Simpson, United Kingdom Roshni Vara, United Kingdom Sara Mancell, United Kingdom Jean-Charles Picaud, France Maartje Singendonk , The Netherlands Elvira Verduci, Italy Javier Martín de Carpi, Spain Corina Pienar, Romania Karin Sipido, Belgium Gábor Veres, Hungary Emmanuel Mas, France Susan Protheroe, United Kingdom Françoise Smets, Belgium Henkjan Verkade, The Netherlands Paraic McGrogan, Qatar Etienne Sokal, Belgium Jérôme Viala, France Iain B. McInnes, United Kingdom R Annamaria Staiano, Italy Arine Vlieger, The Netherlands Valérie McLin, Switzerland Sunita Amar Rajani, United Kingdom Christopher Stewart, United Kingdom Luisa Mearin, The Netherlands Prithviraj Rao, United Kingdom Ekkehard Sturm, Germany W Erasmo Miele, Italy Carmen Ribes Koninckx, Spain Vaios Svolos, United Kingdom Orith Waisbourd-Zinman, Israel Peter Milla, United Kingdom Petra Riznik, Slovenia Hania Szajewska, Poland Gregor Walker, United Kindom Nurul Husna Mohd Shukri, Malaysia Nathalie Rock, Switzerland Jian She Wang, China Sissel Moltu, Norway Claudio Romano, Italy T Michael Wilschanski, Israel Aleixo Muise, Canada Nathalie Rommel, Belgium Jenna Tarr, United Kingdom David Wilson, United Kingdom Simon Murch, United Kingdom Alexander Ross, United Kingdom Rachel Tayler, United Kingdom Victorien Wolters, The Netherlands Karen Murray, USA Kathleen Ross, United Kingdom Nikhil Thapar, United Kingdom Jarod Wong, United Kingdom Frank Ruemmele, France Rut Anne Thomassen, Norway N Richard Russell, United Kingdom Mike Thomson, United Kingdom Y Priya Narula, United Kingdom David Troendle, USA Anat Yerushalmy-Feler, Israel Amit C. Nathwani, United Kingdom S Riccardo Troncone, Italy Natalia Nedelkopoulou, Silvia Salvatore, Italy Dan Turner, Israel Z United Kingdom Camilla Salvestrini, United Kingdom Christos Tzivinikos, United Arab Emirates Tsili Zangen, Israel Emanuele Nicastro, Italy Marianne Samyn, United Kingdom Aglaia Zellos, Greece Tena Niseteo, Croatia Ian Sanderson, United Kingdom U Matthias Zilbauer, United Kingdom Holm Uhlig, United Kingdom

74 ESPGHAN 52nd Annual Meeting www.espghancongress.org 75 Facts & Figures about the Abstract Submission & Reviewing All submitted abstracts underwent a blinded review. The following illustration highlights the ranking structure as well as explains the way of the presentation of all accepted abstracts. We would like to thank all abstract submitters for submitting 1180 abstracts from 66 countries for the ESPGHAN 52nd Oral presentation Annual Meeting! We are very grateful for these efforts being RANKING The top 15% abstracts made. WAY OF PRESENTATION • Oral presentation included in the symposia of We are happy to share some further facts about this year’s the Scientific Programme abstract handling. The following numbers of abstracts have been submitted per field: ePoster RANKING The subsequent 9% of abstracts qualified for presentation as ePoster N I O WAY OF PRESENTATION I T • Available at ePoster stations and as printed poster in R the poster exhibition T U • Oral presentation in the ePoster Session on Saturday

N G morning during coffee break

267 A

S T Poster selected for Poster Walk Total number R

O RANKING of submitted E The subsequent 9% of abstracts qualified for

abstracts: 650 N presentation as posters, complimented with a poster

T walk presentation Y

E WAY OF PRESENTATION

G 1180 R

• Available in the poster exhibition

O O

L • Short oral presentation during the Poster Walk on 263 L

O

O Friday during lunch break

T

G

A

Y

P

E Poster H Posters Exhibition RANKING 67 % of abstracts were rated above the cut-off score for presentation as poster WAY OF PRESENTATION • Available in the poster exhibition

76 ESPGHAN 52nd Annual Meeting www.espghancongress.org 77 Gastroenterology 003 – 146 ePosters

Session 1 G-P-086 Raphaël Enaud, France Chairs: Diana García Tirado, Spain Jernej Dolinšek, Slovenia Early microbiota disturbances and intestinal inflammation in children with cystic fibrosis G-P-003 Ingrid Renes, The Netherlands G-P-096 Jan Krzysztof Nowak, Poland Native whey protein improves maturation of the immature intestine of preterm and Navigating between subclinical near term piglets atherosclerosis and arterial stiffness in cystic fibrosis: a cross-sectional study ePoster Presentations G-P-015 Donatella Cielo, Italy G-P-099 Andrea Párniczky, Hungary Lipidomic profile predicts celiac disease in at-risk infants Explore the childhood onset pancreatitis with the support of APPLE (Analysis G-P-023 of Pediatric Pancreatitis) multicenter, Mariangela Conte, Italy The 95 best scored posters will be presented as ePosters. observational, clinical trial Undigested gliadin P31-43 delays celiac

These posters will be shown electronically at ten ePoster stations during the disease-associated Neisseria flavescens whole meeting starting on Wednesday, 5 June, during the Welcome Reception in early endocytic vesicles in CaCo-2 (18:30 – 20:30) to Saturday, 08 June 2019, in the ePoster area (Hall 4). epithelial cells: role of Lactobacillus Session 2 paracasei CBA L74 Chairs: Marina Aloi, Italy Furthermore, a printed version of each ePoster will be accessible in the Poster Marcus Auth, United Kingdom Exhibition during the opening times. G-P-030 Rita Elek, Hungary G-P-100 Establishing kit-independent calibrators María Roca Llorens, Spain for measuring serum transglutaminase antibody concentrations for the prediction Faecal calprotectin levels in children with of coeliac disease cystic fibrosis are higher as compared to healthy controls G-P-059 Petra Rižnik, Slovenia G-P-101 The ePosters will be Gillian Smith, United Kingdom presented in the ePoster The influence of diagnostic delays on Session on growth of children with coeliac disease in How Vitamin D levels in children with Central-Europe cystic fibrosis have been increased Saturday, 08 June 2019, through supplementation regimens from 10:40 to 11:30. G-P-061 Orit Rozenberg, Israel G-P-131 Frances Lee, USA Automated analyzers are suited for diagnosing celiac disease following the The effect of audit and feedback on ileal ESPGHAN 2012 criteria and cecal intubation rates in pediatric colonoscopy

G-P-072 Poster Sebastian Stricker, Germany G-P-146 Exhibition Chantal A. ten Kate, The Netherlands Subcellular localization of trans­ glutaminases and the regulatory Successful treatment of severe recurrent proteins ERp57 and protein disulphide anastomotic strictures with intralesional isomerase in coeliac disease steroid injections in children with oesophageal atresia: a case series

78 ESPGHAN 52nd Annual Meeting www.espghancongress.org 79 ePosters Gastroenterology 179 – 331 Gastroenterology 332 – 384 ePosters

G-P-179 G-P-255 Session 4 G-P-356 Marcus Auth, United Kingdom Teresa Di Chio, United Kingdom Jan de Laffolie, Germany Chairs: Ilse Broekaert, Germany Differences in implementation of Lack of agreement between colonic mano­ Emmanuel Mas, France Evaluation of gender-specific differences guidelines on diagnosis and treatment metry and colonic transit studies in classi­ in the course of disease of paediatric of Eosinophilic Esophagitis (EoE). An fying children with chronic constipation patients with Inflammatory Bowel G-P-332 overview of current pediatric and adult Disease based on data of the CEDATA- G-P-257 Myrthe M. E. Jongsma, The Netherlands GI practice in Europe GPGE-register John E. Fortunato, USA Trough levels and efficacy of Vedolizumab G-P-198 G-P-358 Evaluation of paediatric nausea: time to in refractory PIBD patients Juan J. Díaz, Spain Jasbir Dhaliwal, Canada think outside the gastroenterology box? G-P-339 Gut changes with milk introduction in Excess adiposity is a common finding G-P-278 David Devadason, United Kingdom infants with outgrowing non-IgE cow`s in children and adolescents with Luca Marciani, United Kingdom milk protein allergy Current practice in UK centres providing inflammatory bowel disease Novel mini-capsules markers and methods surgery in paediatric inflammatory bowel G-P-206 G-P-373 for magnetic resonance imaging of disease - a survey from the BSPGHAN IBD Eun Hye Lee, Republic of Korea Jair Gonzalez Marques Junior, Germany gastro­intestinal transit in paediatric working group Nationwide epidemiologic study on child­ constipation (the MAGIC study) GC QTOF profile of stool metabolome G-P-343 hood intussusception in South Korea: on and machine learning algorithms – a pilot G-P-286 Felipe Briglia, Canada the emphasis of treatment and outcomes study to diagnose Crohn’s disease Robyn Rexwinkel, The Netherlands Infliximab dose optimization during G-P-210 Long-term follow-up of gut-directed maintenance therapy in children with IBD Jan Łukasik, Poland hypno­therapy self-exercises at home G-P-344 Prenatal and early postnatal exposure using CD versus individual therapy by Session 5 Christopher J. Burgess, United Kingdom to antibiotics and autism spectrum qualified therapists in children with Chairs: Frank Bowedes, The Netherlands disorders – a systematic review irritable bowel syndrome or functional Paediatric patients account for less than Isabelle Scheers, Belgium abdominal pain syndrome 1.5% of all prevalent inflammatory bowel G-P-216 disease cases within a defined Scottish Ji Sook Park, Republic of Korea G-P-291 G-P-375 health board Renato Tambucci, Italy Patrick F. van Rheenen, The Netherlands Macrophage migration inhibitory factor G-P-345 as a predictive factor of necrotizing Scintigraphic colonic transit in children Time to reach target calprotectin level Daniela Knafelz, Italy enterocolitis in premature infants with severe constipation: a retrospective and sustained remission in newly chart review Inflammatory bowel diseases associated diagnosed patients with IBD: first results G-P-232 with primary sclerosing cholangitis of the fast forward care prospective Yang Wang, China G-P-293 in children: a ten years case-control registry Erick M. Toro-Monjaraz, Mexico Contribution of common genetic variants retrospective study G-P-379 in Armadillo Repeat gene deleted in Anorectal manometry in children with G-P-353 Rachel Harris, United Kingdom Velo-Cardio-Facial syndrome (ARVCF) and retentive faecal incontinence: what Eileen Crowley, Canada related gene-gene interaction networks parameters should we evaluate? A study of post-induction Infliximab to the risk of hirschsprung disease Variability and suboptimal drug exposure trough levels demonstrates most G-P-309 with standard weight-based Infliximab paediatric patients are being underdosed Sana Barakat, Egypt induction dosing in the youngest G-P-384 Role of bovine colostrum in the children: a multicentre prospective study Sara Isoldi, Italy Session 3 treatment of acute diarrhea in Egyptian of paediatric Crohn’s disease Pouchitis and microscopic inflammation Poster Chairs: Susan Protheroe, United Kingdom children: a randomised double-blinded, Exhibition G-P-354 Camilla Salvestini, United Kingdom placebo-controlled trial at ileal resection margin in children with Giulia D‘Arcangelo, Italy Ulcerative Colitis: is there a relationship? G-P-331 Outcome of pediatric Crohn’s disease G-P-250 Ting Zhang, China Roberto Berni Canani, Italy (CD) before vs after 2014 – is there an Clinical efficacy and microbiome impact of the pediatric guidelines on the Bifidobacteriumanimalissubsp.lactis BB-12 changes following fecal microbiota medical managament of CD? is effective in the treatment of infant colic: transplantation in children with recurrent result of a randomized controlled trial clostridium difficile infection

80 ESPGHAN 52nd Annual Meeting www.espghancongress.org 81 Gastroenterology 401 – 468 · Hepatology 002 – 044 ePosters ePosters Hepatology 049 – 187

G-P-401 H-P-049 H-P-116 Sara Lega, Italy Hepatology Fabiola Di Dato, Italy Bikrant Biharilal Raghuvanshi, India Diagnostic approach to monogenic Spectrum and prevalence of neuro­ Acute Kidney Injury alters the natural inflammatory bowel disease in clinical Session 6 radiological features in neurologically course and is associated with poor practice: a ten-year multicentric Chairs: Tassos Grammatikopoulos, asymptomatic children with Alagille outcome in children with acute liver experience United Kingdom Syndrome failure: Analysis of 227 cases G-P-428 Anil Dhawan, United Kingdom H-P-053 H-P-120 Sahana Shankar, Australia Laura Draijer, The Netherlands Nathalie Rock, Belgium Tacrolimus has superior efficacy in H-P-002 Serum lipidomics profiling as a diagnostic Intracranial hypertension and papilledema Kai-Chi Chang, Taiwan thiopurine naïve as compared to tool for NAFLD in children. A matched in a large cohort of pediatric Alagille thiopurine experienced children with Alterations of gut microbiota in biliary case-control pilot study syndrome steroid dependant or refractory colitis atresia patients with liver cirrhosis H-P-055 H-P-128 G-P-446 H-P-013 Maurizio Giuseppe Fuoti, Italy Daniele Serranti, Italy Dan Turner, Israel Steffeni Mountford, Germany Recurrent intrahepatic cholestasis and Sofosbuvir/Ledipasvir in adolescents First report of national childhood-onset Interleukin-37 reduces pro-inflammatory tight junction protein 2 (TJP2) mutation 12-17 years old with Hepatitis C virus IBD in Israel: an epiIIRN study and pro-fibrotic properties of murine and genotype 1, 3 or 4 infection: a real-world

human hepatic stellate cells experience G-P-449 Johan Van Limbergen, Canada H-P-024 Session 7 H-P-169 Marion Almes, France Piotr Socha, Poland Exclusive enteral nutrition (EEN) and Chairs: Eberhard Lurz, Germany Crohn´s disease exclusion diet (CDED) Targeted-capture next-generation Wendy van der Woerd, Acute liver failure due to DGUOK produce broadly similar taxonomic and sequencing in the diagnosis of pediatric The Netherlands deficiency – five cases in Poland functional changes during the induction cholestasis H-P-187 of remission, with EEN showing a pattern H-P-026 H-P-069 Michele Pinon, Italy of rebound after return to free diet + Aspasia Angelakopoulou, United Kingdom Giuseppe Iorio, Italy partial enteral nutrition (PEN) The role of immunosuppression in post- Hepatic manifestations of X-linked Fertility evaluation in Wilson’s disease transplant idiopathic hepatitis, liver G-P-451 Lymphoproliferative Syndrome (XLP) patients diagnosed in childhood fibrosis and antibody-mediated rejection Marta Velasco Rodríguez-Belvís, Spain in paediatric liver transplant patients H-P-034 H-P-070 Cost-effectiveness of the use of Marie-Eve Chartier, United Kingdom Vandana Jain, United Kingdom HLA-DQA1-HLA-DRB1 polymorphism Intestinal barrier function in Biliary to identify pediatric patients with Hepatic copper concentration mimicking Atresia post-Kasai Portoenterostomy inflammatory bowel disease at risk for wilson disease in children with azathioprine-induced acute pancreatitis cholestatic and non-cholestatic chronic H-P-093 liver disease Jake Mann, United Kingdom G-P-468 Marieke Zijlstra, The Netherlands H-P-042 European Paediatric Non-Alcoholic Fatty Jemma Day, United Kingdom Liver Disease (EU-PNAFLD) Registry: Comparison of Infliximab serum levels design and rationale between venous and capillary blood in Mastery of self-management skills in paediatric IBD patients using novel blood young people with chronic liver disease H-P-111 and liver transplants in the United Corina Pienar, Romania sampling technology Poster

Kingdom Exhibition Feasibility and reproducibility of point H-P-044 shear wave elastography in children Ruth De Bruyne, Belgium Non-invasive assessment of liver abnormalities in pediatric Fontan patients

82 ESPGHAN 52nd Annual Meeting www.espghancongress.org 83 Nutrition 020 – 114 ePosters ePosters Nutrition 126 – 113

N-P-157 N-P-126 N-P-089 Nutrition Hans Demmelmair, Germany Marko Mank, The Netherlands Ivana Trivić, Croatia The effect of Atlantic salmon consumption Label free targeted LC-ESI-MS2 analysis Central venous catheter related sepsis Session 8 on the cognitive per­formance of preschool of 3’- and 6’-galactosyllactose in human in children on long-term parenteral children – a randomized controlled trial milk with enhanced structural selectivity nutrition Chairs: Elaine Buchanan, United Kingdom Konstantinos Gerasimidis, N-P-172 N-P-127 N-P-093 United Kingdom Carla Morgado, Portugal Sarah D. Maria, USA Charlotte Wright, United Kingdom Predicting NAFLD in overweight A global view of human milk B vitamin Overdiagnosis of non IgE cows milk N-P-020 paediatric population: the role of puberty content and contribution to recommended allergy in primary care Angelo Campanozzi, Italy infant intake N-P-187 N-P-098 Iodine deficiency among children and Itay Zamir, Sweden N-P-128 Kateřina Bajerová, Czech Republic adolescents assessed through 24-h Nurul Husna Mohd Shukri, Malaysia urinary iodine excretion Postnatal determinants of blood Our experience with cow´s milk-related pressure at 6.5 years of age in children Breast milk hormones and infant symptoms scoring (CoMiSS™) N-P-074 born extremely preterm appetite as predictors of infant growth Paul Tadeo Ríos Gallardo, Mexico N-P-113 N-P-132 Ajoy Garg, India The stratifiedwaist-height ratio (W/H Edoardo Pisa, Italy ratio) and its association with hypertrans­ Session 9 Evolution of auditory-neural maturation aminasemia and hyperuricemia in Presence of 6’SL in pre-weaning milk or from birth to 4 - 6 months of age in children and adolescents with obesity Chairs: Jutta Koeglmeier, United Kingdom mutation of St6gal1 gene modulated infants ≥ 35 weeks gestation with normal Jiri Bronsky, Czech Republic microbiota composition and improved iron status and latent iron deficiency N-P-120 cognitive functions in adult offspring Zahra Khan, Pakistan N-P-015 N-P-137 Role of gestational age at birth on growth Ardy van Helvoort, The Netherlands Bernd Stahl, The Netherlands and body composition of preterm infants Mineral bioaccessibility from amino Fatty acid profile during lactation of N-P-134 acid based medical nutrition formulas Chinese women: a pooled data analysis Charlotte A. Ruys, The Netherlands for infants and children under different digestive conditions in vitro Neurodevelopment of children born very preterm and/or with a very low birth N-P-112 Session 10 weight: 8-year follow-up of a nutritional Bertram Fong, New Zealand RCT Chairs: Magnus Domellöf, Sweden Milk fat globule membrane (MFGM) Sunita Amar Rajani, N-P-147 proteins: comparison of human MFGM United Kingdom Kanar Ahmed, United Kingdom protein classes and functions with MFGM- rich dairy ingredients for improvement of Dietitians’ experiences of mental N-P-047 infant formula composition health problems in paediatric obesity: Susan Hill, United Kingdom a qualitative study N-P-114 A prospective, open-label, long-term Kaouther Ben-Amor, The Netherlands N-P-153 safety and efficacy study of teduglutide Roberto Berni Canani, Italy Combination of short chain galacto- in paediatric patients with short bowel oligosaccharides and long chain fructo- syndrome associated–intestinal failure: How junk food can contribute to the food oligosaccharides (scGOS/lcFOS 9:1) with 6-month interim analysis (SHP633-303) Poster allergy epidemic: the potential role of Exhibition 2’-fucosyllactose (2’-FL) positively impact advanced glycation endproducts N-P-055 the infant gut microbiota composition Janne Anita Kvammen, Norway and metabolic activity in a simulator of the human intestinal microbial Bone health and vitamin D in paediatric ecosystem (SHIME®) intestinal failure patients receiving home parenteral nutrition

84 ESPGHAN 52nd Annual Meeting www.espghancongress.org 85 86 in aninteractivediscussionabouttheirposters. visited bytheposterwalkchairswhowillbegladtoinvolveallpresenters anddelegates selected forPoster Walk shouldstandbytheirpostersduringthissessionandwillbe The Poster Walk will take placeduring the postersession.AllpresentersofaPoster Poster Walk (Posters selected for Poster Walk) research workwithotherdelegates. presenters shouldstandbytheirpostersduringthissessioninordertotalkabout The Poster Sessionwilltake placeonFriday, 07June2019,from14:00to14:45.Allposter Poster Session numbers inthisprogrammehavebeenpreviouslywithdrawn. this timewillbedisposedofbythemeetingorganisers.Pleasenotethatmissingposter from 8:00andtake themdownbySaturday, 08June,14:15.Any postersnotremovedby (Hall 4)onWednesday evening,05June,from18:30to20:30andonThursday, 06June The presentersofthepostersarerequestedtoset-up theirpostersinthePoster Area Poster Presentations ESPGHAN 52 Poster Exhibition nd Annual Meeting

Plan Exhibition Poster 256 265 275 266 276 285 295 286 296 305 315 306 316 325 335 326 336 345 355 346 356 365 375 366 376 385 396 386 397 406 416 407 417 426 436 427 437 446 456 447 457 466 476 467 477 486 495 487 Gastroenterology G-P-001G-P-495 –

013 022 032 023 033 042 052 043 053 062 072 063 073 082 092 083 093 102 112 103 113 122 132 123 133 042 152 143 153 162 173 163 174 183 193 184 194 203 214 204 215 224 234 225 235 244 255 245 001 012

Hepatology H-P-001 – H-P-199 Nutrition 006 007 N-P-001 – N-P-188

199 187 174 186 188 174 159 173 www.espghancongress.org 173 161 148 160 158 145 131 144 147 134 121 133 130 118 105 117 120 108 095 107 104 092 079 091 094 082 069 081 068 056 078 066 043 055 053 065 ePoster Hall 4 042 030 Area 052 040 027 039 017 029 Catering 016 009 026 014

87 001 008 001 013 Internet Corner ESPGHAN Booth

Poster Exhibition Catering Members Lounge Catering Catering ELZ Gastroenterology Poster Area Poster Area Nutrition Hepatology Poster Area Gastroenterology 002 – 122 Posters selected for Poster Walk Posters selected for Poster Walk Gastroenterology 127 – 234

G-P-127 Session 4 Laura Kelly, United Kingdom Posters selected for Poster Walk Chairs: Ian Sanderson, United Kingdom ‘Is this going to hurt?’ – Understanding Anat Yerushalmy-Feler, Israel acute post-endoscopy pain in a tertiary paediatric gastroenterology centre Gastroenterology G-P-077 G-P-202 Anil Verma, Italy Ishak Isik, Turkey Comparison of R5 and G12 antibody- Investigation of the efficacy of Session 1 based ELISA methods for the Session 3 Lactobacillus rhamnosus GG in infants determination of gluten concentration Chairs: Giulia D‘Arcangelo, Italy Chairs: Petra Rižnik, Slovenia with cow’s milk protein allergy: a in routine gluten-free food products Peter Milla, United Kingdom Nicholas Croft, United Kindom randomised double blind placebo controlled trial G-P-002 G-P-139 G-P-212 Marianna Lucafò, Italy Session 2 Marleena Repo, Finland Lara Navarro, Portugal Long non-coding RNA GAS5 as a regulator Chairs: Atchariya Chanpong, Prevalence and clinical significance of Baby-led weaning: a trend in com­ of intestinal MMP9 and MMP2 expression United Kingdom H.pylori negative gastritis in children plementary feeding? A population and tissue damage in pediatric patients Arun Urs, United Kingdom G-P-154 based cross-sectional study with IBD Ziqing Ye, China G-P-091 G-P-228 G-P-029 Natália Lásztity, Hungary Domperidone does not alter transit time Raquel Vecino López, Spain Neslihan Ekşi Bozbulut, Turkey in paediatric video capsule endoscopy: a Clinical signs of severity and therapeutic Prognostic value of the isolated Determination of growth and dietary randomized controlled trial intervention in pediatric acute pancreatitis determination of plasma citrulline in a adequacy status for Celiac disease – data from APPLE multicentre, G-P-157 Spanish cohort or children with intestinal patients observational clinical trial Elisa Cavalleri, Italy failure due to short intestine syndrome G-P-036 G-P-097 Target therapy for refractory autoimmune G-P-230 Ida Gustafsson, Finland Grzegorz Oracz, Poland enteropathy in two cases of primary Raquel Vecino López, Spain Prevalence of seronegative celiac disease immune deficiency - preliminary report Prevalence rate of diabetes mellitus in Plasma citrulline within the first year and non-celiac duodenal histopathology children with chronic pancreatitis G-P-171 after pediatric small bowel trans­ in children Marc McNulty, United Kingdom plantation in a Spanish cohort G-P-107 G-P-041 Harriet Barraclough, United Kingdom Paediatric Eosinophilic oesophagitis G-P-231 Ozlem Kalaycik Sengul, Turkey outcomes following the introduction Marta Velasco Rodríguez-Belvís, Spain Acquisition of paediatric gastroscopy Does serologic tests reliably reflect of a dedicated clinic competence: how many endoscopies do Faecal calprotectin in healthy children: mucosal recovery in coeliac children? trainees actually need to do? G-P-173 are there factors affecting levels other than age? G-P-048 Arati Rao, United Kingdom G-P-121 Carla Maia, Portugal Luciano Guerra, Italy In children with eosinophilic oesophagitis, G-P-234 Long term follow up of a coeliac disease high rates of symptom resolution do not Tian Zhang, China “Push bougie” percutaneous endoscopic population correspond with endoscopic or histo­ gastrostomy: a new method of placement Autophagy deficiency induced intestinal logical improvement barrier dysfunction contributes to liver

G-P-052 Poster G-P-122 fibrosis in a cholestasis rat model Nazareth Martinon-Torres, Spain Exhibition Warren Hyer, United Kingdom Comorbid autoimmunity and selective Outcomes from gastrointestinal immunoglobuline A deficiency favour surveillance in children and teenagers persisten tissue-transglutaminase anti­ with Peutz-Jeghers syndrome - reducing body seropositivity in coealiac disease the need for laparotomy

88 ESPGHAN 52nd Annual Meeting www.espghancongress.org 89 Gastroenterology 244 – 370 Posters selected for Poster Walk Posters selected for Poster Walk Gastroenterology 371 – 489

Session 5 Session 6 Session 7 G-P-439 Dan Turner, Israel Chairs: Su Bunn, United Kingdom Chairs: Vishnu Biradar, India Chairs: Marco Deganello Saccomani, Italy Jan Nowak, Poland Vaidotas Urbonas, Lithuania Hania Szajewska, Poland Development and validation of the IBD- REFER criteria: when should a general practitioner or pediatrician refer a G-P-244 G-P-279 G-P-371 patient for suspected IBD? Ignacio Ros Arnal, Spain Alex Moretti, Italy Junko Fujino, Japan Predictive factors of positive response Correlation between symptoms, the The efficacy of Japanese herbal medicine to low fodmap diet in children with revised infant gastro-oesophageal reflux on the dextran sulfate sodium (DSS)- functional abdominal pain disorders questionnaire and ph-impedance induced acute colitis in mice: Session 8 a preliminary report Chairs: Tsili Zangen, Israel G-P-246 G-P-294 Zuzana Londt, United Kingdom Marc Benninga, The Netherlands Erick M. Toro-Monjaraz, Mexico G-P-387 Ben Kang, Republic of Korea Magnesium-rich formula for functional High-resolution manometry for diagnosis G-P-445 constipation in infants: a randomized of oesophageal motility disorders in Trough levels of infliximab are associated Dan Turner, Israel comparator-controlled study children with dysphagia with mucosal healing but not with trans­ mural healing at 1 year treatment with A sharp increase of biologics use in G-P-248 G-P-296 infliximab in paediatric Crohn’s disease pediatric IBD– a population- based report Pamela D. Browne, The Netherlands Rossella Turco, Italy patients treated according to dosing from the Israeli epiIIRN database Probiotics in the management of Natural history of Pediatric Achalasia: a intervals based on clinical symptoms G-P-448 pediatric functional gastro-intestinal single center experience Karen van Hoeve, Belgium disorders: analysis of prescribing G-P-405 G-P-316 Mikkel Malham, Denmark practices of clinicians Long-term outcome of Theresa Greimel, Austria The cancerincidence in paediatric immunomodulators use in children with G-P-256 Toxin producing Klebsiella oxytoca in onset inflammatory bowel disease – a inflammatory bowel disease Antonio Di Mauro, Italy infants: commensal or pathobiont? population-based study from Denmark G-P-471 Magnesium alginate in gastro-esophageal G-P-327 Bilge Akkelle, Turkey reflux: a multicenter cross-over study on G-P-410 Rodrigo Vazquez-Frias, Mexico Gemma Pujol Muncunill, Spain efficacy and costs in infancy H.pylori infection may mimic coeliac CadiLAc study: bacillus clausii as an Validation of a new score for pediatric serology and morphology G-P-272 adjuvant therapy in acute community- Crohn´s disease on a pediatric tertiary Lok Hin Adrian Lee, Australia G-P-480 acquired diarrhoea among Latin hospital: the MINI- INDEX (bucosal Nelgin Gerenli, Turkey The impacts of reflux monitoring with American children inflammation non-invasive INDEX) combined multichannel intraluminal Is Helicobacter Pylori gastritis is a risk G-P-370 impedance and pH (MII-pH) testing G-P-416 factor for Hashimato’s Thyroditis? Gili Focht, Israel Laura María Palomino, Spain on clinical outcomes in children with G-P-487 gastroesophageal reflux disease (GORD) Development and validation of a pelvic Selective granulocyte-monocyte Kallirroi Kotilea, Belgium MRI-based pediatric perianal Crohn´s apheresis in paediatric ulcerative colitis. G-P-277 disease index- a report from the Report of 7 cases Efficacy and safety of bismuth based Cecilia Mantegazza, Italy imagekids study quadruple therapy for Helicobacter The role of gastroesophageal reflux G-P-438 pylori eradication in children: an interim Dominique Turck, France disease in non cystic fibrosis paediatric analysis

Poster bronchiectasis and the efficacy of a HRCT Physical activity is associated with G-P-489 Exhibition score to predict reflux: a case-control improved bone health in children with Cam Tu Nguyen, Belgium study inflammatory bowel disease Frequency of heteroresistance of Helicobacter pyloristrains infecting children

90 ESPGHAN 52nd Annual Meeting www.espghancongress.org 91 Hepatology 009 – 136 Posters selected for Poster Walk Posters selected for Poster Walk Hepatology 141 – 196 · Nutrition 005 – 028

Hepatology Session 10 Session 11 Nutrition Chairs: Sara Mancell, United Kingdom Chairs: Steffen Hartleif, Germany Emanuele Nicastro, Italy Session 9 Daniele Serranti, Italy Session 12 Chairs: Orith Waisbourd-Zinman, Israel H-P-079 H-P-141 Chairs: Jiri Bronsky, Czech Republic Victorien Wolters, Aditi Kumar, India Natalia Wasilewska, Poland Nurul Husna Mohd Shukri, Malaysia The Netherlands Non invasive prediction of varices in Serum concentration of fatty acids in N-P-005 children with portal hypertension: obese children with nonalcoholic fatty H-P-009 Elizabeth Carpenter, New Zealand is splenic stiffness by shear wave liver disease Kishwer Kumar, Saudi Arabia elastography the answer? Exploring the link between the skin and H-P-156 Long term disease free survival after gut in allergy Daniela Liccardo, Italy treating PFIC-2 recurrence with modified H-P-081 Noemie Laverdure, Canada N-P-007 protocol of Plasmapharesis, Intravenous Multi-drug resistant germs in pediatric Federica Giachero, Germany Immunoglobulin, Rituximab and immune Liver stiffness measurement by transient liver transplantation: prevention, suppression modification elastography, a marker of hepatic venous treatment strategies and outcomes from MicroRNAs in breast milk: a possible congestion in children after Fontan a prospective single center study vector for species-specific maturation H-P-017 procedure signals Georg-Friedrich Vogel, Austria H-P-178 Daniela Liccardo, Italy N-P-013 Understanding and salvaging hepatocyte H-P-101 Line Modin, United Kingdom Emma M. Savilahti, Finland ER-stress in Wolcott-Rallison syndrome Identification of risk factors for late associated acute liver failure Single center experience with Budd- graft fibrosis and application of the liver Daily lactose intake in children with Chiari syndrome at Birmingham children’s allograft fibrosis score in pediatric liver lactase non-persistent genotype is H-P-031 hospital transplantation associated with greater abundance of Kimberley J. Brook, New Zealand Bifidobacteria in the gut compared to H-P-183 Ultrasound-guided percutaneous liver H-P-106 low-lactose diet or lactase persistence Gema Muñoz Bartolo, Spain Line Modin, United Kingdom biopsy is a safe procedure in children: a N-P-016 retrospective review of practice The study of children with a suspicion of Renal dysfunction after paediatric Soheil Varasteh, The Netherlands Wilson disease intestinal transplantation H-P-038 Human milk oligosaccharide Aurelie Comte, France H-P-184 H-P-112 3’-galactosyllactose can protect the Isabel Pinto Pais, Portugal Line Modin, United Kingdom Prevalence of autoimmune hepatitis intestinal barrier to challenges in APECED, a nationwide multicenter Application of a NGS MultiGene panel in Diverse outcome of liver transplantation N-P-019 descriptive study Biliary Atresia: preliminary results in children with Niemann-Pick Disease type C cannot be predicted by mutation Tatiana Bushueva, Russia H-P-039 H-P-126 analysis The nutritional value of lactose free diets Eduardo Couchonnal, France Moinak Sen Sarma, India in infants with classical galactosaemia H-P-196 Wilson disease: the French paediatric Poor outcome of hyponatremia in compared with healthy brestfed babies Sunitha Vimalesvaran, United Kingdom cohort cirrhotics: correlation with plasma renin N-P-028 activity. Prospective longitudinal study Allograft histology and biopsychosocial H-P-051 health 10 years after liver Xiaopan Chang, China Angelo Di Giorgio, Italy H-P-136 transplantation in children Extensively hydrolysed formula reduces Margarita Maria Suarez Galvis, Spain Poster

Bile ducts involvement in paediatric auto­ the preoperative nutritional risk in Exhibition immune liver disease: a challenging matter Features of biliary lithiasis in a paediatric Hirschsprung’s disease

hepatology department H-P-063 Winita Hardikar, Australia

Early onset cholestatic liver disease associated with novel biallelic ERCC1 variants

92 ESPGHAN 52nd Annual Meeting www.espghancongress.org 93 Nutrition 064 – 168 Posters selected for Poster Walk Posters selected for Poster Walk Nutrition 170 – 186

Session 13 Session 14 Session 15 Chairs: Tena Niseteo, Croatia Chairs: Andrew Barclay, United Kingdom Chairs: Jutta Koeglmeier, United Kingdom Sissel Moltu, Norway Delphine Ley, France Nathalie Rock, Switzerland

N-P-064 N-P-130 N-P-170 Alex Moretti, Italy Srinivas Murki, India Yoo Min Lee, Republic of Korea Test and validation of the Cow’s Milk- Enablers for ‘enteral feeding with Nutrition day survey on nutritional status related Symptom Score (CoMiSS®) in a exclusive mother own milk at hospital of hospitalized children in Korea population of symptomatic and healthy discharge’ in preterm very low birth N-P-176 infants weight infants Jie Shao, China N-P-065 N-P-141 Outcome of growth pattern and Sjoerd C. J. Nagelkerke, The Netherlands Janna A. van Diepen, The Netherlands neurodevelopment in premature infants Standardized versus individualized Brain lipidome from milk fat globule in one-year old post- discharge parenteral nutrition mixtures in a membrane supplemented rodents N-P-177 paediatric home parenteral nutrition parallels changes in plasma lipid patterns Tali Sinai, Israel population N-P-149 Decline in age at menarche and Akshay Batra, United Kingdom N-P-080 associations with nutritional status: results Ghada Said, United Kingdom Paediatric e-BANS: establishing a national from two representative national surveys Intestinal failure associated liver disease database of children requiring home of Israeli adolescents, 2003 to 2016 in patients receiving home parenteral parenteral nutrition (HPN) in England N-P-178 nutrition: experience from a large N-P-152 Norbert Sprenger, Switzerland tertiary Referral Hospital in United Cristina Campoy, Spain Kingdom HMO stimulated bifidobacteria contribute Effects of maternal gestational diabetes to risk reduction for lower respiratory N-P-100 and sustained attention in the offspring tract illnesses with a 2-HMO containing Reeta Bora, India at 6 years old infant formula through protective effects Efficacy of oral sugar in management of on mucosal barrier function N-P-159 neonatal hypoglycaemia in small for date Laura Flannagan, United Kingdom N-P-182 neonates is comparable to intravenous Yvan Vandenplas, Belgium sugar in resource poor setting A retrospective case review of a structured dietetic intervention in infants The cow’s milk-related symptoms score N-P-102 with hypoplastic left heart syndrome (CoMiSS™): a useful tool in the clinical Cristina Campoy, Spain setting – results from an observational N-P-168 Long-term influence of a milk fat globule study Victoria Kuryaninova, Russia membrane (MFGM)-enriched formula N-P-186 on brain structure in healthy children at Level of vitamin D and proinflammatory Bartlomiej Mateusz Zalewski, Poland 6 years old cytokines in children born from mothers with carbohydrate metabolism disorders No effect of glucomannan on body N-P-117 weight reduction in children with

Jonas Hauser, Switzerland Poster overweight and obesity: a randomized Exhibition Availability of 6´SL in pre-weaning milk controlled trial influences caecal microbiota and plasma molecular phenotype in pre-weaning offspring

94 ESPGHAN 52nd Annual Meeting www.espghancongress.org 95 Gastroenterology 001 – 016 Posters Posters Gastroenterology 017 – 035

G-P-017 G-P-026 Posters Elif Gokce Basa, Turkey Ádám Diós , Hungary Evaluation of nutritional characteristics Investigation of binding properties and with mediterranean diet in coeliac patients kinetics of antibodies against deamidated gliadin peptides from coeliac and non- G-P-018 coeliac subjects Efrat Broide, Israel Gastroenterology Revealing the puzzle of adherence in G-P-027 pediatric patients with coeliac-disease Ester Donat, Spain Screening detected positive serology for G-P-019 Celiac Disease: a real clinical challenge BASIC AND/OR TRANSLATIONAL COELIAC DISEASE Andres Bodas- Pinedo, Spain SCIENCE Differences in the geographical distri­ G-P-028 G-P-009 bution of genotypes at risk in pediatric Hazel Duncan, United Kingdom G-P-001 Abdelhak Abkari, Morocco patients with coeliac disease (CD) in Spain Review following an introduction of You Clara Coppola, Italy Early infant feeding practices may Tube videos to provide education for G-P-020 Narrative medicine in gastrointestinal influence the onset of symptomatic newly diagnosed patients with Coeliac Filipa Briosa, Portugal diseases: a brand new approach coeliac disease Disease Oedemas in a teenager: an atypical G-P-004 G-P-011 coeliac disease and/or primary intestinal G-P-031 Mihriban Özsoy, Austria Souhaila Al-Khodor, Qatar lymphangiectasia? Nabil El-Lababidi, Czech Republic Expression of respiratory chain complexes Characterization of gut microbiota in Effect of gluten-free diet on growth and G-P-021 in the human intestinal epithelium in children with type 1 diabetes and coeliac anti-tissue transglutaminase antibody Tracey Cardigan, United Kingdom ageing disease levels in newly diagnosed coeliac children Outcomes of high dose of vitamin D in using the biopsy and non-biopsy pathways G-P-005 G-P-012 children with vitamin D deficiency and Alexander Potapov, Russia Wesam Al-Masri, Qatar coeliac disease G-P-032 Informativeness of immunological para­ High prevalence of micronutrient Jade Fokkens, The Netherlands G-P-022 meters in assessing of the efficacy of anti- deficiencies in patients with coeliac Short stature in coeliac disease: Gemma Castillejo, Spain TNF-α treatment (Infliximab) in children disease a tall problem with inflammatory bowel diseases (IBD) Prospective longitudinal study: use of G-P-013 fecal gluten immunogenic peptides to G-P-033 G-P-006 Pegah Amir Yazdani, Canada monitor children diagnosed with celiac Elisa Franceschini, Italy Christopher Stewart, United Kingdom A systematic review of disease-specific disease during transition to a gluten-free Screening of celiac disease: Developing preterm gut ex vivo co-culture quality of life questionnaires in children diet adherence to the ESPGHAN guidelines models to explore microbiome-host and adults with coeliac disease crosstalk in health and disease G-P-024 G-P-034 G-P-014 Mehmet Enes Coskun, Turkey Caterina Grosso, Italy G-P-007 Daniela Araújo, Portugal Performance of the proposed ESPGHAN Yield and costs of point-of-care screening Bálint Tél, Hungary Comparison between the percentage of score based diagnostic approach and test versus case finding to diagnose Azathioprine and mesalamine impair undiagnosed celiac disease children in possible contribution of bone mineral pediatric coeliac disease pancreatic ductal bicarbonate secretion ESPGHAN coeliac disease awareness day density value in mice 2018 manifest and in an European Region G-P-035 G-P-025 Alejandro Guouman, Argentina G-P-008 G-P-016 Luigina De Leo, Italy Epidemiological and genetic aspects in Intan Faizura Yeop, United Kingdom Josefa Barrio, Spain Poster

Prospective study on celiac disease 20 patients with Type 1 Diabetes and Exhibition Intestinal microbiota, its corresponding Cross-cultural adaptation to Euskera prevalence in children with severe food Celiac Disease short chain fatty acids and host immune language of the disease-specific, health allergy responses in children with Inflammatory related quality of life questionnaire Bowel Disease CDDUX for its use in coeliac children from the Basque Country

96 ESPGHAN 52nd Annual Meeting www.espghancongress.org 97 Gastroenterology 037 – 055 Posters Posters Gastroenterology 056 – 076

G-P-037 G-P-046 G-P-056 G-P-067 Anat Guz Mark, Israel Marina Stoyan, Russia Hadas Paz, Israel Naire Sansotta, Italy High rates of testing for coeliac disease Level of vitamins D, parathormone, bone Does short segment coeliac disease Trend of anti-tissue transglutaminase serology, and low rates of endoscopy in tissue metabolites in children with coeliac confined to the duodenal bulb have a normalization in celiac children on gluten- children and adults. Lessons from a large disease and bone fractures unique clinical, serological or histological free diet: a comparative study between real-world database profile? chemiluminescence and ELISA serum G-P-047 assays G-P-038 Sadhna Lal, India G-P-057 Omer Haber, Israel Spectrum of coeliac disease in children Olivia Portolese, Canada G-P-068 Hypertransaminasemia in newly diagnosed at a tertiary care centre in the coeliac belt Trends in the clinical presentation of celiac Eylem Sevinc, Turkey paediatric patients with coeliac disease in of India disease at diagnosis in children in Quebec Reduced levels of circulating natural killer Israel cells in children with coeliac disease G-P-049 G-P-058 G-P-039 Rohan Malik, India Luigina De Leo, Italy G-P-069 Şamil Hızlı, Turkey Validation of an indigenous point-of-care Detection of anti-TG2 deposits in the Ajay Sharma, Australia Determination of duration and frequency test for celiac disease among children and myocardial tissue of a child affected by Diagnostic yield of isolated deamidated of medical follow up, dietary compliance adults in a tertiary hospital in North India dilated cardiomyopathy associated to gliadin peptide antibody for coeliac rates and assessment of the quality of life celiac disease disease in paediatric age group G-P-050 in celiac patients between 8-18 years of Roberta Mandile, Italy G-P-060 G-P-070 age in Ankara Quantitative histology of small intestinal Petra Rižnik, Slovenia Lyndsay Sinclair, United Kingdom G-P-040 mucosa: validation of morphometrical The impact of clinical presentation of Diagnosis of coeliac disease in the under Donatella Iorfida, Italy parameters in control, non-celiac children coeliac disease on diagnostic delays in 2 year olds since the advent of serology Neurotensin: any clue in paediatric coeliac children in Central-Europe only diagnosis G-P-051 disease? María Angeles Martínez Ibeas, Spain G-P-062 G-P-071 G-P-042 Faecal calprotectin concentration in Yasin Sahin, Turkey Ketil Størdal, Norway Muhammad Rehan Khan, USA paediatric coeliac disease: correlation with The frequency of coeliac disease in siblings Maternal microchimerism in cord blood The utility of IgA based serologic markers clinical, serological and histopathological of coeliac patients and celiac disease in diagnosing celiac disease in children ≤ findings G-P-063 G-P-073 24 months of age G-P-053 Yasin Sahin, Turkey Caterina Strisciuglio, Italy G-P-043 Nazareth Martinon-Torres, Spain The frequency of coeliac disease in Celiac patients with low adherence Laura Kivelä, Finland Quantifyan the risk of overnutrition: children with chronic constipation to gluten free diet can have negative Coexisting type 1 diabetes and nutritional status in coeliac disease at serology, but their nutritional status is G-P-064 experiences of gluten-free diet are diagnosis and after a five year follow-up impaired Bilge Sahin Akkelle, Turkey associated with long-term dietary in a tertiary hospital Presentation of coeliac disease diagnosed G-P-074 adherence in paediatric coeliac disease G-P-054 by screening in children with type 1 Chiara Maria Trovato, Italy G-P-044 Lucy McDermott, United Kingdom diabetes: is it different? Growth assessment and eating habits in Vinod Kolimarala, United Kingdom A dietetic-led coeliac clinic patient service children with coeliac disease G-P-065 Outcomes of children with borderline tTG review in a tertiary paediatric centre Virginia Michela Salvati, Italy G-P-075 in Hampshire G-P-055 The EMA biopsy is a highly sensitive and Raquel Vecino López, Spain G-P-045 Cong Minh Tam Nguyen, Canada specific test for celiac disease diagnosis Coeliac disease in children with selective Poster Poster

Maciej Kołodziej, Poland Validation of the ESPGHAN guidelines immunoglobulin A deficiency: do we know Exhibition G-P-066 Association between early life (prenatal for the diagnosis of coeliac disease in a how to diagnose? Maria Camila Sanchez, Argentina and postnatal) antibiotic administration Canadian population Impact of associated diseases on quality G-P-076 and celiac disease. A systematic review of life of children with coeliac disease: Raquel Vecino López, Spain a multicenter study in Argentina Utility of serology in the follow-up of coeliac children with selective immunoglobulin A deficiency

98 ESPGHAN 52nd Annual Meeting www.espghancongress.org 99 Gastroenterology 078 – 098 Posters Posters Gastroenterology 102 – 123

G-P-078 G-P-087 G-P-102 G-P-112 Anil Verma, Italy Marta Garcia Quijada, Spain Sinan Sari, Turkey Estefanía Carrión-Jaramillo, Ecuador Distribution of HLA-DQ2 and HLA-DQ8 Study of hepatic fibrosis in children Pancreatitis in Turkish children: Endoscopic balloon dilatation for alleles in native South Indian population with liver disease associated with cystic A single center experience treatment of congenital antral web fibrosis using a non-invasive technique: G-P-079 G-P-103 G-P-113 quantitative elastography type ARFI Radim Vyhnánek, Czech Republic Venkatesh Vybhav, India Busara Charoenwat, Thailand Adherence to the gluten-free diet of G-P-088 Spectrum of paediatric pancreatitis in a Cap-assisted colonoscopy in pediatric children with coeliac disease assessed by Panagiota Kafritsa, Greece tertiary care centre of North India population measuring gluten-related immunogenic Silmutanous resolution of two pancreatic G-P-104 G-P-114 peptides: pilot study pseudocysts by endoscopic cyst Sabina Wiecek, Poland Marco Deganello Saccomani, Italy gastrostomy in hereditary pancreatitis G-P-080 Evaluation of the selected parameters of The current status of paediatric endoscopy Mozhgan Zahmatkeshan, Iran G-P-089 liver fibrosis and inflammation in patients in Italy: a national survey Prevalence of coeliac disease in infertile Adnaan Kala, United Kingdom with cystic fibrosis G-P-115 women PRSS1 pancreatitis presenting as pleural Marco Deganello Saccomani, Italy effusion with mediastinal shift Endoscopic management of esophageal ENDOSCOPY G-P-090 stenosis in patients with congenital CYSTIC FIBROSIS AND PANCREATIC Sadhna Lal, India G-P-105 esophageal atresia: the experience of our DISORDERS Paediatric acute pancreatitis: clinical Ulas Emre Akbulut, Turkey center G-P-081 profile and natural history of collections A comparison of sedation with midazolam- G-P-116 Victor Aguiriano-Moser, Austria ketamine versus propofol-fentanyl during G-P-092 Christopher Eke, South Africa Correlations between bile acid values colonoscopy in children Julie Lemale, France Medical gastrointestinal endoscopy in and biomarkers of coagulation and Acute pancreatitis secondary to G-P-106 children: experience in red cross war inflammation in cystic fibrosis liver disease hypertriglyceridemia in children: Patcharin Amornvipas, Thailand memorial children´s hospital G-P-082 a rare cause to discuss Endoscopic balloon dilatation in a child G-P-117 Susana Almeida, Portugal with pyloric stricture post corrosive agent G-P-093 Simona Faraci, Italy Hereditary pancreatitis in children: three Rohan Malik, India G-P-108 Safety and feasibility of endoscopic clinical cases, three different mutations Autoimmune pancreatitis presenting Tal Berger, Israel management of anastomotic biliary G-P-083 as a pancreatic head mass in a 5 year The yield of upper gastrointestinal endo­ stricture after ortho-topic liver transplant Omer Faruk Beser, Turkey old boy scopy in a paediatric tertiary care center in children: a preliminary experience Evaluation and follow-up of nutritional G-P-094 G-P-109 G-P-118 status in children with cystic fibrosis Thi Viet Ha Nguyen, Vietnam Ilse Broekaert, Germany Sergio Fernández, Mexico G-P-084 Evaluation of treatment efficacy for acute Single center results of 400 diagnostic Arginine-induced esophagitis in children Liron Birimberg-Schwartz, Canada pancreatitis in children at the national esophagogastroduodenoscopies in and adolescents: A case series Management of acute pancreatitis in children’s hospital, Vietnam children and adolescents G-P-119 children: a single center experience G-P-095 G-P-110 Douglas S. Fishman, USA G-P-085 Jan Krzysztof Nowak, Poland Jan Stanisław Bukowski, Poland Early presentation in Peutz-Jeghers Constanza Beatriz Camargo Santacruz, Serum myoglobin is elevated in cystic Endoscopic stenting of grade III pancreatic Syndrome: a single-center study Colombia fibrosis: a cross-sectional study injury in children: a systematic review of G-P-120 Poster

The challenge of diagnosing cystic fibrosis case reports and case series Exhibition G-P-098 Ayesha Girach, United Kingdom in a Colombian hospital Grzegorz Oracz, Poland G-P-111 Anastomotic ulcers: a tertiary centre Chronic pancreatitis associated with toxic- Otto Gerardo Calderón Guerrero, Colombia experience of novel endoscopic techniques metabolic risk factors in large pediatric Sociodemographic, endoscopic and G-P-123 cohort histological characterization of paediatric Prevost Jantchou, Canada patients with intestinal metaplasia in a Worldwide survey of current digestive pediatric gastroenterology service in Cali, endoscopy practice in children Colombia

100 ESPGHAN 52nd Annual Meeting www.espghancongress.org 101 Gastroenterology 124 – 145 Posters Posters Gastroenterology 147 – 167

G-P-124 G-P-136 G-P-147 ENTEROPATHY Sinem Kahveci Celik, Turkey Oleana Belei, Romania Chantal A. ten Kate, The Netherlands (OTHER THAN COELIAC DISEASE) Endoscopic management of Peutz-Jeghers Are intra-gastric adjustable balloon system Management of anastomotic strictures G-P-156 syndrome in children from western part of safe?-case presentation after oesophageal atresia repair: results of Renata Auricchio, Italy Turkey a global survey G-P-137 Non-coeliac villous atrophy in children: G-P-125 Eva Ott-Chouki, France G-P-148 clinical and immunohistochemical features Adnaan Kala, United Kingdom Sedation for diagnostic gastrointestinal Filippo Torroni, Italy G-P-158 Soft vs normal diet during bowel endoscopy in children: a prospective Usefull of capsule endoscopy in surgical Elena Cernat, United Kingdom preparation prior to paediatric colonoscopy french study decision Renal tubular acidosis associated with G-P-126 G-P-138 G-P-149 microvillus Inclusion disease Jaswinder Kaur, India Rosalind Rabone, United Kingdom Luz Esthella Tovar Correa, Mexico G-P-159 Percutaneous endoscopic gastrostomy in Annual endoscopy re-audit in a tertiary Endoscopic management of gastro­ Yulia Dmitrieva, Russia children: a single centre experience! paediatric endoscopy service to facilitate intestinal bleeding (GIB) with hemostatic Gastrointestinal manifestations of immune quality improvement powder. Experience in a tertiary paediatric G-P-128 dysregulation, polyendocrinopathy, referral hospital Ezgi Kiran Tasci, Turkey G-P-140 enteropathy, X-linked (IPEX) syndrome: Does bile reflux decrease Helicobacter Gillian Rivlin, United Kingdom G-P-150 single center experience pylori gastritis? Lactulose: a well-tolerated and effective Luz Esthella Tovar Correa, Mexico G-P-160 contrast agent for magnetic resonance Associated factors with gastrointestinal G-P-129 Maja Klaudel-Dreszler, Poland enterography bleeding secondary to graft-versus-host Martin W. Laass, Germany Tricho-hepato-enteric syndrome – a series disease in children of the instituto Foreign body ingestion in children – G-P-141 of 2 children with different severity of nacional de pediatria from January 2010 a 15-year retrospective analysis from a Erminia Francesca Romeo, Italy clinical course to January 2017 single academic center Small bowel capsule endoscopy retention G-P-161 and clinical outcomes G-P-151 G-P-130 Ken-Ichiro Konishi, Japan Dan Turner, Israel Mounia Lakhdar Idrissi, Morocco G-P-142 Genetic features of congenital chloride Pediatric gastrointestinal endoscopy: Stent placement in oesophageal stenosis Michal Rozenfeld Bar Lev, Israel diarrhea: a nationwide survey in Japan diagnostic yield and appropriateness of in children Upper endoscopy in morbid obese children referral based on clinical presentation G-P-162 prior to bariatric surgery in a single G-P-132 Günsel Kutluk, Turkey tertiary pediatric center G-P-152 Thomas Mårtensson, Sweden CHAPLE Syndrome: CD55 deficiency, early- Nuray Uslu Kızılkan, Turkey Histopathology based gastrointestinal G-P-143 onset protein-losing enteropathy, and Succesful endoscopic balloon dilatation of GVHD diagnosis - the influence of Elif Sag, Turkey thrombosis gastric output obstruction after corrosive interobserver disagreement Endoscopic findings of children with gastric injury G-P-163 severe anemia G-P-133 Inna Larkova, Russia G-P-153 Neil McConnell, United Kingdom G-P-144 The multi-strain probiotic in children with Els Van de Vijver, Belgium Real world completion rates of capsule César Sanchez, Spain gastrointestinal food allergy Decision rules for the use of endoscopy endoscopy studies in children Endoscopic dilation with a secondary in chronic abdominal pain and non-bloody G-P-165 duodenal stenosis balloon to an intestinal G-P-134 diarrhoea: prospective validation Silvia Saottini, Italy lymphoma in a patient with a heart Andreia Florina Nita, United Kingdom Clinical features, response to treatment transplant G-P-155 Endoscopic retrieval of doll trichobezoar and evolution of eosinophilic gastro­ Poster

Dotan Yogev, Israel Exhibition and unexpected complications G-P-145 enteropathy in a paediatric cohort Hijab pin ingestion: conservative Camila Sanchez, Argentina G-P-135 management of a unique foreign body G-P-167 Clinical outcome of children with Lorenzo Norsa, Italy Natalia Zvonkova, Russia gastrointestinal and liver acute graft Scoring endoscopy in pediatric Protein-losing enteropathy in cardiologic versus host disease after bone marrow inflammatory bowel disease: a way children transplantation in a single center in to improve quality Argentina

102 ESPGHAN 52nd Annual Meeting www.espghancongress.org 103 Gastroenterology 168 – 188 Posters Posters Gastroenterology 189 – 208

EOSINOPHILIC ESOPHAGITIS GASTROENTEROLOGY OTHER G-P-189 G-P-197 Amir Ben Tov, Israel Svetlana Denisova, Russia G-P-168 G-P-180 Adoption of paediatric gastroenterology Biochemical markers of the functional Sita Tarini Clark, New Zealand Shokoufeh Ahmadipour, Iran societal guidelines regarding coeliac condition of neonatal gut microbiome Eosinophilic esophagitis - audit of Prognosis and treatment of allergic disease and helicobacter pylori infection practice since establishment of combined proctocolitis in infants; according feeding G-P-199 among general paediatricians gastroenterology/immunology paediatric Valentina Discepolo, USA G-P-181 clinic and introduction of a new joint G-P-190 Training in paediatric gastroenterology: Inês Aires Martins, Portugal management protocol Navya Bezawada, United Kingdom a survey among italian trainees Infantile colic: episodic syndrome that Autism spectrum disorder and the gut G-P-169 may be associated with migraine? G-P-200 microbiota in children: a systematic review Odul Egritas Gurkan, Turkey Elizabeth Griffiths, United Kingdom G-P-182 Eosinophilic esophagitis might be the first G-P-191 Lysosomal acid lipase deficiency Ahmed AlSalem, Saudi Arabia finding of eosinophilic gastrointestinal Carolin Sigrid Blueml, Germany presenting as apparent GORD and Congenital pyloric atresia: the spectrum system disorders Collagenous gastritis and colitis – a rare faltering growth G-P-183 clinical entity in children G-P-170 G-P-203 Alfiia Aminova, Russia Buket Dalgıç, Turkey G-P-192 Jooyoung Jang, Republic of Korea Factor analysis in pediatric gastro­­ The characteristics of Turkish children with Christopher J. Burgess, United Kingdom IgE patterns to common food allergens in enterology eosinophilic esophagitis Rectal bleeding in children – predictors younger infant with allergic proctocolitis G-P-184 of organic pathology during endoscopic G-P-172 G-P-204 Mirna Natalija Anicic, Croatia assessment: a regional cohort study Diana Marcela Montoya Villa, Spain Mizu Jiang, China Protein losing enteropathy-extremely Oral salbutamol therapy for food G-P-193 Analysis of risk factors and development rare presentation of Langerhans cell impaction in patients with Eosinophilic Tomislav Caleta, Croatia of scoring system to predict severity of histiocytosis Esophagitis - An alternative to endoscopy? Short-term outcome of patients with upper gastrointestinal bleeding in children G-P-185 gastroschisis treated at the Clinical G-P-174 G-P-205 Katerina Bajerova, Czech Republic Hospital Center in Zagreb – a ten-year Amin J Roberts, New Zealand Muzal Kadim, Indonesia Cow´s milk-related symptoms scoring – review Eosinophilic Oesophagitis in New Zealand: Benefits of zinc, glutamine, fiber and values in healthy breastfed infants under 3-year prospective study G-P-194 prebiotics supplementation formula on 6 months of age Sanchari Chakravarty, India the growth and morbidity of children G-P-175 G-P-186 Impact of acidemia at birth on gut 1-3 years: analysis of intestinal mucosal James Taylor, United Kingdom Hany Banoub, United Kingdom circulation in term neonates integrity and nutrition absorption Adherence to biopsy guidelines in children Evaluation and treatment of gastro­ diagnosed with eosinophilic oesophagitis G-P-195 G-P-207 intestinal and nutritional complications Jeng Haw Cheng, United Kingdom Rosaura Leis, Spain G-P-176 in children with neurological impairment, Experience of gastro-jejunal tube Diagnosis of lactose malabsorption by James Taylor, United Kingdom a U.K. district general hospital model for placement in children intolerant to exhaled hydrogen test and polymorphism Incidence of eosinophilic oesophagitis in improvement gastrostomy feeding haplotypes C / T-13910 a UK paediatric population over a 10-year G-P-187 period G-P-196 G-P-208 Claudia Banzato, Italy Silvana Dadan, Colombia Rosaura Leis, Spain G-P-177 Food Protein Enterocolitis syndrome: 10 years’ experience in multidisciplinary Study of C / T-13910 polymorphism James Taylor, United Kingdom single tertiary care centre experience management of patients with food haplotypes in patients with suspected Eosinophilic oesophagitis frequency in Poster

G-P-188 allergies and its impact on the nutritional lactose intolerance. Can the genetic study Exhibition children undergoing upper gastrointestinal Catarina Barroso, Portugal status in an outpatient medical center of be the gold standard for its diagnosis? endoscopy Gastroenterological audit of the program paediatric gastroenterology, hepatology G-P-178 of thoracoscopic repair of esophageal and nutrition (gastronutriped) of Colombia Meltem Ugras, Turkey atresia by the ESPGHAN references Eosinophilic esophagitis and H pylori in children

104 ESPGHAN 52nd Annual Meeting www.espghancongress.org 105 Gastroenterology 209 – 233 Posters Posters Gastroenterology 235 – 258

G-P-209 G-P-222 GI MOTILITY, GERD AND FUNCTIONAL G-P-245 Maria Janelle Liwanag, Singapore Vilma Alexandra Salvador Medina, Ecuador GI DISORDERS Abdelhak Abkari, Morocco Cost analysis and healthcare resource Prevalence of eosinophilic digestive The gasel study: family impact, G-P-235 utilization in home parenteral nutrition diseases in Hospital de niños Dr. Roberto management, and overlap of functional Bhaswati Acharyya, India for paediatric chronic intestinal failure: Gilbert in Guayaquil-Ecuador gastrointestinal disorders in African Should all children with functional data from the early experience of a single- infants G-P-223 oesophagogastroduodenal symptoms be centre intestinal rehabilitation program in Moinak Sen Sarma, India evaluated for small intestinal bacterial G-P-247 Southeast Asia Gastrointestinal polyps and polyposis overgrowth? Omer Faruk Beser, Turkey G-P-211 syndromes in children Prevalence and clinical characteristics of G-P-236 Alex Moretti, Italy functional gastrointestinal disorders in G-P-224 Majid Aflatoonian, Iran Gastrointestinal symptoms after antibiotic infants Mubashir Hassan Shah, India Sleep disorder in children with functional treatment: risk and protective factors in Superior mesenteric artery Doppler on abdominal pain G-P-249 children first day of life in very low birth weight Florence Campeotto, France G-P-237 G-P-214 neonates and prediction of necrotizing Prevalence and management of functional Annalisa Alessandrella, Italy Suchandra Pande, United Kingdom enterocolitis; a prospective blinded cohort gastrointestinal disorders in French infants High resolution anorectal manometry in Drainage of a complex pancreatic pseudo­ study – the Rome study in France children with functional constipation with cyst with an endoscopic ultrasound-guided G-P-225 or without fecal incontinence G-P-251 metal stent Palittiya Sintusek, Thailand Isabel Casas Gallegos, Spain G-P-239 G-P-215 Intussusception in children: the value Breath test in children with gastro­ Mirna Natalija Anicic, Croatia Laura Paradiso, Italy of combined clinical presentation and intestinal diseases in primary care Functional gastrointestinal disorders in Utility of sIgE in the diagnostic work-up abdominal x-ray a tertiary hospital setting G-P-253 of cow’s milk allergy in a tertiary referral G-P-226 Silvana Dadan, Colombia centre G-P-240 Jose Carlos Salazar-Quero, Spain Improvement of digestive symptoms with Sun Hwan Bae, Republic of Korea G-P-217 Importance of speech and language a partially hydrolyzed serum, reduced Pelvic floor dysfunction in chronic Pierre Poinsot, Canada therapist in the treatment of oro­ lactose and Lactobacillus reuteri DSM constipated children Acute paediatric hypertrophic disease or pharyngeal dysphagia 17938 – based functional infant formula a benign type of Menetrier disease G-P-241 in infants younger than 5 months old with G-P-227 Simona Faraci, Italy infantile colic, in outpatient pediatric G-P-218 Andrea Vasconez, Ecuador Utility of a modified dysphagia score in centers of Bogota, Colombia Esra Polat, Turkey Food protein induced enterocolitis the diagnosis and the management of Heterotopic gastric mucosa in adolescent syndrome to quinoa – a usually safe food G-P-254 children with achalasia girl Lissa De la Vega Morales, Mexico G-P-229 G-P-242 A novel mutation TYMP gene causes G-P-219 Raquel Vecino López, Spain Marcin Banasiuk, Poland mitochondrial neurogastrointestinal Celeste Lidia Raguseo, Italy Prognostic value of the serial 3D high resolution manometry and balloon encephalopathy syndrome Evaluation of the intestinal microbiota of determination of plasma citrulline during expulsion test in diagnosis of dyssynergic pediatric patients in therapy with proton the intestinal rehabilitation process in G-P-258 defecation in children pump inhibitor children with intestinal failure due to short Tanja Fritz, Germany intestinal syndrome G-P-243 Assessment of whole gut motility in G-P-220 Anna M. Banc-Husu, USA children using the wireless motility Erica Rezende, Brazil G-P-233 High-resolution oesophageal manometry capsule test Poster

Caustic ingestion in childhood: still a Ting Zhang, China Exhibition to diagnosis achalasia in infants: problem in countries in development Safety of fecal microbiota transplantation a case series in Chinese single-center children: G-P-221 a retrospective analysis Elif Sag, Turkey Ileocolonic lymhonodular hyperpilasia in children

106 ESPGHAN 52nd Annual Meeting www.espghancongress.org 107 Gastroenterology 260 – 276 Posters Posters Gastroenterology 280 – 299

G-P-260 G-P-267 G-P-280 G-P-289 Tut Galai, Israel Karen Ignorosa Arellano, Mexico Kornilia Nikaki, United Kingdom Eylem Sevinc, Turkey Children with functional abdominal pain Main causes of dyspepsia in mexican Distal oesophageal mucosa innervation in The association of gastroesophageal disorders have higher prevalence of children and adolescents from a tertiary children: preliminary report reflux and chest pain in children with obesity hospital mitral valve prolapse G-P-281 G-P-261 G-P-268 Kornilia Nikaki, United Kingdom G-P-290 Frédéric Gottrand, France Mikki Ives, United Kingdom Rumination syndrome in children: a distinct Adam Smith, United Kingdom First year risk factors of mortality and Multidisciplinary assessment of paediatric diagnostic pattern during ambulatory reflux A meta-analysis to evaluate the effect morbidity in esophageal atresia with chronic refractory constipation monitoring with impedance pH-metry of feed thickeners and alginate-based tracheo-esophageal fistula: data from a products in infants with gastro- G-P-269 G-P-282 population-based national register oesophageal reflux Hyo-Jeong Jang, Republic of Korea Alicia Isabel Pascual Pérez, Spain G-P-262 National survey of management for Paediatric Intestinal Pseudo-obstruction: G-P-292 Azin Gouran, Iran functional constipation in Korean children The experience of a national reference Erin Cathrina Tayag-Lacsina, Philippines Evaluation of the effects of lactobacillus hospital The effectiveness of a constipation G-P-270 reuteri on children with recurrent pamphlet in improving outcomes among Muzal Kadim, Indonesia G-P-283 abdominal pain (RAP) paediatric patients with functional Factors affecting recurrent abdominal pain Ujjal Poddar, India constipation: a single blinded randomised G-P-263 in junior high school students in South Solitary Rectal Ulcer Syndrome (SRUS) in controlled trial Rafael Guerrero-Lozano, Colombia jakarta children: is it really uncommon? Water load test in school children with G-P-295 G-P-271 G-P-284 functional gastrointestinal disorders Erick M. Toro-Monjaraz, Mexico Charlotte Knatten, Norway Rebecca Poole, United Kingdom Safety of sucralfate suspension in children G-P-264 Outcome after Roux-En-Y used for The role of fundoplication in ameliorating aged 1 to 13 years with esophagitis and Johann Hammer, Austria antireflux and jejunal feeding purposes the need for transpyloric feeding in erosive gastropathy Development and validation of a test- children with gastroesophageal reflux G-P-273 specific perception questionnaire for disease and complex enteral nutritional G-P-297 Anna Liber, Poland the assessment of carbohydrate induced needs: a single centre experience Marinde van Lennep, The Netherlands Double-blind placebo-controlled trial of gastrointestinal symptoms during The Eckardt score in paediatric achalasia omeprazole in children with cystic fibrosis G-P-285 breath tests: the paediatric carboception patients: is assessing weight loss in the and gastroesophageal reflux disease Paolo Quitadamo, Italy questionnaire (PCCQ) developing child of added value? Influence of body positioning on G-P-274 G-P-265 gastroesophageal reflux in pediatric age G-P-298 Lina Lu, China Noora Helin, Finland Jojanneke van Summeren, Mutations of ACTG2 in 16 Chinese children G-P-287 The role of upper endoscopy in small The Netherlands with intestinal pseudo-obstruction Robyn Rexwinkel, The Netherlands children with undiagnosed gastrointestinal Physiotherapy for children with functional Diagnostic value of inflammatory or respiratory symptoms G-P-275 constipation: a pragmatic randomized parameters in the work-up of functional Thomas Ludwig, Singapore controlled trial in primary care G-P-266 abdominal pain Quantification of infant crying and fussing Michelle Higuera, Colombia G-P-299 by parental electronic diaries versus G-P-288 Alleviation of symptoms of uncomplicated Jojanneke van Summeren, The Netherlands automated machine based learning: Maddalena Riva, Italy gastroesophageal reflux in infants under Cost-effectiveness of physiotherapy an in-home observational study Abdominal migraine: epidemiology, 12 months old with a functional infant in childhood functional constipation: clinical features, response to therapy and formula based in partially hydrolyzed G-P-276 a pragmatic randomized controlled trial Poster

evolution in 44 children Exhibition serum protein thickened with potato Thomas Ludwig, Singapore in primary care starch and with added Lactobacillus Observational study shows high degree reuteri DSM 17938, in outpatient of inter-observer agreement for the paediatric centers of Colombia Brussels Infant and toddler stool scale for non-toilet trained children

108 ESPGHAN 52nd Annual Meeting www.espghancongress.org 109 Gastroenterology 300 – 318 Posters Posters Gastroenterology 319 – 338

G-P-300 GI-INFECTIONS G-P-319 G-P-329 Yvan Vandenplas, Belgium Smaragdi Fessatou, Greece Burcu Volkan, Turkey G-P-308 Safe use of fibers in infant anti- Faecal biomarkers in paediatric How frequent is acute pancreatitis due to Adel Al Shahrani, Saudi Arabia regurgitation formulas: compiled gastroenteritis versus inflammatory bowel rotavirus gastroenteritis in children? Infiltrating, quasi-cancerous rectal analysis of 4 clinical trials disease lesions: unique manifestation of visceral G-P-330 G-P-301 basidiobolus ranarum G-P-320 Yuhuan Wang, China Jon Vanderhoof, USA Sara Elisa Ortega-Alonzo, Mexico Cytomegalovirus colitis with intractable G-P-311 The value of breath test in the diagnosis Lactose restriction and dietary diarrhoea in immunocompetent infants Maria Victoria Bovo, Spain of fructose malabsorption as a cause of modification for the management of acute from a tertiary care center in China Role of Dientamoeba fragilis in recurrent abdominal pain in children diarrhea, a single-blinded study gastrointestinal symptoms in paediatric G-P-302 patients: a case – control study G-P-321 INFLAMMATORY BOWEL DISEASE Ilaria Venezia, Italy Carlos Ivan Oyervides-Garcia, Mexico G-P-312 Psycho-gastroenterological profile Lactose-free milk formula usefulness G-P-333 Fabiola Di Dato, Italy in paediatric outpatients affected by supplemented added with pectin and S Oluwafunmilayo Adeniyi, Nigeria Diarrhea in children with Plasmodium disorders of gut-brain interaction boulardii in chidren´s with not complicated Inflammatory bowel disease in African falciparum malaria: preliminary data of a acute gastroenteritis (LFPS) children: experience and challenges in a G-P-303 case-control study tertiary centre in Nigeria Raluca Maria Vlad, Romania G-P-322 G-P-313 Functional gastrointestinal disorders, up Marcos Perez, Philippines G-P-334 Anna Falszewska, Poland to date topic. Applying Rome iv criteria to Coddle study: bacillus clausii as an David Devadason, United Kingdom Accuracy of laboratory parameters in a Romanian cohort of young children adjunctive treatment of acute community- Performance of unrestricted faecal identifying dehydration in children with acquired diarrhoea in Filipino children calprotectin in paediatric inflammatory G-P-304 acute gastroenteritis: a systematic review bowel disease Mana H. Vriesman, The Netherlands G-P-323 G-P-314 Health related quality of life in childhood Marcos Perez, Philippines G-P-335 George Fowler, United Kingdom functional constipation: a systematic The probiotic bacillus clausii in the Marina Aloi, Italy Intestinal Spirochaetosis: an infectious review and meta-analysis prevention of antibiotic-associated Clinical outcomes of 2012 ECCO/ESPGHAN colitis with normal calprotectin diarrhoea in children: a pooled analysis guidelines in a large cohort of children G-P-305 G-P-315 of controlled clinical trials with ulcerative colitis Mana H. Vriesman, The Netherlands Steven Frese, USA Prevalence of child abuse in children with G-P-325 G-P-336 Gut barrier function is improved in infants functional constipation Kinga Cristina Slavescu, Romania Marina Aloi, Italy colonized by Bifidobacterium longum How big is the gap between guidelines and Quality of life and disease activity G-P-306 subsp. infantis EVC001 clinical practice in antimicrobial therapy? – in children and adolescents with Dae Yong Yi, Republic of Korea G-P-317 Gastrointestinal vs. respiratory infections inflammatory bowel disease The effects of proton pump inhibitor Alfredo Guarino, Italy therapy on small bowel bacterial G-P-326 G-P-337 Medical attitudes toward probiotics and overgrowth development in children as Luz Esthella Tovar Correa, Colombia Patrizia Alvisi, Italy antibiotics co-prescription in children assessed by fecal calprotectin Medical treatment to biliary ascariasis Abdominal surgery in pediatric Crohn living in Asian pacific region from January 2014 to December 2015 at disease: a real life experience of the Italian G-P-307 G-P-318 hospital infantil Napoleon Franco Pareja Society of Pediatric Gastroenterology, Marc Benninga, The Netherlands Cristina Oana Marginean, Romania Hepatology and Nutrition Functional gastrointestinal disorders and G-P-328 The role of TLR4 rs4986790 gene Poster behavioral problems in adolescents with a Alvaro Vega, Chile G-P-338 Exhibition polymorphism in determining Helicobacter history of infant colic Diagnostic performance of two oesophageal Gayane Amaryan, Armenia pylori gastritis in children tissue sampling techniques for etiological The frequency of MEFV gene mutations study of infectious esophagitis in children and familial mediterranean fever in with cancer Armenian children with inflammatory bowel disease

110 ESPGHAN 52nd Annual Meeting www.espghancongress.org 111 Gastroenterology 340 – 363 Posters Posters Gastroenterology 364 – 386

G-P-340 G-P-352 G-P-364 G-P-377 Amit Assa, Israel Daniela Knafelz, Italy Johanna Escher, The Netherlands Rumneek Hampal, United Kingdom Nutritional deficiencies in children with Observational study on transition care for Effect of cognitive behavioural therapy on Evaluation of clinical outcomes in a inflammatory bowel diseases young adults with inflammatory bowel clinical disease course in adolescents and prospective cohort of paediatric Crohn’s disease: results and perspectives young adults with inflammatory bowel disease patients receiving exclusive G-P-341 disease and subclinical anxiety and/or enteral nutrition – A single tertiary centre Hemant Bhavsar, United Kingdom G-P-355 depression: results of a randomised trial experience Exclusive enteral nutrition uptake rates in Chiara De Carlo, Italy treatment naive Crohn’s disease patient The role of anxiety, depression and G-P-365 G-P-378 catastrophizing in quality of life of Sylwia Fabiszewska, Poland Maryam Haneef, United Kingdom G-P-342 children with inflammatory bowel disease: Vedolizumab induction therapy after Surgical management of paediatric Kriszta Katinka Boros, Hungary a prospective multi-centre study failure of TNF-alfa antagonists in children inflammatory bowel disease in the era Characteristics and followup­ on body of biological therapy - a single centre composition, physical activity and G-P-357 G-P-366 experience quality of life in paediatric patients with Nazli Deveci, Turkey Sergio Fernández Oritz, Mexico inflammatory bowel disease Anti-inflammatory and anti-oxidant effects Nailfold videocApillaroscopy in juvenile G-P-380 of thiamine in dextran sulfate-induced Inflammatory boweL disease pilot Study. Rachel Harris, United Kingdom G-P-346 colitis in rats NAILS pilot study Utilising a steroid sparing tool in >200 Jeng Haw Cheng, United Kingdom paediatric IBD patients demonstrates low Incidence and outcome of surgical G-P-359 G-P-367 rates of steroid dependency compared to intervention in our paediatric crohn’s Anna Dilillo, Italy Smaragdi Fessatou, Greece adult practice patients over 5 years A new therapeutic approach: top down Faecal biomarkers in the diagnosis and vs step up in paediatric Crohn’s disease follow-up of children with inflammatory G-P-381 G-P-347 bowel disease Zuzana Havlíčeková, Slovakia Jeng Haw Cheng, United Kingdom G-P-360 Urinary concentration of 8-isoprostane A home infusion programme for Infliximab Theonymfi Doudouliaki, United Kingdom G-P-368 as marker of severity of paediatric (RemiCare) in paediatric Crohn’s patients is Experience and outcomes in Paediatric Aleksandra Filimoniuk, Poland inflammatory bowel disease feasible, safe and cost-saving Inflammatory Bowel Disease (pIBD) Lactosylceramide as a non-invasive marker on Vedolizumab with Biomarker and in diagnosis of ulcerative colitis in children G-P-382 G-P-348 Therapeutic Drug Monitoring (TDM) – preliminary study James Guoxian Huang, Singapore Jie Chien, China Clinical differences at diagnosis between Lower efficacy and safety of infliximab G-P-361 G-P-369 South East Asian (SEA) children with very therapy in very early onset Crohn’s disease Hazel Duncan, United Kingdom Maria Teresa Fioretti, Italy early onset (VEO) inflammatory bowel Quality of life improvement following Predictors of outcome in children with G-P-349 disease (IBD) and non-VEO IBD completion of induction remission Crohn’s Crohn’s Disease Mu-Ming Chien, Taiwan disease via exclusive enteral nutrition G-P-383 The characteristics of ulcerative colitis of G-P-372 Takashi Ishige, Japan paediatric primary sclerosing cholangitis: G-P-362 Maria Julieta Gallo, Argentina Use and efficacy of enteral nutrition a single-centre study in Asia Mohammad El Mouzan, Saudi Arabia Inflammatory bowel disease in three as maintenance therapy for paediatric Diagnostic delay of paediatric inflamma­ pediatric centers in latin America: outcome G-P-350 Crohn’s disease: analysis of a Japanese tory bowel disease in Saudi-Arabia: of patients with early onset disease Lucia Cococcioni, United Kingdom nationwide registry a multicenter national study Safety and efficacy of ferric carboxymaltose G-P-374 G-P-385 [FCM] for the treatment of iron deficiency G-P-363 Ersin Gumus, Turkey Martyna Jasielska, Poland anaemia in paediatric patients affected by Johanna Escher, The Netherlands Children with very early-onset

Lactose intolerance in children with Poster

inflammatory bowel disease (pIBD) Health care transition outcomes inflammatory bowel disease: Exhibition inflammatory bowel diseases in inflammatory bowel disease: a tertiary centre experience G-P-351 an inter­national Delphi study G-P-386 Lucia Cococcioni, United Kingdom G-P-376 Adnaan Kala, United Kingdom Experience with therapeutic Drug Rumneek Hampal, United Kingdom Use of Vedolizumab in paediatric IBD: Moni­toring (TDM) on Infliximab (IFX) in Clinical outcomes in a prospective cohort experience in royal Manchester childrens Paediatric Inflammatory Bowel Disease of children with Crohn’s disease (CD) hospital (pIBD) commenced on anti-TNF therapy – A single tertiary centre experience

112 ESPGHAN 52nd Annual Meeting www.espghancongress.org 113 Gastroenterology 389 – 406 Posters Posters Gastroenterology 407 – 424

G-P-389 G-P-397 G-P-407 G-P-417 Hyun Jin Kim, Republic of Korea Paulina Krawiec, Poland Monika Meglicka, Poland Alicia Isabel Pascual Pérez, Spain Clinical characteristics of pediatric Crohn’s Clinical utility of hepcidin in diagnosis of Safety and efficacy of Budesonide MMX in Paradoxical cutaneous manifestations disease patients with perianal fistula: iron deficiency anaemia in children with children with ulcerative colitis associated to biological treatment in a single-center experience inflammatory bowel disease paediatric inflammatory bowel disease G-P-408 G-P-390 G-P-398 Annette Mulchay, United Kingdom G-P-418 Mijin Kim, Republic of Korea Paulina Krawiec, Poland Gamma Interferon based latent Julia Pazmandi, Austria Top-down strategy is superior to step-up Zonulin in children with newly diagnosed Tuberculosis testing prior to commencing Systems biology based analysis of early- strategy in deep remission in pediatric inflammatory bowel disease – a pilot study biologic treatment in children with IBD is onset and adult inflammatory bowel ulcerative colitis patients more cost-effective with risk based testing disease G-P-399 strategies G-P-391 Milena Krzyżanowska, Poland G-P-419 Aelita Kamalova, Russia Clostridium difficile in newly diagnosed G-P-409 Giacomo Perrone, Italy Evaluation of nutritional status and body children with inflammatory bowel disease: Katalin Müller, Hungary Endoscopic dilation in Crohn‘s disease composition in children with inflammatory carriage or infection Diagnostic work-up and frequency of strictures intestinal disease IBD-U in a nation-wide Hungarian Pediatric G-P-400 G-P-420 Inflammatory Bowel Disease Registry G-P-392 Sung Hee Lee, Republic of Korea Gemma Pujol Muncunill, Spain (HUPIR) Zoltan Kiss, Hungary Reclassification of Korean pediatric onset Surgery management of Crohn‘s disease Characteristics of the microbiome under inflammatory bowel disease using the G-P-411 in children: our experience biological theraphy in pediatric patients revised Porto criteria: a single-center Lorenzo Norsa, Italy G-P-421 with inflammatory bowel disease experience Congenital chloride diarrhea Rosalind Rabone, United Kingdom and inflammatory bowel disease: G-P-393 G-P-402 A case report on the role of exclusive an emerging association Daniela Knafelz, Italy Batia Weiss, Israel enteral nutrition and CDED as remission Chronic non-bacterial osteomyelitis and Longitudinal follow up of bone density G-P-412 maintenance in a severely atopic teen SAPHO as extraintestinal manifestation and anthropometry of children with Jane Oba, Brazil with Crohn’s disease of paediatric inflammatory bowel inflammatory bowel diseases Double balloon enteroscopy for decision G-P-422 disease (IBD), results from a national diagnosis and therapy in paediatric G-P-403 Gillian Rivlin, United Kingdom survey of the Italian Society of Paediatric Crohn´s disease and 10 years follow up Joana Lima, Portugal A single centre experience in the use of Gastroenterology Hepatology and Vitamin d deficiency and its association G-P-413 Vedolizumab in paediatric inflammatory Nutrition (SIGENP) IBD Group with clinical outcomes in children, Christine Olbjørn, Norway bowel disease G-P-394 adolescents and young adults with Combining biological agents in severe G-P-423 Michał Kolejwa, Poland inflammatory bowel disease paediatric inflammatory bowel disease, Marta Ruskań-Bakun, Poland The life quality assessment in IBD children an experience of fourteen cases G-P-404 Colonic fibrosis in paediatric ulcerative in regards the treatment method Svetlana Makarova, Russia G-P-414 colitis: histopathology characterisation G-P-395 The use of allergy–focused history Joyce Omatseye, United Kingdom at diagnosis and correlation with clinical Marta Kotkowicz-Szczur, Poland questionnaire allows to suspect cow´s Effects of nutritional status on the onset parameters The influence of children´s inflammatory milk allergy in children with inflammatory of liver abnormalities in children starting G-P-424 bowel disease (IBD) on the relationship bowel diseases methotrexate maintenance in IBD Bilge Sahin Akkelle, Turkey between parents and their married life G-P-406 G-P-415 The prevalence in coeliac related hla Poster Poster

G-P-396 Massimo Martinelli, Italy Marcin Osiecki, Poland haplotypes in paediatric IBD patients Exhibition Kinga Kowalska-Duplaga, Poland Post-induction Infliximab trough levels in The risk of cardio-vascular complications in Dependence of colonization of the large severe and moderate pediatric Ulcerative paediatric inflammatory bowel disesase intestine by Candida on the treatment of Colitis: preliminary data of a retrospective, Crohn’s disease population cohort-based study

114 ESPGHAN 52nd Annual Meeting www.espghancongress.org 115 Gastroenterology 425 – 443 Posters Posters Gastroenterology 444 – 466

G-P-425 G-P-434 G-P-444 G-P-457 Natasha Sasankan, United Kingdom Lewis Steell, United Kingdom Dan Turner, Israel Lin Wang, China Ferric carboxymaltose across all High-resolution MRI assessment of the Half of children with acute severe Long-term outcomes of thalidomide indications and ages in paediatric gastro­ muscle-fat-bone unit in young adults with colitis have predominant single fecal treatment for children and adolescents enterology shows efficacy without childhood onset Crohn´s disease bacterial species, mostly Escherichia coli: inflammatory bowel disease increased safety concerns microbiome results from the PRASCO trial G-P-435 G-P-458 G-P-426 Caterina Strisciuglio, Italy G-P-447 Batia Weiss, Israel Luca Scarallo, Italy Exclusive Enteral Nutrition therapy Joris J. van Ginkel, The Netherlands Mucosal healing with methotrexate Predictive factors for surgery in pediatric induces immunological tolerance in Crohn A 6-month period of concomitant versus azathioprine treatment in pediatric inflammatory bowel diseases: a national disease children: potential impact on immunomodulators is as effective as a Crohn´s disease patients referrall center experience immunometabolic asset and T regulatory 12-month period in the treatment of G-P-459 cells function pediatric inflammatory bowel disease with G-P-427 Thomas Whitby, United Kingdom Infliximab Rafeeq Muhammed, United Kingdom G-P-436 A retrospective review of tertiary Higher adalimumab drug levels during Zifei Tang, China G-P-450 management of paediatric crohn’s disease maintenance therapy for paediatric The cause and risks factors of death in Elsa A. van Wassenaer, The Netherlands G-P-460 Crohn’s disease are not associated with Chinese infantile-onset inflammatory Premedication with steroids does not Talya Wittmann Dayagi, Israel better endoscopic healing or biologic bowel disease patients with IL10RA gene influence the incidence of Infusion Characterisation of IL10 and IL10 receptor remission mutation Reactions after Infliximab Infusions in expression patterns in paediatric patients paediatric IBD patients – a retrospective G-P-429 G-P-437 with ulcerative colitis case-control study Rayna Shentova-Eneva, Bulgaria Christopher Todd, United Kingdom G-P-462 Risk factors for complicated disease in Thiopurine-induced hepatotoxicity in G-P-452 Yuan Xiao, China paediatric patients with crohn’s disease paediatric inflammatory bowel disease Angharad Vernon-Roberts, New Zealand Two cases of GSD Ib complicated with (IBD) patients A novel self-report symptom assessment G-P-430 Crohn-like colitis tool for children with inflammatory bowel Rayna Shentova-Eneva, Bulgaria G-P-440 disease: IBDnow G-P-463 Extraintestinal manifestations in Dan Turner, Israel Aijuan Xue, China paediatric patients with inflammatory The effect of nutritional therapy on bone G-P-453 Longitudinal development of intestinal bowel diseases mineral density and bone metabolism in Angharad Vernon-Roberts, New Zealand microbiome after haematopoietic stem pediatric Crohn’s disease Validation of a newly revised knowledge G-P-431 cell transplantation in IL10RA-deficient assessment tool for children with Engy Shokry, Germany G-P-441 patients inflammatory bowel disease: IBD-KID2 MTX and 5-ASA affect metabolic profiles Dan Turner, Israel G-P-464 of paediatric Crohn’s disease patients in A nationwide quality improvement G-P-454 Dilay Yerlioglu, United Kingdom remission program in children with Crohn´s disease Alejandro Víquez Víquez, Costa Rica Outcome of treat to target strategy in improves outcomes within 12 months Paediatric inflammatory bowel disease in G-P-432 paediatric patients with Crohn’s disease Costa Rica: a 15-year study Rotem Sigall Boneh, Israel G-P-442 and ulcerative colitis on Infliximab Dietary therapies induce rapid response Dan Turner, Israel G-P-455 G-P-465 and remission in active paediatric Crohn’s Diagnostic criteria for IBD subtype Burcu Volkan, Turkey Dilay Yerlioglu, United Kingdom disease classification: a multicenter validation Vitamin deficiencies in children with Outcome of treat to target strategy in cohort inflammatory bowel disease G-P-433 paediatric patients with Crohn’s disease Poster Poster

Yasmine Sobeih, Qatar G-P-443 G-P-456 and ulcerative colitis on Adalimumab Exhibition Screening and prevalence of iron Dan Turner, Israel David Wands, Australia G-P-466 deficiency anaemia in children with Prediction factors for low bone mineral Exclusive enteral nutrition in the Anat Yerushalmy-Feler, Israel inflammatory bowel disease density in children with Crohn’s disease management of paediatric Crohn’s Longitudinal follow up of body mass index disease: an Australian cohort as a predictor for severe disease course in children with inflammatory bowel disease

116 ESPGHAN 52nd Annual Meeting www.espghancongress.org 117 Gastroenterology 467 – 485 Posters Posters Gastroenterology 486 – 495

G-P-467 G-P-477 G-P-486 Anat Yerushalmy-Feler, Israel Otto Gerardo Calderon-Guerrero, Colombia Michal Kori, Israel Predictors for poor outcome of Paediatric H.pylori infection and is Helicobacter pylori infection and hospitalizations in children with relationship with low weight childhood overweight/obesity Inflammatory bowel disease G-P-478 G-P-488 G-P-469 Felicia Galos, Romania Thi Viet Ha Nguyen, Vietnam Joachim Zobel, Austria Correlation between bacterial culture Comparison of two different regimens Serum zinc concentration: a biomarker and histological findings in children with for eradication of H. pylori infection for mucosal inflammation in children with Helicobacter pylori gastritis in Vietnamese children: an opened, Crohn’s disease randomized clinical trial G-P-479 Felicia Galos, Romania G-P-491 Correlation between clinical and Yasin Sahin, Turkey PEPTIC DISEASE AND HELICOBACTER endoscopic aspects in children with Evaluation of the relationship between the PYLORI Helicobacter pylori gastritis severity of Helicobacter pylori infection G-P-470 and neutrophil and lymphocyte ratio and G-P-481 Maha Abouzekri, Egypt mean platelet volume Hacer Fulya Gülerman, Turkey Helicobacter pylori in children: prevalence, Comparison of histopathology and G-P-492 predictors and effect on growth PCR in the diagnosis of Helicobacter Luis Felipe Salcedo, Colombia G-P-472 pylori infection and determination Paediatric H.pylori infection and Derya Altay, Turkey of Helicobacter pylori sensitivity to contributing socioeconomic factors Is H.pylori infection a risk factor for clarithromycin and fluoroquinolone in the G-P-493 functional constipation? pediatric population in Kırıkkale, Turkey Tatevik Shahinyan, Armenia G-P-473 G-P-482 Effectiveness of Helicobacter pylori Sana Barakat, Egypt Hayriye Hizarcioglu-Gulsen, Turkey eradication standard triple therapy in Comparative study of H.pylori eradication Evaluation of ghrelin and leptin levels Armenian children with gastroduodenal rates of high and frequent dose of in sera and gastric tissues of paediatric disease and functional dyspepsia Omeprazole and Amoxicillin dual therapy patients with chronic gastritis G-P-494 versus standard triple therapy in children G-P-483 Nafiye Urganci, Turkey G-P-474 Mizu Jiang, China Assessment of bone metabolism and Josefa Barrio, Spain Helicobacter pylori infection alters gastric bone mineral density in children with Can the diagnosis of Helicobacter pylori and duodenal microbiotas of children Helicobacter pylori infection infection be improved by taking samples G-P-484 G-P-495 from stomach corpus in addition to those Nicolas Kalach, France Ying Zhou, China from the antrum? Systematic review and meta-analysis The efficacy and changes of gut microbiota G-P-475 of histological gastritis according to with 14-day bismuth quadruple therapy in Josefa Barrio, Spain the updated Sydney classification in penicillin allergic children Helicobacter pylori infection in a group of Helicobacter pylori positive and negative Spanish children children Poster Poster

G-P-476 G-P-485 Exhibition Gilad Ben-Yehudah, Israel Kotilea Kallirroi, Belgium Efficacy and safety of breath ID® Low efficacy of second line treatments for diagnostic for HP detection in children H. pylori eradication in children

118 ESPGHAN 52nd Annual Meeting www.espghancongress.org 119 Hepatology 001 – 019 Posters Posters Hepatology 020 – 043

GENERAL HEPATOLOGY H-P-030 Vishnu Biradar, India Hepatology H-P-020 Budd chiary syndrome in infants: Linnea Äärelä, Finland single centre experience of radiological First Scandinavian case of successful intervention from Western India BASIC AND/OR TRANSLATIONAL H-P-010 pregnancy during nitisinone treatment for SCIENCE Kishwer Kumar, Saudi Arabia tyrosinemia type 1 H-P-032 A diagnostic dilemma: Copper metabolism Yeliz Cagan Appak, Turkey H-P-001 H-P-021 in MDR3 deficiency causing false Renal-hepatic-pancreatic dysplasia: an Vibhor Borkar, India Hala Abdullatif, Egypt laboratory and clinical presentation ultrarare ciliopathy with a novel NPHP3 Porto-pulmonary hypertension in children Drug-Drug interactions in children resembling Wilson disease genotype with portal hypertension. Is routine and adolescents receiving Ledipasvir/ screening required? H-P-011 Sofosbuvir for treatment of Hepatitis C H-P-033 Yu-Cheng Lin, Taiwan virus infection Elif Sag, Turkey H-P-003 Therapeutic effects of lactobacillus Etiology and long-term outcome of Eduardo Couchonnal, France H-P-022 rhamnosus GG plus bifidobacterium lactis extrahepatic portal vein thrombosis in The influence of chelators on total blood Ulas Emre Akbulut, Turkey Bb12 and lactobacillus reuteri DSM 17938 children copper isotopic composition in Wilson‘s Evaluation of plasma microRNA on fatty liver in high-fat diet induced disease patients expressions in obese children with non- H-P-035 obese mice alcoholic fatty liver disease Jeng Haw Cheng, United Kingdom H-P-004 H-P-012 Single centre experience of congenital Miri Dotan, Israel H-P-023 Katharina Meinel, Austria portosystemic shunts The effect of bile acids on the sub-epithelial Rubaiyat Alam, Bangladesh Active paediatric inflammatory bowel layer of mouse extrahepatic bile ducts Association between severity of chronic H-P-036 disease: lack of secondary and taurine- liver disease with grading of oesophageal Jeng Haw Cheng, United Kingdom H-P-005 conjugated bile acids in serum varices in children Radiological management of a complex Paola Francalanci, Italy H-P-014 congenital porto-systemic shunt Progressive familial intrahepatic H-P-025 Onne Ronda, The Netherlands cholestasis: new pieces of the puzzle Monerah Alsaleh, Saudi Arabia H-P-037 Relationship between liver size and liver Arthrogryposis – renal dysfunction – Youngsun Cho, Republic of Korea H-P-006 function in mice cholestasis syndrome, single center The association of BMI and seropositivity Nelgin Gerenli, Turkey H-P-015 experience of hepatitis B antibody in children who Gilbert syndrome: testing or not? Is vaccinated in infancy with three doses of Ira Shah, India H-P-027 genetic testing is necessary? hepatitis B vaccine Hepatic interferon gamma and TNF Aline Azabdaftari, Germany H-P-007 alpha expression in infants with neonatal Homozygous DCDC2 splice site mutation H-P-040 Theresa Greimel, Austria cholestasis and cytomegalovirus infection causing neonatal sclerosing cholangitis Piotr Czubkowski, Poland Bile acids trigger coagulation activation H-P-016 Farnesoid X receptor deficiency causing potential in hepatocytes: a contributor to H-P-028 Eyal Shteyer, Israel progressive familial intrahepatic progression of paediatric cholestatic liver Mohamed Bar, Saudi Arabia Alginate biomaterial for stabilization after cholestasis diseases? Next generation sequencing reveals a hepatic injury in abdominal trauma homozygous ABCB4 gene mutation as a H-P-041 H-P-008 H-P-018 cause of cholestasis in a girl with coeliac Nedim Hadzic, United Kingdom Srikanth Kadyada Puttaiah, India Jie Wen, China disease and suspected autoimmune Epidemiology of biliary atresia in England Normal gamma-glutamy-transferase Sodium butyrate prevents liver injury and hepatitis vs Overlap syndrome and Wales (1999-2015) cholestasis, ABCD3 mutation; response to Poster fibrosis by promoting liver stem cell- Exhibition Rifampicin: is this a new PFIC? H-P-029 H-P-043 mediated repair and regeneration Ulrich Baumann, Germany Jemma Day, United Kingdom H-P-019 Effects of the ileal bile acid transport Barriers to medication adherence in Mozhgan Zahmatkeshan, Iran inhibitor A4250 on pruritus and serum individuals with chronic liver disease and The combined effect of recombinant bile acids in patients with biliary atresia: post-liver transplant: a comparison of human erythropoietin and human growth phase 2 study results those in paediatric and adult services factor on liver regeneration after partial hepatectomy in rats

120 ESPGHAN 52nd Annual Meeting www.espghancongress.org 121 Hepatology 045 – 067 Posters Posters Hepatology 068 – 089

H-P-045 H-P-059 H-P-068 H-P-080 Tim De Maayer, South Africa Lynette Goh, Singapore Eliška Hloušková, Czech Republic Nagendra Kumar, India Hepatic sinusoidal obstruction syndrome – Effect of peri-operative intravenous Autoimunne sclerosing cholangitis and Langerhans cell histiocytosis with report of a South African outbreak antibiotic use at Kasai portoenterostomy inflammatory bowel disease in children: sclerosing cholangitis in children: on cholangitis rates and outcomes in experience from single University centrum an entity for recognition H-P-046 children with biliary atresia at a single Anna Degtyareva, Russia H-P-071 H-P-082 centre Long-term outcome of the Kasai procedure Wojciech Jańczyk, Poland Usha Krishnan, Australia in children with biliary atresia H-P-060 Autoimmunity in children with Wilson’s Cholestatic jaundice in neonates: Theresa Greimel, Austria disease how common is biliary atresia? H-P-047 Revising the nomenclature of paediatric Experience at an Australian tertiary centre Adrian Delgado, Spain H-P-072 sclerosing cholangitis: results of an Prevalence of hepatobiliar disease Kamil Janowski, Poland H-P-083 international poll associated with cystic fibrosis in Quantitative MRCP imaging: preliminary Patryk Lipiński, Poland paediatrics H-P-061 observations in a cohort of paediatric Next-generation sequencing in diagnostic Ersin Gumus, Turkey patients with liver and biliary diseases approach to cholestatic liver disease – H-P-048 Tenofovir in the management of chronic one-centre experience Fabiola Di Dato, Italy H-P-073 hepatitis B infection in children: a single Wilson disease and metabolic syndrome: Kavitha Jayaprakash, United Kingdom H-P-084 center experience is there a link? Hepatitis C treatment in children optimism Zuzana Londt, United Kingdom H-P-062 justified Thiopurine drug monitoring in paediatric H-P-050 Patrick F. van Rheenen, The Netherlands patients with autoimmune liver disease Fabiola Di Dato, Italy H-P-074 Disease progression in paediatric patients Elastography in children with Biliary Norman Junge, Germany H-P-085 with sclerosing cholangitis: results from Atresia surviving with native liver Dubin-Johnson syndrome and neonatal Olha Lukianenko, Ukraine two independent Dutch registries cholestasis – single center experience for Liver and pancreatic stiffness in obese H-P-052 H-P-064 an ultra rare disease as cause for neonatal children Laura Di Michele, Italy Corina Hartman, Israel cholestasis High incidence of overlooked Metabolic H-P-086 Prevalence of elevated hepatocellular liver syndrome in subjects addressed to a liver H-P-075 Olha Lukianenko, Ukraine enzymes in obese/overweight pediatric steatosis and obesity clinic Aikaterini Kakotrichi, United Kingdom Liver and pancreatic ultrasound population in Israel Liver involvement in infants with attenuation coefficient in obese children H-P-054 H-P-065 hyperinsulinaemic hypoglycaemia Emilie Favre, France H-P-087 Paul Henderson, United Kingdom Neurocognitive phenotype of children H-P-076 Olha Lukianenko, Ukraine The epidemiology of conjugated with liver form of Wilson disease Yunkoo kang, Republic of Korea Quality of life and features of eating hyperbilirubinaemia in the first year of life: Validation of the baveno vi criteria to behavior in children with non-alcoholic H-P-056 a population-based cohort study identify low risk of biliary atresia patients fatty liver disease Diana García Tirado, Spain H-P-066 not requiring endoscopic surveillance for Endoscopic prophylaxis for upper digestive H-P-088 Paul Henderson, United Kingdom esophageal varix bleeding prevention in patients with portal Isobel Makin, United Kingdom The epidemiology of non-alcoholic fatty cavernoma H-P-077 Depression, anxiety and health related liver disease in children: a real world Simone Kathemann, Germany quality of life in paediatric non-alcoholic H-P-057 regional cohort study Is it autoimmune hepatitis or Wilson’s fatty liver disease; under-recognised and Muhammad Umer Ghafoor, United Kingdom H-P-067 disease – diagnostic dilemma in paediatric under-managed? Case reports about two patients with Poster

Kai O. Hensel, United Kingdom liver disease? Exhibition Abernethy malformation (congenital H-P-089 Outcome of sclerosing cholangitis in portosystemic shunts) H-P-078 Isobel Makin, United Kingdom paediatric inflammatory bowel disease: Denitza Kofinova, Bulgaria Systematic review of studies assessing H-P-058 do early diagnosis and treatment improve Non-invasive methods for assessment of the effect of psychological intervention Haytham Ghita, Egypt outcome? liver fibrosis in paediatric patients on clinical outcomes in patients with non- Secondary hepatic dysfunction in pediatric alcoholic fatty liver disease intensive care unit: a single center experience

122 ESPGHAN 52nd Annual Meeting www.espghancongress.org 123 Hepatology 090 – 109 Posters Posters Hepatology 110 – 132

H-P-090 H-P-099 H-P-110 H-P-122 Rohan Malik, India Valérie McLin, Switzerland Luting Peng, China Norberto Rodriguez-Baez, USA Autoimmune hepatitis in children: initial Portopulmonary hypertension in children – Clinical characteristics and influencing Wilson disease: a novel mutation in the experience from an Indian tertiary a severe complication of cirrhosis or porto­ factors of nonalcoholic fatty liver disease ATP7B gene pediatric centre systemic shunting in obese children and adolescents H-P-123 H-P-091 H-P-100 H-P-113 Elena Roslavtseva, Russia Rohan Malik, India Ajua Mensah, United Kingdom Prabhas Prasun Giri, India A case of wolman disease with two novel Balloon-occluded retrograde transvenous Improving engagement of young people Acute liver failure in children – a 10 year lipa gene mutations obliteration (BRTO) – an under-utilised with liver disease: the role of youth worker single center experience from India H-P-125 treatment option in children H-P-102 H-P-114 Srinivas Sankaranarayanan, India H-P-092 Hadar Moran-Lev, Israel Yi-Ling Qiu, China Has the time come to include molecular Claudia Mandato, Italy Predictors for fibrosis in obese pediatric Novel missense mutation in VPS33B genetics in the evaluation of cryptogenic/ Retrospective analysis of effects of fatty liver patients and the effect of low is associated with isolated low-GGT undiagnosed metabolic liver disease? lipoprotein levels on length of hospital carbohydrate diet on steatosis and fibrosis cholestasis: incomplete phenotype of H-P-127 stay in children with concurrent ARC syndrome H-P-103 Tatyana Sentsova, Russia hypertransaminasemia Gisela Silva, Portugal H-P-115 Polymorphic variants of the gene of H-P-094 Long term outcome of pediatric Bikrant Biharilal Raghuvanshi, India interferon lambda 3 and features of Karishma Manwani, United Kingdom autoimmune liver disease: current Transjugular liver biopsy is feasible and immune response in children with chronic Long-term linear growth in children and challenges and new directions safe in high risk children older than viral hepatitis C young people with autoimmune liver 5 years: largest pediatric experience H-P-104 H-P-129 disease treated with daily maintenance in 75 children Helen Mortimer, United Kingdom Gisela Silva, Portugal dose of prednisolone Is there a role for bioelectric impedance H-P-117 Gallstone disease in children: an evolving H-P-095 analysis in managing non-alcoholic fatty Eberhard Luz, Germany entity? Inez Martincevic, Canada liver disease? Sarcopenia as an independent outcome H-P-130 Early growth patterns of infants following marker in children with hepatoblastoma H-P-105 Christoph Slavetinsky, Germany Kasai portoenterostomy: QI update of Gema Muñoz Bartolo, Spain H-P-118 Impact of an ileal bile acid transporter single center standardized nutrition Severe citrin deficiency in a European Alessia Rizzo, Italy inhibitor versus partial external biliary protocol country Synchronous diagnosis of liver ALK- diversion in progressive familial H-P-096 positive histiocytosis and Cystic Fibrosis: intrahepatic cholestasis – a case providing H-P-107 Greta Mastrangelo, Italy an infant case direct comparison of medical and surgical Satoshi Nakano, Japan Oral N-acetyl-cysteine as a sulphur donor therapies Effect of food on pharmacokinetics and H-P-119 in a child with TRMU-associated liver therapeutic efficacy of 4-phenylbutyrate Nathalie Rock, Switzerland H-P-131 disease in progressive familial intrahepatic Contrast-enhanced echocardiogram for Min Ji Sohn, Republic of Korea H-P-097 cholestasis the detection of intrapulmonary shunts Molecular diagnosis of glycogen storage Lorenza Matarazzo, Italy in children with portal hypertension or disease type IX using GSD gene panel H-P-108 Hepatitis D in children: a long-term follow- portosystemic shunt Daniela Pacurar, Romania H-P-132 up Epidemiology of chronic hepatitis C in H-P-121 Vikrant Sood, India H-P-098 children – the experience of a paediatrics Lyan Hendrika Rodijk, The Netherlands Significance of hepatitis A virus related Poster Poster

Lorenza Matarazzo, Italy department Long-term neurodevelopmental outcomes pediatric liver disease burden and Exhibition Myelodysplastic syndrome in children with in children with biliary atresia its seroprevalence analysis in Indian H-P-109 autoimmune hepatitis subcontinent Martina Peluso, Italy Biochemical markers of copper metabolism in Wilson disease heterozygotes

124 ESPGHAN 52nd Annual Meeting www.espghancongress.org 125 Hepatology 133 – 153 Posters Posters Hepatology 154 – 172

H-P-133 H-P-144 H-P-154 H-P-164 Vikrant Sood, India Jung Min Yoon, Republic of Korea Sema Aydogdu, Turkey Charleen Gravenberch, The Netherlands Changing spectrum and predictors of Usefulness of transient elastography in Aplastic anemia insidence and manage­ Management of portal vein anastomotic severity of pediatric liver abscess in Indian pediatric nonalcoholic steatohepatitis ment in paediatric liver transplantations stenosis after paediatric liver trans­ subcontinent due to non A-E hepatitis plantation: evaluation of single centre H-P-146 experience H-P-134 Nataliya Zavhorodnia, Ukraine H-P-155 Vikrant Sood, India Assessment of liver stiffness and cytokine Zeren Barış, Turkey H-P-165 Pediatric Gilbert’s syndrome in Indian profile sex-specific differences in pediatric Evaluation of spleen volume with Orith Waisbourd-Zinman, Israel subcontinent - an analysis of 170 cases non-alcoholic fatty liver disease patients computed tomography after liver Biliary strictures in pediatric liver transplantation in pediatric recipients trans­plant recipients – a single center H-P-135 H-P-147 experience Eleanna Stasinou, Greece Nataliya Zavhorodnia, Ukraine H-P-157 Atherosclerosis risk and genetic variants Faecal short chain fatty acids in children Maciej Dadalski, Poland H-P-166 in adiponutrin gene in Greek children and with obesity and nonalcoholic fatty liver Basiliximab treatment for steroid and Christian Hudert, Germany adolescents disease anti-CD3 resistant rejection in paediatric Mycophenolate motefil monotherapy in patients after liver transplantation paediatric primary liver transplant patients H-P-137 H-P-148 Harry Sutton, United Kingdom Ting Ge, China H-P-158 H-P-167 A Scotland-wide analysis of children with Novel compound heterozygote mutations Lorenzo D‘Antiga, Italy Homin Huh, Republic of Korea autoimmune hepatitis: a retrospective of TJP2 in a Chinese child with progressive Long-term outcome of portal vein Risk factors of hepatopulmonary prevalence study cholestatic liver disease thrombosis after paediatric liver syndrome in children transplantation H-P-138 H-P-168 Richard J. Thompson, United Kingdom H-P-159 Vandana Jain, United Kingdom TRANSPLANTATION Development of patient- and observer- Ruth De Bruyne, Belgium Early transient elastography for prediction reported outcome measures for paediatric H-P-149 The presence of serum autoantibodies of clinical outcomes in Biliary Atresia post- cholestatic liver diseases Rayna Alamurova, United Kingdom and donor-specific anti-HLA antibodies Kasai Portoenterostomy: a pilot study A single center experience in using in pediatric liver transplant recipients is H-P-139 H-P-170 Sirolimus in paediatric liver transplant associated with histological and bio­ Sinan Sari, Turkey Diana Kamińska, Poland chemical parameters of graft dysfunction The liver disease and gene mutations of H-P-150 MBOAT7, PNPLA3 and TM6SF2 Alpha-1 Antitrypsin deficiency in Turkish Roberta Angelico, Italy H-P-160 polymorphism in liver donor and recipient children: a single center experience Early referral to transplant centers is a Lev Dorfman, Israel as potential modifiers of outcome in prognostic factor influencing outcomes ABO-incompatible paediatric liver children post liver related transplantation H-P-140 of pediatric liver transplantation transplantation: a single center experience – the preliminary study Nafiye Urganci, Turkey Rare complications of hepatitis A virus H-P-151 H-P-161 H-P-171 infection Cigdem Arikan, Turkey Paola Francalanci, Italy Sivaramakrishnan Venkatesh Karthik, Living donor liver transplantation for Vascular disorders: uncommon indications Singapore H-P-142 PFIC type 3 for liver transplantation in pediatric age Idiopathic post-transplant hepatitis, Ye Yang, China graft fibrosis and histological changes Discovery of an intronic long-interspersed- H-P-162 H-P-152 in long-term survivors after paediatric element 1 insertion in SLCO1B3 by next Songpon Getsuwan, Thailand Cigdem Arikan, Turkey liver transplantation – the Singapore generation sequencing Frequency, charecteristics and outcome Cognitive and behavioural issues in experience Poster

of Eosinophilic Eosophagitis and paediatric liver transplant recipients Exhibition H-P-143 gastrointestinal disease after liver H-P-172 May Yip, United Kingdom H-P-163 transplantation Yu Bin Kim, Republic of Korea Use of transcutaneous bilirubinometer Imeke Goldschmidt, Germany A comparison study: fulminant Wilson’s to determine the need for prolonged Factors associated with subclinical H-P-153 disease vs. acute liver failure in children jaundice screen Sergio Assia-Zamora, United Kingdom cardiovascular damage after pediatric Pancreatic tumours in children liver transplantation: a longitudinal observational study

126 ESPGHAN 52nd Annual Meeting www.espghancongress.org 127 Hepatology 173 – 193 Posters Posters Hepatology 194 – 199

H-P-173 H-P-182 H-P-194 Ezgi Kiran Tasci, Turkey Maria Mercadal-Hally, Spain Sharat Varma, India Evaluation of hepatitis B- antibody Food allergy in paediatric patients with Evaluation of new-onset acute diarrhoea titration loss after liver transplanstation liver transplantation after liver transplantation in children using in children nested PCR multiplex panel H-P-185 H-P-174 Kathryn Louise Mullany, Australia H-P-195 Kishwer Kumar, Saudi Arabia A tale of two patients: adverse effects Silvio Veraldi, Italy Familial hypercholanemia presenting of low dose oral glucocorticoids in two Status of vitamins A, E and D in paediatric with severe progressive intrahepatic paediatric liver transplant recipients patients pre and 1-year post liver cholestasis, secondary to homozygous transplant: a single center experience H-P-186 mutation of TJP2 and BAAT Natasha Su Lynn Ng, United Kingdom H-P-197 H-P-175 Paediatric liver transplantation for Muhammed Yuksel, Turkey Tobias Laue, Germany inherited metabolic disorders: experience The significance of panel reactive antibody Biomarkers for Immune function after from Leeds children’s hospital (PRA) positivity in graft rejection in liver transplantation in children and paediatric orthotopic liver transplantation H-P-188 adolescents with standard calcineurin Ioannis Roilidis, United Kingdom H-P-198 inhibitor-based versus reduced minimal Diagnosis and management of antibody Muhammed Yuksel, Turkey immunosuppression mediated rejection in paediatric liver Pretransplant low rate vaccination status H-P-176 transplantation of children with liver disease Christoph Leiskau, Germany H-P-189 H-P-199 Low dose steroids do make a difference Palittiya Sintusek, Thailand Mozhgan Zahmatkeshan, Iran - failure to thrive after pediatric liver Humoral and cellular response to standard Evaluation of correlation between serum Transplantation and double dose of hepatitis B vaccine in eosinophil count and acute cellular H-P-177 children after liver transplantation rejection in liver transplant recipient in Daniela Liccardo, Italy Namazi hospital during 2008-2016 H-P-190 The multidisciplinary management Palittiya Sintusek, Thailand and the early referral to a specialized Prevalence of hepatitis E infection in liver center improve outcomes after liver transplanted children: a single centre transplantation in children with metabolic experience disease H-P-191 H-P-179 Yildiz Tütüncü, Turkey Eberhard Lurz, Germany Does accelerated vaccination schedule Reference charts of total psoas muscle achieves same seroconversion rate as area in children (tPMA) conventional schedule in infants with H-P-180 chronic liver disease? Maciej Dadalski, Poland H-P-192 Problems with antibody mediated Sharat Varma, India rejection after pediatric liver 3 year follow up after liver transplantation transplantation Poster

for mitochondrial depletion syndrome Exhibition H-P-181 associated with MPV17 mutation Maria Mercadal-Hally, Spain H-P-193 Endovascular treatment of early throm­ Sharat Varma, India bosis of the hepatic artery in paediatric Significance of intrapulmonary vascular patients with liver trans­plantation dilatations in paediatric candidates for liver transplant

128 ESPGHAN 52nd Annual Meeting www.espghancongress.org 129 Nutrition 001 – 023 Posters Posters Nutrition 024 – 042

of home parenteral nutrition (HPN) with Nutrition N-P-024 Elvira Cañedo Villarroya, Spain use of third generation, intravenous lipid Ketogenic diet during the first year of life. emulsion Experience in a tertiary reference hospital N-P-034 BASIC AND/OR TRANSLATIONAL N-P-011 Hazel Duncan, United Kingdom SCIENCE Maria Ramirez, Spain N-P-025 An audit and service review following the Synergistic activity of 2’-fucosyllactose Elena Cernat, United Kingdom N-P-001 introduction of a dietetic phone clinic with a blend of lutein and natural vitamin Is bowel lengthening a step towards Betül Aksoy, Turkey E on intestinal microbiota modulation enteral autonomy? N-P-035 Effects of breastfeeding on growth in Hazel Duncan, United Kingdom preschool children from west region of N-P-012 N-P-026 Blended diet use across Scotland with cost Turkey Krista Salli, Finland Charmaine Chai, United Kingdom savings on standard dietetic management 2’-Fucossyllactose fermentation in an Review of weaning strategies in short N-P-002 infant gut simulator model bowel syndrome intestinal failure patients N-P-036 Cristina Campoy, Spain in a single centre Claire Dupont-Lucas, France Gut microbiota is associated with the N-P-014 Predictive formulas overestimate resting infant cognitive development Nataliya Shilina, Russia N-P-027 energy expenditure compared to indirect Mothers´ BMI influence on physical Charmaine Chai, United Kingdom N-P-003 calorimetry, in teenage girls hospitalized development of infants genetically 5-year outcome of children with short Roberto Berni Canani, Italy for anorexia nervosa predisposed to obesity bowel syndrome(SBS) related intestinal Comparative evaluation of tolerogenic failure (IF) from infancy and dependent N-P-037 action elicited by protein fraction derived N-P-017 on parenteral nutrition(PN) for over Christopher Eke, South Africa from different hypoallergenic formulas Renato Augusto Zorzo, Brazil 12 months A new variant of microsomal triglyceride Methylation patterns of LDLR, APOB N-P-004 transfer protein (MTTP) deletion in a child and PCSK9 genes in patients with clinical N-P-029 Roberto Berni Canani, Italy with abetalipoproteinaemia diagnosis of Familial Hypercholesterolemia Shuiqing Chi, China How breast milk protects against food Early enteral nutrition after surgery leads N-P-038 allergy: the immunoregulatory action of to better nutritional support to children Sophia Elmehdi, France butyrate CLINICAL NUTRITION with hirschsprung´s disease: a prospective Efficacy and safety of perendoscopic N-P-006 study gastrojejunostomy in children N-P-018 Dianne Delsing, The Netherlands Irene Bacelo Ruano, Spain N-P-030 N-P-039 Gut microbiota modulating effects of GOS Children feeding difficulties and disorders Jie Chien, China Sohair A. Elsiddig , Qatar and 2’-FL studied by in vitro infant and due to organic disease in a reference Unit Nutrition therapy in paediatric radiation Effect of major changes in mody mass toddler faecal fermentations enteritis with intestinal failure: a case index (BMI) and standardized BMI N-P-021 N-P-008 report and literature review (BMISDS) on linear growth of prepubertal Elvira Cañedo Villarroya, Spain Hae Jeong Lee, Republic of Korea children Effectiveness and safety of the ketogenic N-P-031 The relationship between socioeconomic diet as a treatment for refractory epilepsy Ky Young Cho, Republic of Korea N-P-040 status and obesity in Korean children: and cerebral glucose transporter deficit Gut microbiota in obese and normal- Raphaël Enaud, France analysis from the Korean national survey weight Korean children: a cross-sectional Assessment of nutritional status in children (2007–2015) N-P-022 observational study with multiple disabilities (polynut study) Elvira Cañedo Villarroya, Spain N-P-009 Ketogenic diet in patients with deficit N-P-032 N-P-041 Laura María Palomino Pérez, Spain Elena Crehuá-Gaudiza, Spain Raphaël Enaud, France

of brain glucose transporter type 1: Poster Expanded newborn screening. Seven-year experience in 5 years Assesment of nutritional status and bone Evaluation of undernutrition scores in Exhibition experience in a single centre health in neurologically impaired children hospitalized children N-P-023 N-P-010 Elvira Cañedo Villarroya, Spain N-P-033 N-P-042 Linxi Qian, China Treatment with ketogenic diet in patients Mikołaj Danko, Poland Renate Eveleens, The Netherlands Bile salt-dependent lipase promotes with mitochondrial disease and refractory The incidence of Intestinal failure Peptide nutrient-energy dense enteral the proliferation and barrier function of epilepsy associated liver disease (IFALD) in children feeding in critically ill infants to reach Caco-2 cells by activating Wnt/β-catenin with intestinal failure during first year nutritional targets – a comparison study signaling via LRP6 receptor

130 ESPGHAN 52nd Annual Meeting www.espghancongress.org 131 Nutrition 043 – 061 Posters Posters Nutrition 062 – 082

N-P-043 N-P-052 N-P-062 N-P-073 Camila García-Volpe, Spain Koen Huysentruyt, Belgium Virginia Martínez Jiménez, Spain Razilya Rakhmaeva, Russia Sitosterolemia: an uncommon cause of Case studies on clinical scenarios of Use of omega 3 fatty acids in parenteral Anthropometric indicators, body hypercholesterolemia in childhood paediatric malnutrition: results from an nutrition in paediatric patients undergoing composition and actual nutrition international survey hematopoietic stem cell transplantation evaluation in children with cerebral palsy N-P-044 Dominique Guimber, France N-P-053 N-P-063 N-P-075 Incidence and prevalence of home artificial Hamidreza Kianifar, Iran Maria Misiou, United Kingdom Silvia Rodriguez Manchon, Spain nutrition in children in the North of France Oral budesonide for esophageal stenosis Iron status in paediatric patients receiving Children feeding difficulties and disorders « Hauts-de-France region » in epidermolysis bullosa: an open-label Home Parenteral Nutrition (HPN) in a reference unit: follow up after six trial in twenty children months N-P-045 N-P-066 Ruth Hamblin, United Kingdom N-P-054 Shivani Nivedita, India N-P-076 Copper deficiency and the importance of Hilde Krom, The Netherlands Association between complimentary Silvia Rodriguez Manchon, Spain trace element monitoring in jejunally tube Efficacy and long-term outcomes following feeding practice adherence and nutritional Children feeding difficulties and disorders fed children a clinical hunger provocation program to status of children – a cross sectional study in a reference unit: Integral approach wean feeding tube dependent children from Northern India N-P-046 N-P-077 María De los Ángeles Hernández López, N-P-056 N-P-067 Silvia Rodriguez Manchon, Spain Mexico Ariada Guadalupe Lara Campos, Mexico Raj Singh Parmar, United Kingdom Children feeding difficulties and disorders Neck Circumference and its association Waist-height ratio as an indicator of blood Daily intravenous Octreotide to control in a reference unit: clinical, anthropometric with the biochemical components of the pressure alterations in obese paediatric high output gastrostomy losses in and analytical characteristics metabolic syndrome and other markers patients intestinal failure N-P-078 of systemic involvement in paediatric N-P-057 N-P-068 Matilde Rossi, France patients with obesity Eun Hye Lee, Republic of Korea Barbara Borsani, Italy Acute dehydration and hypercalcemia in N-P-048 A nationwide survey on paediatric Body composition in paediatric patients with total intestinal aganglionosis Hayriye Hizarcioglu-Gulsen, Turkey nutritional support team activity in South inflammatory bowel disease: development on long term parenteral nutrition Nutritional characteristics of patients Korea of population specific formulae based on N-P-079 with functional constipation aged 4 years anthropometry N-P-058 Huijuan Ruan, China and older Dina Levy, Israel N-P-069 The influence factors of energy N-P-049 Malnutrition is frequent among children Aranza Lilian Perea Caballero, Mexico metabolism of patients with mechanical Li Hong, China with spinal muscular atrophy The waist-height ratio stratified and ventilation after cardiac valve surgery Computerized data analysis of the its association with haematological undergoing cardiopulmonary bypass N-P-059 nutritional risk screening and clinical abnormalities in obese paediatric patients Carla Maia, Portugal N-P-081 outcomes in hospitalized children in Nutritional support for hospitalized N-P-070 Lilia Mayrel Santiago Lagunes, Mexico Shanghai children‘s medical center chronic patients – where do we stand? Arturo Perea Martínez, Mexico Metabolic syndrome. Association of N-P-050 Waist-height ratio as an indicator of biochemical components with the N-P-060 Amy-Jo Hooley, United Kingdom systemic alterations in obese paediatric stratified waist-height ratio in obese Hélcio Maranhão, Brazil Sub-optimal supplementation of ascorbic patients paediatric patients Record of anthropometric parameters acid in parenteral nutrition and the prophylactic supplementation of N-P-071 N-P-082 N-P-051 iron, vitamin A and vitamin D in Brazilian Sunita Amar Rajani, United Kingdom Laura Sealy, United Kingdom Poster Poster

Koen Huysentruyt, Belgium children´s health booklets Micronutrient levels in intestinal failure(IF) Audit of nutrition support for patients Exhibition Day to day and inter-rater variability of patients dependent on parenteral undergoing treatment for medullo­blas­ N-P-061 the Cow’s Milk-related Symptom Score nutrition(PN) at home over a 5-year period toma (MB) at Bristol children’s hospital. Maria Angeles Martinez Ibeas, Spain (CoMiSSTM) Are we following the children’s cancer Children feeding difficulties and disorders N-P-072 and leukaemia group (CCLG) guidelines in a reference unit: frequency and Sunita Amar Rajani, United Kingdom for this group? diagnostic subtypes The role of parenteral nutrition in children after bone marrow transplantation

132 ESPGHAN 52nd Annual Meeting www.espghancongress.org 133 Nutrition 083 – 105 Posters Posters Nutrition 106 – 133

N-P-083 N-P-094 N-P-106 N-P-119 Sara Sila, Croatia Zhuoming Xu, China Hannah Duggan, United Kingdom Aydan Kansu, Turkey Characteristics of polymeric formula and Growth faltering in Chinese children with Can biochemical variables be used to Growth, tolerance and compliance of an route of delivery of exclusive enteral nutri­ congenital heart defects and mid-term predict weight gain of very low birth intended use population of infants with tion have no effect on disease outcome and follow-up weight preterm infants? cow milk protein allergy to an extensively weight gain in children with Crohn’s disease hydrolysed casein-based powder infant NEONATAL AND INFANT NUTRITION N-P-107 formula N-P-084 Hannah Duggan, United Kingdom N-P-095 Fotini Sotiriadou, Greece What impact does gastro-intestinal N-P-121 Shokoufeh Ahmadipour, Iran Feeding problems in children with gastro­ surgery have on the growth of very low Sai Sunil Kishore, India Are synbiotics effective in the treatment intestinal diseases: a controlled study birth weight preterm infants? Study of daily vitamin D supplementation of jaundice in neonates? in preterm infants: a randomized trial N-P-085 N-P-108 N-P-096 Lekha Sreedharan, India Oraporn Dumrongwongsiri, Germany N-P-122 Ann Anderson-Berry, USA Evaluation of semi -elemental formulae vs Intrauterine zinc and iron storage were Rajagopal Kishore Kumar, India Maternal and cord serum carotenoid levels polymeric formulae as exclusive enteral associated with maternal nutrients status Prevalence of vitamin D deficiency among and their impact on neonatal hearing nutrition in pediatric Crohn’s disease in and mode of delivery Indian newborns screen results India N-P-123 N-P-109 N-P-097 Nadia Liotto, Italy N-P-086 Fabian Eibensteiner, Austria Kumar Ankur, India Osmolality and microbiological assessment Margarita M. Suarez Galvis, Spain Sodium intake in extremely-low-birth- Tongue ties affecting breastfeeding in of targeted fortified human milk Experience in primary trimethylaminuria in weight-infants: a meticulous breakdown early term & full term neonates a third level paediatric hospital N-P-124 N-P-110 N-P-099 Olga Lukoyanova, Russia N-P-087 Rubens Feferbaum, Brazil Reeta Bora, India The lactoferrin level in the breast milk of Michelle Li Nien Tan, Singapore Colostrum therapy modulates preterm Effect of fetal malnutrition on insulin Russian mothers and in the feces of their A comparison of feeding styles of parents newborn´s gut microbiome resistance in newborn children whose children visit the feeding clinic with N-P-111 those who do not attend feeding clinic N-P-101 N-P-125 Yi Feng, China Maria Victoria Bovo, Spain Vijay Mali, United Kingdom N-P-088 Feeding intolerance of hospitalized Neonatal and maternal vitamin B12 Human milk componenet administration Ramon Tormo, Spain very low birth weight neonates fed with deficiency detected in the expanded in preterm neonates: a randomised Lactose intake and brain functions different types of formula newborn screening controlled trial N-P-090 N-P-115 N-P-129 N-P-103 Giulia Vizzari, Italy Corrine Hanson, USA Srinivas Murki, India Jean-Pierre Chouraqui, Switzerland Circulating salicylic acid and metabolic Maternal, social, and demographic factors Availability of an electronic breast pump An evaluation of physician’s advice and profile after 1-year nutritional-behavioral influence placental concentrations of 24/7 reduces the time to reach full milk parents’ adherence about infant nutrition intervention in obese children lutein+zeaxanthin in mothers of preterm VLBW infants N-P-104 admitted to the NICU N-P-091 N-P-116 Jemma Cleminson, United Kingdom Brock Williams, Canada Corrine Hanson, USA N-P-131 Audit of medical staff knowledge of how Serum folate concentrations in Canadian Maternal serum nutrient levels Beheshteh Olang, Iran to support mothers to initiate and to children with sickle cell disease: a pilot are associated with biomarkers of Validation of the NutriCHEQ tool for continue providing breastmilk for infants project inflammation at the time of delivery identifying children aged 1 to 3 years at admitted to the neonatal unit Poster

nutritional risk Exhibition N-P-092 N-P-118 N-P-105 Charlotte M Wright, United Kingdom Joanah Ikobah, Nigeria N-P-133 Sarah Dib, United Kingdom Weight loss in children being weaned from Pattern of breastfeeding in a developing Jose Manuel Ramos Nieves, Switzerland Does infant sex predict maternal long term tube feeding African country – A facility based study Supplementation of human milk oligo­ breastfeeding perception, expressed among mothers attending a tertiary saccharides during early life improves the breast milk volume and breastfeeding hospital in Calabar, Nigeria long-term pancreatic insulin content of a status at 3 and 6 months in China, Russia preclinical model of intra-uterine growth and the United Kingdom? retardation

134 ESPGHAN 52nd Annual Meeting www.espghancongress.org 135 Nutrition 135 – 158 Posters Posters Nutrition 160 – 188

N-P-135 N-P-145 N-P-160 N-P-173 Olga Sakwinska, Switzerland MengYa Zhao, China Tiziana Galeazzi, Italy Nezha Mouane, Morocco The gut microbiota of exclusively A systematic review: Fatty acid Estimation of vitamin D deficiency in Occurrence and levels of aflatoxin M1 and breastfed infants: a world-wide analysis composition of mature human milk in healthy school-age children: current status ochratoxin A in human milk of lactating showing a dominance of bifidobacteria, China in Italy mothers despite pronounced regional differences N-P-146 N-P-161 N-P-174 in species composition Xu Zhuoming, China Antonio Marseglia, Italy Renata Nahuys Tebyrica Prioli, Brazil N-P-136 Factors impacting postoperative growth in Mediterranean diet: let’s give the scores! Cost-effectiveness of Lactobacillus Olga Sakwinska, Switzerland infants with congenital heart disease rhamnosus GG associated with oral N-P-162 Breastfeeding is associated with a reduced rehydration therapy compared with NUTRITION AND HEALTH OUTCOMES Fulya Gülerman, Turkey risk of acute respiratory infections in the oral rehydration therapy alone on the Feeding behaviours of healthcare microbiota and health cohort N-P-148 treatment of children with acute diarrhea professional mothers for their 0-24 month- Katarzyna Babik, Poland in Mexico N-P-138 old children The timing of complementary feeding Neelam Kler, India N-P-175 introduction and feeding difficulties in N-P-163 Macronutrient composition of human milk María Del Carmen Rivero de la Rosa, Spain childhood: a systematic review Tugba Gursoy Koca, Turkey from mothers of very preterm infants ≤ 32 Alterations of the metabolism of iron and Measurement of body composition using weeks (CTRI/2017/02/007895) N-P-150 obesity: a frequent binomy bioelectrical impedance analysis: effects Ewa Winnicka, Poland N-P-139 of obesity, physical activity N-P-180 Evaluation of physical and emotional Dominique Turck, France Anne Laure Tardy, France well-being of children undergoing N-P-165 The European food safety authority’s Children’s intake of key vitamins & electrostimulation of swallowing Anna Kasyanova, Russia approach in updating the tolerable upper minerals for cognitive and immune Correlation between parathormone level intake level of vitamin D for infants N-P-151 development: a cross-country comparison and vitamin D apply in the early childhood Yeliz Cagan Appak, Turkey N-P-140 N-P-181 Evaluation of the frequency of obesity and N-P-166 Hiroshi M. Ueno, Japan Glenn A.A. van Lieshout, The Netherlands associated factors in children of obese and Faran Khan, Pakistan Mature milk macronutrients and maternal The glycation level of milk protein strongly overweight mothers Comparison of school going children dietary factors in Japanese mothers: modulates post-prandial plasma lysine dietary practices with my pyramid a cross-sectional study N-P-154 availability in vivo in humans guidelines Elena Cernat, United Kingdom N-P-142 N-P-183 Scurvy during home parenteral nutrition N-P-167 Karine Vidal, Switzerland Chonnikant Visuthranukul, Thailand Katarzyna Kowalska, Poland Respiratory and diarrhoeal infections in N-P-155 The composition of gut mcrobiota and its Improvement of oral feeding due to the microbiota and health prospective Raffaella de Franchis, Italy associations with BMI, adiposity and stool electrical stimulation in children with cohort of Bangladeshi infants under two Taste development and eating habits short chain fatty acids in obese children primary dysphagia years of age of children following complementary N-P-184 feeding with adult food typical of the N-P-169 N-P-143 Raluca Maria Vlad, Romania mediterranean diet Günsel Kutluk, Turkey Yi Xiang, China How do children “carry” their weight - a Retrospective evaluation of our Exploration of specific nutritional deficits N-P-156 quality of life assessment patients with percutaneous endoscopic in very low birth weight infants with Anna Pia Delli Bovi, Italy gastrostomy N-P-185 extrauterine growth restriction Experience of an obesity and fatty liver Katarzyna Wolochowska, Poland disease clinic: application of a personalized N-P-171 Poster

N-P-144 Improvement of biting skills during Exhibition mobile based intervention (PediaFit) Rebecca Little, United Kingdom Jinyue Yu, United Kingdom feeding therapy Central venous catheter use and outcomes Maternal feeding attitudes, infant eating N-P-158 in parenteral nutrition patients across N-P-188 behaviour and exclusive breastfeeding: Rania El-Haddad, Egypt Northern Ireland 2013-2018 Yueyue Zhang, China data from a multi-centre study A comparative study of efficacy and Investigation of nutrition management in tolerability of micro-dispersed iron and children with ECMO after congenital heart lactoferrin in treatment of iron deficiency surgery anemia

136 ESPGHAN 52nd Annual Meeting www.espghancongress.org 137 2019 Abstract Reviewers 2019

Abstract Reviewers

ESPGHAN would like to thank all Abstract Reviewers for their Suzanne Davison Jackie Falconer Figen Gurakan contribution to a successful Annual Meeting: Ruth De Bruyne Mary Fewtrell Anat Guz Mark Barbara de Koning Natasa Fidler Mis Lissy de Ridder Yigael Finkel Désirée Haaften-Visser Mona Abdel-Hady Ulrich Baumann Samy Cadranel Thierry De Vreker Bjorn Fischler Richard Hansen Elie Abi Nader Mark Beattie Jaoquim Calvo Lerma Dominique Debray Diana Flynn SteffenHartleif Nadeem Afzal Dominique Belli Fiona Cameron Rodrigo del Brio Castillo Maria Fotoulaki Jane Hartley Daniel Agardh Amir Ben -Tov Angelo Campanozzi David Devadason Otilia-Elena Frasinariu Corina Hartman Carlo Agostoni Marc Benninga Cristina Campoy Antal Dezsofi Michael Friedt Almuthe Christina Hauer Mansoor Ahmed Beint Bentsen Katrine Carlsen Sarumathi Dhanapal Raoul Furlano Bruno Hauser Rayna Alamurova StaffanBerglund Isabel Casas Gallegos Teresa Di Chio Paul Henderson Fatima SafiraAlatas Hemant Bhavsar Valeria Casotti Angelo Di Giorgio Dolores García-Arenas Denise Herzog Irena Aldhoon-Hainerova Vishnu Biradar Gemma Castillejo Tietie Dijkstra Victoria Garrick James Heubi Matthieu Allez Alexandra Bobarnac Carlo Catassi Yulia Dmitrieva Luca Garzoni Klaas Heyland Marina Aloi Patrick Bontems Elena Cernat Jernej Dolinšek Marco Gasparetto Mel Heyman Jorge Amil Dias Vibhor Borkar Iain Chalmers Magnus Domellöf Edward Gaynor Loreto Hierro Mirna Natalija Anicic Osvaldo Borrelli Atchariya Chanpong Natasa Dragutinovic Konstantinos Gerasimidis Johannes Hilberath Andras Arato SofiaBota Fabienne Charbit-Henrion Joost Drenth Marta Germán Díaz Susan Hill J. Vicent Arcos Samir Boukthir Christophe Chassard Rémi Duclaux-Loras Mariam Ghughunishvili Jonathan Hind Machancoses Maria Victoria Bovo Jeng Haw Cheng Claire Dupont-Lucas Edward Giles Andre Hoerning Cigdem Arikan Christian Braegger Fang Kuan Chiou Ozlem Durmaz Peter Gillett Ilse Hoffman James Ashton Matteo Bramuzzo Tracey Coelho Stine Dydensborg Sander Laurianne Giovannoni Iva Hojsak Amit Assa Ronald Bremner Maria Carmen Collado Marcin Dziekiewicz Imeke Goldschmidt Bert Holvast Renata Auricchio Ilse Broekaert Cæcilie Crawley Emmanuel Gonzales Matjaž Homan Salvatore Auricchio Efrat Broide Paula Crespo-Escobar Nils Ekvall Frédéric Gottrand Roderick Houwen Naeem Ayub Jiri Bronsky Nicholas Croft Yigal Elenberg-Alter Enke Grabhorn Lucy Howarth Pierre Broue Aron Cseh Nicholas Embleton Tassos Grammatikopoulos Ondrej Hradsky

Alastair Baker Elchanan Bruckheimer Fugen Çullu Çokuğraş Pablo Ercoli Melanie Greifer Tomas Hucl Poster Exhibition Marcin Banasiuk Elaine Buchanan Johanna Escher Jenny Greig Jessie Hulst Hany Banoub Stephan Buderus Lorenzo D‘ Antiga Jessica Ezri Anne Griffiths SteffenHusby Andrew Barclay Yoram Bujanover Gerard Damen Alfredo Guarino Seamus Hussey Aikaterini Bargiota Martin Burdelski Giulia D‘Arcangelo Girish Gupte Koen Huysentruyt

138 ESPGHAN 52nd Annual Meeting www.espghancongress.org 139 Abstract Reviewers 2019 Abstract Reviewers 2019

Warren Hyer Anastasia Konidari Sara Mancell Sandhia Naik Bénédicte Pigneur Michal Rozenfeld Bar Lev Bart Koot Roberta Mandile Priya Narula Pierre Poinsot Frank Ruemmele Joanah Ikobah Michal Kori Jake Mann Antal Nemeth Isabel Polanco Carlos Jose Ruiz Hernandez Giuseppe Indolfi Kallirroi Kotilea Karl Mårild Jiri Nevoral Tudor Pop Richard Russell Flavia Indrio Daniel Kotlarz Luise Marino Emanuele Nicastro Daniela Pop Nicola Ruth Javier Martin de Carpi Tsinuel Girma Nigatu Irina Pop Anna Rybak Tytti Jaakkola Florence Lacaille Massimo Martinelli Kornilia Nikaki Radu Samuel Pop Jörg Jahnel Alain Lachaux Johanna Martínez Osorio Tena Niseteo Alina Popp Amit Saha Christian Jakobsen Christophe Lacroix Emmanuel Mas Andreia Florina Nita Susan Protheroe Efstratios Saliakellis Andreas Jenke Alexandre Lapillonne Manar Matar Valerio Nobili Hildegard Przyrembel Silvia Salvatore Binita Joshi Kelly Larmour Lorenza Matarazzo Sara Nóbrega Gemma Pujol Camilla Salvestrini Norman Junge Mauricio Larrarte King Patricia McClean Lorenzo Norsa John Puntis Marianne Samyn Noémie Laverdure Patrick McKiernan Jan Nowak Ian Sanderson Ahmed Kadir Dariusz Lebensztejn Valérie McLin Mame Yaa Nyarkon Paolo Quitadamo Naire Sansotta Panayota Kafritsa Emanuel Lebenthal Luisa Mearin Andreas Nydegger Michele Scaillon Aikaterini Kakotrichi Huey Miin Lee Jan Melek Rosalind Rabone Elena Scarpato Nicolas Kalach Hélène Lengliné Victoria Merrick Giuseppina Oderda Sunita Amar Rajani Reene Scheenstra Jochen Kammermeier Michael Lentze Assylzhan Messova Salvatore Oliva Alberto Ravelli Isabelle Scheers Ino Kanavaki Aaron Lerner Dusanka Micetic-Turk Grzegorz Oracz Shimon Reif Susanne Schibli Eva Karaskova RaffiLev-Tzion Erasmo Miele Rok Orel Ana Clara Reis Dominique Schluckebier Savvas V Karkelis Delphine Ley Walter A. Mihatsch Raquel Revuelta Iniesta Anna Schneider Stavroula Karyda Daniela Liccardo Zrinjka Mišak Anders Paerregaard Carmen Ribes Koninckx Joachim Schweizer Alemka Jaklin Kekez Rosa Maria Lima Mar Miserachs Alexandra Papadopoulou Amanda Ricciuto Tobias Schwerd Paul Kelly Torbjörn Lind Maria Misiou Raj Singh Parmar Jacques Rigo Marco Sciveres Zahra Khan Elena Lionetti Sally Mitton Andrea Párniczky Firas Rinawi Oscar Segarra Katayoun Khatami Paolo Lionetti Line Modin Bernadeta Patro-Golab Edmond Rings Mohammad Ali Shagrani Seung Kim Carla Lloyd Nicolette Moes Joanna Pawlowska Juan Rivera Medina Philip Chak On Sham Fevronia Kiparissi Andrea Lo Vecchio Nurul Husna Mohd Shukri Licia Pensabene Hina Rizvi Raanan Shamir Martina Klemenak Ines Loverdos Christian Mølgaard Noel Peretti Nathalie Rock Shishu Sharma Jutta Koeglmeier Eberhard Lurz Helena Moreira-Silva Enrique Pérez-Cuadrado Juliana Roda Rayna Shentova-Eneva

Denitza Kofinova Nezha Mouane Robles Astor Rodrigues Eyal Shteyer Poster Exhibition Henrik Köhler Thomas MacDonald Yael Mozer - Glassberg Laetitia-Marie Petit Pejman Rohani Marc Sidler Sanja Kolaček Sarah MacDonald Rafeeq Muhammed Eva Pfister Eleftheria Roma Susan Siew Berthold Koletzko Giuseppe Maggiore Thomas Müller Alan Phillips Claudio Romano Daniel Sifrim Sibylle Koletzko János Major Katalin Müller Judith Pichler Kathleen Ross Marco Silano Simon Murch

140 ESPGHAN 52nd Annual Meeting www.espghancongress.org 141 Abstract Reviewers 2019

Ari Silbermintz Léa Tran Radim Vyhnanek Gisela Silva Stefan Trenkel Satu Simell Riccardo Troncone Orith Waisbourd-Zinman Maartje Singendonk Natia Tsirdava Evelyn Ward Palittiya SIntusek Dominique Turck Batia Weiss Viswanathan Melarcod Dan Turner Zvi Weizman Sivaramakrishan Christos Tzivinikos Tobias Wenzl Françoise Smets Katharina Werkstetter Piotr Socha Holm Uhlig Michael Wilschanski Industry & Christiane Sokollik Shuichiro Umetsu David Wilson Johannes Spalinger Vaidotas Urbonas Eytan Wine General Information Daniela Spirea Arun Urs Harland Winter Christine Spray Philip Wintermeyer Annamaria Staiano Babu Vadamalayan Heiko Witt Marketa Stanclova Pietro Vajro Birgitta Strandvik Francesco Valitutti Ioannis Xinias Caterina Strisciuglio Justo Valverde Fernandez Ekkehard Sturm Saskia Van de Velde Sawsan Yassin Analou Sugar Hubert van der Doef Intan Yeop Josef Sykora Wendy van der Woerd Anat Yerushalmy-Feler Hania Szajewska Hans van Goudoever Dae Yong Yi Peter Szitányi Indra van Mourik Kseniya Yurchyk Laszlo Szonyi Patrick van Rheenen Michiel P. van Wijk Gitte Zachariassen Merit Tabbers Myriam Van Winckel Veena Zamvar Johannes Taminiau Yvan Vandenplas Kristýna Zárubová Dimitrios Tapsas Sharat Varma Aglaia Zellos Merit Tavares Genevieve Veereman Noam Zevit Nikhil Thapar Virtut Velmishi Matthias Zilbauer Rut Anne Thomassen Krishnappa Venkatesh Richard Thompson Elvira Verduci Diana Tirado Gábor Veres Côme Tissandier Henkjan Verkade Georgia Valentina Tita Eleni Volonaki Patrick Tounian Rakesh Vora Industry & 142 ESPGHAN 52nd Annual Meeting www.espghancongress.org 143 General Information European Society for Paediatric Gastroenterology, Hepatology and Nutrition

ESPGHAN has a variety of educational activities, events and information that are available throughout the year. EuropeanEuropean Society Society for for Paediatric Paediatric EDUCATION PARTNER PROGRAMME Gastroenterology,Gastroenterology, Hepatology Hepatology and and Nutrition Nutrition ESPGHANEvents EDUCATION PARTNERDate PROGRAMMEVenue ESPGHAN Mentorship Training March 22–23, 2019 Porto, Portugal The ESPGHANESPGHAN Monothematic Education Conference Partner Programme (EPP) was launched in 2015. on the Gastrointestinal, Hepatologic and April 04–05, 2019 Valencia, Spain BasedNutritional on the Aspects adopted of Cystic ESPGHAN Fibrosis Code of Conduct, the EPP has been developedESPGHAN and Endoscopy implemented Course to ensure the on-goingJune 19–23, 2019 developmentAthens, Greece and EDUCATIONEDUCATION PARTNER PARTNER PROGRAMME PROGRAMME implementationESPGHAN GI Summer of an School up-to-date, independent,June 26–29, high 2019 quality Montecatini,educational Italy programmeESPGHAN Nutritionfor health Summer care School professionals. TheJuly dedicated 01–05, 2019 supportLago Maggiore, and Italy EventsEvents DateDate VenueVenue financialESPGHAN commitment AHP Summer School from our founding partnersSeptember 12–15, helps 2019 toOxford enhance or Cambridge, support UK ESPGHANESPGHAN Mentorship Mentorship Training Training MarchMarch 22–23, 22–23, 2019 2019 Porto,Porto, Portugal Portugal for ESPGHAN‘sESPGHAN Young educational Investigator Forum activities. September 18–21, 2019 Bergen, the Netherlands ESPGHANESPGHAN Monothematic Monothematic Conference Conference ESPGHAN Eastern European Summer School: onon the the Gastrointestinal, Gastrointestinal, Hepatologic Hepatologic and and AprilApril 04–05, 04–05, 2019 2019 Valencia,Valencia, Spain Spain A glance of paediatric gastroenterology, September 20–23, 2019 Varna, Bulgaria The EPPhepatology educational and nutrition activities in Eastern Europe for 2019 can be viewed on our website in the NutritionalNutritional Aspects Aspects of ofCystic Cystic Fibrosis Fibrosis MeetingsESPGHAN and 5th IBDEvents Masterclass section: www.espghan.org/meetings-and-eventsNovember 28–30, 2019 Malaga, Spain ESPGHANESPGHAN Endoscopy Endoscopy Course Course JuneJune 19–23, 19–23, 2019 2019 Athens,Athens, Greece Greece ESPGHAN Monothematic Conference: Jan. 30 – Feb. 01, 2020 Athens, Greece ESPGHANESPGHAN GI GISummer Summer School School JuneJune 26–29, 26–29, 2019 2019 Montecatini,Montecatini, Italy Italy In additionAcute Liver to Failure our established and very successful Summer Schools and the Young Investigator Forum Thethat ESPGHAN address Education primarily Partner colleaguesProgramme is based in subspecialty on educational ESPGHANESPGHAN Nutrition Nutrition Summer Summer School School JulyJuly 01–05, 01–05, 2019 2019 LagoLago Maggiore, Maggiore, Italy Italy grants and has been developed to ensure the on-going development and research training, we areand implementationdelighted to of offer an up-to-date, Master independent, Classes that high focusquality ESPGHANESPGHAN AHP AHP Summer Summer School School SeptemberSeptember 12–15, 12–15, 2019 2019OxfordOxford or Cambridge,or Cambridge, UK UK educational programme for health care professionals. on a specific topic and are open to all ESPGHAN members with an active ESPGHANESPGHAN Young Young Investigator Investigator Forum Forum SeptemberSeptember 18–21, 18–21, 2019 2019 Bergen,Bergen, the the Netherlands Netherlands interest in the field. More details on the ESPGHAN Educational Partner Programme and all ESPGHAN educational events can be found on our website: ESPGHANESPGHAN Eastern Eastern European European Summer Summer School: School: www.espghan.org. A glanceA glance of ofpaediatric paediatric gastroenterology, gastroenterology, SeptemberSeptember 20–23, 20–23, 2019 2019 Varna,Varna, Bulgaria Bulgaria ESPGHAN’s EPP Partners in 2019 are: hepatologyhepatology and and nutrition nutrition in Easternin Eastern Europe Europe www.espghan.org We sincerely thank the following EPP partners for their generous support and commitment: ESPGHANESPGHAN 5th 5 IBDth IBD Masterclass Masterclass NovemberNovember 28–30, 28–30, 2019 2019 Malaga,Malaga, Spain Spain ESPGHANESPGHAN Monothematic Monothematic Conference: Conference: Jan.Jan. 30 30– Feb. – Feb. 01, 01, 2020 2020 Athens,Athens, Greece Greece AcuteAcute Liver Liver Failure Failure

TheThe ESPGHAN ESPGHAN Education Education Partner Partner Programme Programme is basedis based on on educational educational grantsgrants and and has has been been developed developed to toensure ensure the the on-going on-going development development andand implementation implementation of ofan an up-to-date, up-to-date, independent, independent, high high quality quality educationaleducational programme programme for for health health care care professionals. professionals. On behalf of ESPGHAN and its members, I wish to thank our EPP partners for their generous support and their commitment which is greatly appreciated MoreMore details details on on the the ESPGHAN ESPGHAN Educational Educational Partner Partner Programme Programme and and allall ESPGHAN ESPGHAN educational educational events events can can be be found found on on our our website: website: indeed. www.espghan.orgwww.espghan.org. .

Raanan Shamir www.espghan.orgwww.espghan.org WeWe sincerely sincerely thank thank the the following following EPP EPP partners partners for fortheir their generous generous support support and and commitment: commitment: ESPGHAN President

144 ESPGHAN 52nd Annual Meeting Congress Sponsors

The organiser would like to thank the following companies for their generous support of the ESPGHAN 52nd Annual Meeting.

Diamond Silver

Bronze

Platinum

Chrome Industry & 146 ESPGHAN 52nd Annual Meeting www.espghancongress.org 147 General Information Endoscopy Learning Zone Tutors 2019 Endoscopy Learning Zone

The ESPGHAN 52nd Annual Meeting hosts this BEGINNERS ELZ 1 ELZ 3 Friday, Saturday, year again an Endoscopy Learning Zone. 07 June 2019 08 June 2019 The ELZ is located in the exhibition hall.

11:00 – 13:30 08:00 – 10:30 Upper Endoscopy Paul Henderson Rok Orel Upper Endoscopy Luigi Dall‘Oglio Claudio Romano Colonoscopy Gabor Veres Andrew Barclay Endoscopy Learning Zone Colonoscopy Simona Faraci Rachel Tayler Colonoscopy Matjaž Homan Arun Urs The Endoscopy Learning Zone will provide hands-on training Gastrostomy placement Erasmo Miele Warren Hyer in the following diagnostic and therapeutic endoscopy techniques: Gastrostomy placement Jérôme Viala Alexandra • Capsule endoscopy Papadopoulou The Endoscopist‘s Toolbox Ari Silbermintz Samy Cadranel • Colonoscopy Capsule Endoscopy Ronald Bremner Priya Narula • Endoscopy simulator Foreign Bodies Removal Claudio Romano Jorge Amil-Dias • Esophageal balloon dilatation Endoscopy Simulator Natalia Nedokopolou Shishu Sharma • Esophageal / varices banding • Foreign body removal ADVANCED ELZ 2 ELZ 4 • Gastrostomy placement Friday, Saturday, 07 June 2019 08 June 2019 • Gastric varices bleeding

15:15 – 17:45 11:00 – 13:30 • Polypectomies Esophageal / Varices banding Simona Faraci Patrick Bontems • Upper endoscopy Polypectomies +/- clips Matjaž Homan Warren Hyer • The endoscopist’s toolbox Gastric Varices bleeding Ari Silbermintz Douglas Fishman Esophageal balloon dilatation Frédéric Gottrand Ronald Bremner The training will be on biologic models and mannequins to achieve optimum Foreign Bodies Removal Rok Orel Jorge Amil-Dias simulation and interaction. The hands-on training will Gastrostomy placement Erasmo Miele Gabor Veres be supervised by some of the most experienced Gastrostomy placement Jérôme Viala Arun Urs paediatric endoscopists in Europe. The Endoscopy Colonoscopy Patrick Bontems Andrew Barclay Learning Zone training Colonoscopy Muftah Eltumi Rachel Tayler sessions are restricted to a very limited number of places. Capsule Endoscopy Priya Narula Muftah Eltumi If you have booked to attend Endoscopy Simulator David Troendle Salvatore Oliva one of the sessions please ensure that you show up on time. Industry & 148 ESPGHAN 52nd Annual Meeting www.espghancongress.org 149 General Information The Endoscopy Learning Zone is generously supported by the following companies to which we are very grateful for their contribution:

Aquilant is proud to be the UK‘s sole distributor of Fujifilm endoscopy products, Boston Scientific transforms lives through innovative medical solutions that enormous investment by Fujifilm Japan since the 1990s has seen Fujifilm products improve the health of patients around the world. As a global medical technology remain consistently at the cutting edge of endoscope technology. The latest 7000 leader for more than 30 years, we advance science for life by providing a broad series processor utilises innovative 4-LED multi light technology and the 700 series range of high performance solutions that address unmet patient needs and reduce range of endoscopes feature CMOS chip, anti-blur and close focus technology. the cost of healthcare. Fujifilm leads the way in detection and characterisation with the advanced observation modes, Blue Light Imaging (BLI) and Linked Colour Imaging (LCI) which In endoscopy, we develop technologies for diagnosing and treating diseases of provide clinicians with unsurpassed endoscopic visualisation. the digestive system, airway and lungs, such as malignant and benign tumors, gastrointestinal diseases and cancers, abscesses as well as pulmonary diseases, Membership of the Healthcare 21 Group provides the solid foundation required for us to continue investing in the long-term development of the business. Our vision including severe asthma. is to be recognised as commercially innovative, patient focussed and ultimately, as For more information, visit www.bostonscientific.com your partner of choice.

Avanos is a medical device company focused on delivering clinically superior Diagmed Healthcare Ltd is an independent, family owned distributor of numerous breakthrough solutions that will help patients get back to the things that matter. Gold Standard devices. By continuously striving to improve our service and offering for over 35 years we have remained relevant and competitive in an Avanos is committed to creating the next generation of innovative healthcare increasingly globalized market place. Our values of honesty, open communication, solutions which will address our most important healthcare needs, such as reducing integrity and passion for our products and services allows us to meet and exceed the use of opioids while helping patients move from surgery to recovery. customer expectations and ultimately benefit the patients. Avanos delivers recognised brands (MIC*, MIC-KEY*, CORFLO*, ENTRAL*) and For more information, visit http://diagmed.healthcare reliable Digestive Health solutions that help improve patient outcomes and quality of life, particularly for patients in need of supplemental nutrition delivery through enteral feeding. For more information, visit www.avanosmedicaldevices.com/digestive-health Industry & 150 ESPGHAN 52nd Annual Meeting www.espghancongress.org 151 General Information The Endoscopy Learning Zone is generously supported by the following companies to which we are very grateful for their contribution:

VIO3 from Erbe – “power your performance” Olympus delivers a wide range of specialist paediatric diagnostic and therapeutic technologies such as gastrointestinal endoscopes, surgical endoscopy systems, Erbe have shaped electrosurgery, developing it into today’s leading-edge and other peripherals, covering early diagnosis to minimally invasive therapy to technology, making Erbe an essential and reliable partner for many users provide the best possible outcomes for patients and society. This year, Olympus worldwide. celebrates 100 years of making people‘s lives healthier, safer and more fulfilling VIO3 is yet another of our milestones in electro-surgical technology. around the world. VIO3 has the right mode for all GI applications and with its logical and intuitive For more information, visit https://www.olympus.co.uk/medical/en/Home interface the VIO3 is designed to be optimally user-friendly. The VIO3 combined with APC3 and the Erbe Jet 2 system provide the complete workstation for the most complex advanced endoscopic procedures.

OKB Medical specialise in providing unique and innovative healthcare products in PENTAX Medical is an established leading provider of flexible endoscopy products the UK for use in a range of medical disciplines and in the training of surgical skills. and accessories designed to meet a wide range of clinical and economic needs 3D Systems is the world’s leading producer of simulators for medical professionals across a spectrum of clinical specialties including Gastroenterology, Pulmonology, and is at the cutting-edge of Virtual Reality Simulation Technology. Each simulator Urology and ENT. Our mission is to improve the standard of patient care and platform has been designed with medical specialists, encompassing all the necessary quality of healthcare delivery with a focus on QUALITY, CLINICALLY RELEVANT training elements from Basic Skills Practice through to complex Full Procedures. INNOVATION, and SIMPLICITY The Simbionix GI MentorTM Express Endoscopy Simulator is available in the For more information, visit https://www.pentaxmedical.com Endoscopy Learning Zone Area. For more information, visit www.okbmedical.com Industry & 152 ESPGHAN 52nd Annual Meeting www.espghancongress.org 153 General Information Satellite Symposia – Information

Breakfast Symposium Thursday, 06 June 2019

Inspired by Human Milk Research

Print CMYK | Blue = C 100% / M 72% / B 18% | Green = C 80% / Y 90%

Time 07:15 – 08:15 You Are Invited to a Breakfast Symposium Room Hall 3 Chair Bo Lönnerdal, USA Long Term Health Outcomes: 07:15 Protein: what did we learn from human milk Sagar Thakkar, Singapore The Role of Early Childhood Nutrition 07:45 The long term impact of early nutrition Ferdinand Haschke, Austria Date: Thursday, 6 June 2019 Location: Glasgow, Scotland Scottish Event Campus (SEC) - Lomond Hall Time: 07:15 - 08:15 Breakfast Symposium Thursday, 06 June 2019 The Role of Early Childhood Nutrition on Later Life Long Term Health Outcomes: Rosan Meyer, RD, PhD Paediatric Dietitian The Role of Early Childhood Nutrition Honorary Senior Lecturer, Imperial College, London, England

Time 07:15 – 08:15 How Intestinal Bacteria Modulate The Immune Response; Room Lomond Hall Studies in “Humanized” Gnotobiotic Mice Cathryn Nagler, PhD Chair Rosan Meyer, United Kingdom Professor of Pathology, Medicine, Pediatrics and the College Biological Sciences Division, The University of Chicago, USA

07:15 The Role of Early Childhood Nutrition on Later Life Nutrition for Cognitive, Health and LT Performance. Rosan Meyer, United Kingdom Benefits of Feeding a Milk Fat Globule Membrane (MFGM) 07:25 How Intestinal Bacteria Modulate The Immune Response; Javier Fontecha Alonso, PhD Studies in “Humanized” Gnotobiotic Mice Researcher, Spanish National Research Council (CSIC) at Institute of Food Science Cathryn Nagler, USA Research (CIAL-UAM), Madrid, Spain 07:45 Nutrition for Cognitive, Health and LT Performance. Moderator: Benefits of Feeding a Milk Fat Globule Membrane (MFGM) Javier Fontecha Alonso, Spain Rosan Meyer Honorary Senior Lecturer, Imperial College, London, England 08:05 Q&A Rosan Meyer, United Kingdom Visit us at Booth 11

154 ESPGHAN 52nd Annual Meeting www.espghancongress.org 155 Satellite Symposia – Information

The first and Breakfast Symposium Thursday, 06 June 2019 only** complete NUTRICIA allergy range Next Generation of infant formular – prebiotics, postbiotics * with patented and HMOs to support the immune system through the gut SYNEO RANGE synbiotics Time 07:15 – 08:15

TM Room Hall 2

NEO Discover you can do more Y

S

Chair 1-3 Hania Szajewska, Poland

tic

io ides

by targeting the gut b har c

e ac

r os

P lig

O

07:15 Critical milestones in infant formular – how close we can get to breastmilk

e v O re Hania Szajewska, Poland B m c U eriu i N Bifidobact t R io IO Prob T 07:35 The next generation of infant formular – how composition meets P A A N TE BI functionality NTED COM Bernd Stahl, The Netherlands 07:55 The exciting potential of prebiotics, postbiotics and HMOs to support the immune system through the gut Flavio Indrio, Italy

Lunch Symposium Thursday, 06 June 2019 Human Milk Oligosaccharides and Their potential in Immune System Development Print CMYK | Blue = C 100% / M 72% / B 18% | Green = C 80% / Y 90%

Hydrolyzed Infant Extensively Hydrolyzed Amino Acid Time 13:00 – 14:00 Formula Formula Formula Room Clyde Hall For sensitive infants1,4,5 For infants with For infants with Chair Hania Szajewska, Poland • with family history of allergy mild to moderate CMA2,6,7 severe/complex CMA or 3,8,9 • delivered by C-section multiple food allergies • exposed to antibiotics 13:00 Human milk oligosaccharides as primers for the microbiome and immune system? Lars Bode, USA

* Product availability and/or design varies by country. To find out more, speak to one of our 13:30 The Gut Microbiome and its Role in Early Immune Development Nutricia representatives at booth no. 3 and Allergies **Based on Innova Market Insights, 11th February 2019. Liam O’Mahony, Ireland References: 1. Chua M, et al. JPGN, 2017;65:102–6. 2. Van der Aa LB, et al. Clin Exp Allergy, 2010;40:795–804. 3. Candy, DCA et al. Pediatr Res, 201;83(3):677-86. 4. Tang M, et al. Abstract at EAACI;17-21 June 2017; Helsinki, Finland. 5. Wopereis H, et al. JACI 2018;141(4):1332. 13:45 The Role of Human Milk Oligosaccharides in Allergy Management 6. Giampetro PG, et al. Pediatr Allergy Immunol, 2001;12:83-6. 7. Van der Aa LB, et al. Allergy, Yvan Vandenplas, Belgium 2011;66:170-7. 8. DeBoissieu D, Dupont C. J Pediatr 2002;141(2):271-3. 9. De Boissieu D, et al. Visit Nutricia J Pediatr, 1997;131(5):744-7. to get For Healthcare Professionals use only - not for distribution to the general public. booth Breastfeeding is best for babies. Pepti Syneo and Neocate Syneo are Food for Special Medical Purpose and must be used under medical supervision. more information Industry & 156 ESPGHAN 52nd Annual Meeting www.espghancongress.org 157 General Information Satellite Symposia – Information

Lunch Symposium Thursday, 06 June 2019 2’-Fucosyllactose: An Allergy Modulating Human Milk Oligosaccharide?

Time 13:00 – 14:00 Room Hall 2 Chair Ardythe L. Morrow, USA

13:00 The Role of Human Milk Oligosaccharide (HMO) in Infant Nutrition Ardythe L. Morrow, USA 13:25 2’-Fucosyllactose: An Allergy Modulating Human Milk Oligosaccharide? Paul Forsythe, Canada 13:50 Q&A All faculty

Lunch Symposium Thursday, 06 June 2019

When breast milk turns into a true challenge 2.0!

Time 13:00 - 14:00 Room Lomond Hall Chair Florence Lacaille, France

13:00 Welcome and Introduction Florence Lacaille, France 13:05 When the initial challenge of breast milk was mastered well! Florence Lacaille, France 13:25 Our Babies grow – so do their appetites and needs Suresh Vijay, United Kingdom 13:45 Q&A All faculty

158 ESPGHAN 52nd Annual Meeting www.espghancongress.org 159 Satellite Symposia – Information Satellite Symposia – Information

Evening Symposium Thursday, 06 June 2019 Evening Symposium Thursday, 06 June 2019 One Vision: Bringing Together Physicians and Patients For infant health, what could bioactive proteins to Achieve Their Goals in human milk do?

Time 18:30 – 19:30 Time 18:30 – 19:30 Room Hall 2 Room Lomond Hall Chair Dan Turner, Israel Chair Ardythe Morrow, USA

18:30 Disease Remission: I Want It All Dan Turner, Israel 18:30 Specific bioactive supplements for enterally fed (preterm and term) 18:40 Under Pressure: Physicians’ Perspectives on Setting Goals infants: what is the evidence? Amit Assa, Israel Hans van Goudoever, The Netherlands 18:57 I Want to Break Free: Supporting Patients to Achieve Their Goals 19:00 New insights on the human milk proteome from clinical studies: Nick Croft, United Kindom How does it vary and why? 19:14 Don’t Stop Me Now: Understanding How Physicians’ and Patients’ Adrienne Weiss, The Netherlands Goals Can Align All faculty 19:24 Q&A and Closing Remarks All faculty Breakfast Symposium Friday, 07 June 2019 Evening Symposium Thursday, 06 June 2019 Human Microbiota Shift; Consequences and Opportunities Why do we need dietary therapy in Crohn’s disease

in an era of biologics? Time 07:15 – 08:15 Print CMYK | Blue = C 100% / M 72% / B 18% | Green = C 80% / Y 90% Room Hall 2 Time 18:30 – 19:30 Chair Paul Cotter, Ireland Room Hall 3 Chair Frank Ruemmele, France 07:15 Disorders Impacted By The Gut Microbiome, Opportunities For Microbiome Manipulation 18:30 Why do we need nutrition therapy in an era of biologics? Jon A. Vanderhoof, USA David Wilson, United Kingdom 18:40 What are the targets for dietary therapy? 07:35 Probiotic Solutions to Dysbiotic Drift: the need for integrative Rotem Sigall-Boneh, Israel ecological approaches for the health of Person, Place and Planet Susan Prescott, Australia 18:50 Present state of the art on Dietary management in Crohn’s Disease Eytan Wine, Canada 07:55 Q&A All faculty 19:10 The new kid on the block: The Crohn’s Disease Exclusion Diet for induction of remission Arie Levine, Israel Industry & 160 ESPGHAN 52nd Annual Meeting www.espghancongress.org 161 General Information The best from nature. Satellite Symposia – Information The best for nature.

Breakfast Symposium Friday, 07 June 2019 It‘s All About the Mother: Maternal Factors Influencing Human Milk Composition

Time 07:15 – 08:15 Room Lomond Hall Chair Catherine Stanton, Ireland

07:15 Milk Microbiome: Origin and Impact of Maternal Diet? Michelle McGuire, USA 07:45 Current Insights into Maternal Genetic Contribution to Human Milk Composition Janet Williams, USA

Breakfast Symposium Friday, 07 June 2019 L. reuteri DSM 17938 in Functional GI Disorders and beyond – The potential role in infection protection and fighting antibiotic resistance Come to our breakfast symposium Time 07:15 – 08:15 Chair and introduction: Room Hall 3 Catherine Stanton, Ireland Chair Ruggiero Francavilla, Italy It’s All About the Mother: It’s All About the Mother

Maternal Factors Speakers: Evidence on L. reuteri DSM 17938 in functional GI disorders Influencing Human Milk Michelle McGuire, USA Hania Szajewska, Poland Milk Microbiome: New perspectives of L. reuteri DSM 17938 in preventing GI Composition Origin and Impact of and upper respiratory infections Maternal Diet? Diego Peroni, Italy Janet Williams, USA Disruption of the infant gut microbiota emergence: Current Insights into can we prevent the clinical consequences? Friday, 07 June 2019 Maternal Genetic Contribution Alexis Mosca, France to Human Milk Composition 07:15 - 08:15 am SEC Glasgow, Lomond Hall Breakfast will be provided. hipp.com/hcp 162 ESPGHAN 52nd Annual Meeting www.espghancongress.org 163

az_ESPGHAN_2019.indd 1 09.04.19 09:37 Sponsors & as of 26 April 2019 Exhibitors List

Company · Country Booth No. Company · Country Booth No.

AB-BIOTICS · Spain 34 European Foundation for the Care of Newborn Infants (EFCNI) · Germany 41

ABBOTT · USA 12 Eurospital S.p.A. · Italy 31

AbbVie · USA – FrieslandCampina · The Netherlands 10

Advanced Lipids · Israel 5 FrieslandCampina Ingredients · The Netherlands 4

Alexion Pharma GmbH · Switzerland 14 HiPP · Germany 15

Applied Medical Technology, Inc. · USA 19 IMMUNDIAGNOSTIK AG · Germany 32

Arla Foods Ingredients · Denmark 6 Inbiose NV · Belgium 46

Association of European Coeliac Societies (AOECS) · Belgium 40 Jennewein Biotechnologie GmbH · Germany 1

Ausnutria B.V. · The Netherlands 29 Karger Publishers · Switzerland 33

Avanos · Belgium 20 Kendal Nutricare Ltd. · United Kingdom 22

BASF · Germany 28 Laboratoires CTRS · France 24

Baxter · Switzerland 26 MDPI · Switzerland 45

Betapol – Bunge Loders Croklaan · The Netherlands 30 Mead Johnson Nutrition · USA 11

BINC – Geneva · Switzerland 16 Miris AB · Sweden 23

BIOCODEX · France 17 Nestlé · Switzerland 13

BioGaia · Sweden 7 NOVALAC · France 2

BÜHLMANN Laboratories AG · Switzerland 18 Noventure · Spain 25

Children‘s Liver Disease Foundation (CLDF) · United Kingdom 38 Nutricia · The Netherlands 3

Chr. Hansen A/S · Denmark 9 Takeda Pharmaceutical Company Limited · Japan 36

Dairy Goat Co-operative (N.Z.) Ltd. · New Zealand 8 vaneeghen · The Netherlands 47

DEKAsvitamins.com/Callion Pharma · The Netherlands & USA 43 Wisepress Medical Bookshop · United Kingdom 42

DICOFARM · Italy 27 Wyeth Nutrition · Switzerland 21

European Federation of Crohn‘s & Ulcerative Colitis Associations (EFCCA) · 39 Yili Maternal and Infant Nutrition Institute (YMINI) · China – Belgium Industry & 164 ESPGHAN 52nd Annual Meeting www.espghancongress.org 165 General Information ESPGHAN 2019 · Glasgow, Scotland Exhibition & Poster Area Scottish Event Campus (SEC) · Hall 4

Exhibition Plan Scottish Event Campus (SEC) · Hall 4

Poster Area ePoster ESPGHAN Members ELZ Nutrition Area Booth Lounge

Internet Corner 5 3 2 1 4 6

Poster Area Gastroenterology 7 Catering Catering

to 8 Registration

10 11 12 13 14 15 9

Catering Catering

Poster Area 36 33 32 29 21 Hepatology 26 25 20 17 16 34 31 23 22 30 28 27 24 19 18

42 38 39 40 41 43 45 46 47 Industry & 166 ESPGHAN 52nd Annual Meeting www.espghancongress.org 167 Entrance Entrance Entrance Entrance General Information as of 9 November 2018 Scale 1 : 200 VISIT US AT BOOTH #12

Exhibitor Directory Listing ABBOTT NUTRITION SYMPOSIUM

2’-FUCOSYLLACTOSE: AN ALLERGY MODULATING HUMAN MILK OLIGOSACCHARIDE? Thursday, 6 June, 13:00–14:00, Hall 2 TOPIC: 2’-FL HMO & Allergy Learn about the emerging role of 2’-fucosyllactose (2’-FL) human milk oligosaccharide (HMO) in allergy modulation as well as its role in shaping the human gut microbiome, immunity and more. SPEAKERS: Professor Ardythe Morrow, PHD Associate Professor Paul Forsythe, PHD Cincinnati Children’s Hospital, USA McMaster University, Canada

LIVE Q&A SESSION WITH SPEAKERS AT THE ABBOTT BOOTH Thursday, 6 June, 16:30–17:00, Booth 12 Join us at BOOTH #12 for a Q&A session with our speakers, Dr. Ardythe Morrow and Dr. Paul Forsythe, where you’ll have an opportunity to ask questions about the evidence presented at the symposium.

IMPORTANT NOTICE: Breastfeeding is best for babies, and is recommended for as long as possible during infancy. © 2019 Abbott Laboratories. JP-19645 Industry & 168 ESPGHAN 52nd Annual Meeting www.espghancongress.org 169 General Information ani-2427c_espghan-symp-ad_v3.indd 1 4/16/19 8:10 AM Exhibitor Directory Listing ABBOTT NUTRITION

Booth No. Booth No. HEALTH INSTITUTE 34 12

Country Country Spain USA

More information More information www.ab-biotics.com www.abbottnutrition.com

AB-Biotics is a global biotechnology At Abbott, we‘re all about helping you company focused on well-documented live the best life you can through good probiotics and precision medicine. health. We keep your heart healthy, Pharmaceutical, dietary supplement nourish your body at every stage of and functional food industries under life, help you feel and move better, B2B premises are our main partners. and bring you information, medicines Our probiotics for children, and breakthroughs to manage your AB-KOLICARE and AB-KOLICARE health. Every day and around the DIGEST are marketed worldwide under world, we‘re discovering new ways to different brand names. make life better.

At ANHI, our mission is to connect and empower people through science-based nutrition resources to optimize health worldwide. Our goal is to make it easier for you to help your patients be well-nourished.

EDUCATION • CONFERENCES • RESOURCES LEARN MORE ABOUT ANHI OR TAKE A COURSE TODAY BY VISITING ANHI.ORG

VISIT US AT BOOTH #12

IMPORTANT NOTICE: Breastfeeding is best for babies, and is recommended

for as long as possible during infancy. © 2019 Abbott Laboratories. JP-19525 Industry & 170 ESPGHAN 52nd Annual Meeting www.espghancongress.org 171 General Information

ani-2427d_espghan-anhi-ad_v2.indd 1 4/12/19 5:32 PM Exhibitor Directory Listing

MIC-KEY*SF (SECURE FLOW)

Booth No. Booth No. SOON AVAILABLE – 5 CONFIDENCE

Country Country IS MIC-KEY* SF USA Israel More information More information Empower families to feel www.abbvie.com www.advancedlipids.com confident with tube feeding.

* We are a global, research-based Advanced Lipids is a joint venture Registered Trademark or Trademark of Avanos Medical, Inc. or its affiliates. © 2019 AVNS. All rights reserved. rights All AVNS. 2019 © affiliates. its or Inc. Medical, Avanos of Trademark or Trademark Registered biopharmaceutical company dedicated between Frutarom, a global leader to developing and delivering a in the fields of taste and health, and consistent stream of innovative AAK, a global provider of value-adding medicines. We are driven by cutting- vegetable oils and fats to the infant edge science and passionate people formula industry and many other on a relentless pursuit to discover industries. Combining Frutarom’s new and better outcomes, which go clinical and chemical expertise in lipid beyond care, to transform the lives technologies with AAK’s international of patients living with inflammatory strength in food safety, production bowel disease and other autoimmune and logistics, Advanced Lipids offers diseases. For more information a unique package of clinical research, about AbbVie, please visit us at development, flexible blending, quality www.abbvie.co.uk and logistics.

Come and see our latest innovation at booth number 20 Industry & 172 ESPGHAN 52nd Annual Meeting www.espghancongress.org 173 General Information Exhibitor Directory Listing

Booth No. Booth No. 14 19

Country Country Switzerland USA

More information More information www.alexion.com www.appliedmedical.net

Alexion is a global biopharmaceutical Applied Medical Technology, Inc. AMT company focused on serving is a global leader and manufacturer patients and families affected by of enteral feeding devices and rare diseases through the discovery, accessories, providing the best development and commercialization medical device products to increase of life-changing therapies. Alexion’s patient comfort and improve patient metabolic franchise includes two outcomes. Our products include highly innovative enzyme replacement the MiniONE® low-profile Balloon, therapies – Kanuma™ (sebelipase Non-Balloon & Capsule Non-Balloon alfa) for patients with lysosomal Buttons, G-JET® low-profile Gastric- acid lipase deficiency (LAL-D), and Jejunal Enteral Tube, Capsule Monarch® Strensiq® (asfotase alfa) for patients G-Tube, AMT Bridle™ Nasal Tube with hypophosphatasia (HPP). Alexion Retaining System, MiniACE™ low-profile also developed and commercializes Antegrade Continence Enema Button Soliris® (eculizumab), the first and and the CINCH™ Tube Securement only approved complement inhibitor Device. All AMT products are proudly to treat paroxysmal nocturnal made in the USA! hemoglobinuria (PNH), atypical Innovating. Educating. Changing hemolytic uremic syndrome (aHUS), Lives.™ and refractory generalized myasthenia gravis (gMG). Alexion focuses its development efforts on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders.

174 ESPGHAN 52nd Annual Meeting www.espghancongress.org 175 Lacprodan® MFGM-10 Exhibitor Directory Listing Booth No. Booth No. Supporting early life 6 40 cognitive development

Country Country Denmark Belgium

More information More information www.arlafoodsingredients.com www.aoecs.org

Ingredients for the next generation: Founded in 1988, the Association Our overriding goal is continuously of European Coeliac Societies developing a range of scientifically (AOECS) is an independent, non- documented ingredients that profit organisation. It is the umbrella resemble key functionalities in human organisation of European national milk. Used in infant formula they coeliac societies with currently 39 contribute to healthy growth and enrolled Member societies across development of formula fed infants. Europe and internationally. AOECS Our dedicated infant nutrition and represents people who are affected product development teams draw by coeliac disease or dermatitis expertise from a broad base of herpetiformis (DH) and seeks to specialists from academic key opinion collaborate with international leaders. As well as offering extensive coeliac organisations worldwide. support, our specialists work towards The Association is actively involved a common goal: to help you meet the in several international initiatives to current and future needs of both your raise awareness of coeliac disease, to business and your customers. promote research into the diagnosis and management of this illness.

Booth #6 Industry & 176 ESPGHAN 52nd Annual Meeting www.espghancongress.org 177 General Information Exhibitor Directory Listing

Visit us at booth Booth No. Booth No. 29 20 #29

Country Country The Netherlands Belgium

More information More information www.kabrita.com www.avanos.com

Ausnutria B.V. is a Dutch dairy company Avanos is a medical device company specialized in the development focused on delivering clinically and production of advanced infant superior breakthrough solutions that nutrition. We are the pioneers will help patients get back to the behind the world’s leading goat milk things that matter. based infant formula brand ‘Kabrita’. Avanos is committed to creating Goat milk is well known for its easy the next generation of innovative digestibility, high levels of important Complete, safe Gentleness Dutch heritage healthcare solutions which will address nutrients and pleasant mild taste. For and advanced of goat milk and expertise our most important healthcare needs, formula Kabrita we combined these natural such as reducing the use of opioids characteristics of goat milk with while helping patients move from advanced formula compositions, surgery to recovery. based on over 70 years of experience Kabrita infant formula is based on 100% Dutch goat milk. and expertise in infant formula. The Avanos delivers recognised brands Goat milk has a number of natural characteristics, including the result is a full range of gentle goat (MIC*, MIC-KEY*, CORFLO*, ENTRAL*) easy digestibility of goat milk protein. Maathuis et al. conclude milk based formulas for every stage, and reliable Digestive Health solutions that “the kinetics of protein digestion of the goat milk infant suitable and available for healthy that help improve patient outcomes babies and toddlers all around the and quality of life, particularly for formula is more comparable to that of human milk than that world. patients in need of supplemental of the cow’s milk infant formula”(JPGN 2017;65(6):661-6). nutrition delivery through enteral feeding.

Kabrita is a brand of Ausnutria B.V. www.kabrita.com [email protected]

Important notice: breast milk is the best source of nutrition for infants. References: Almaas, Cases et al. 2006; Ceballos, Morales et al. 2009; Inglingstad, Devold et al. 2010; 178 ESPGHAN 52nd Annual Meeting Maathuis, Havenaar et al. 2017; Park and Haenlein 2017; Pintadowww.espghancongress.org and Malcata 2000. 179

10090209_AUSNUTRIA_Adv-Kabrita-HCP_A5.indd 1 15-03-19 11:20 Exhibitor Directory Listing Exhibitor Directory Listing

Booth No. Booth No. Booth No. Booth No. 28 26 30 16

Country Country Country Country Germany Switzerland The Netherlands Switzerland

More information More information More information More information www.newtrition.basf.com www.baxter.com www.bungeloders.com www.binc-geneva.org

BASF, a leading player in the human Baxter International Inc. provides a Bunge Loders Croklaan is a trusted BINC GENEVA: A scientific platform for nutrition industry, is a global supplier broad portfolio of essential hospital global producer and supplier of infant and maternal health of high quality ingredients for a and renal products, including home, sustainable high-quality oils and fats. Biostime Institute for nutrition and wide range of applications in early acute and in-center dialysis: sterile Its products are used in a wide range care is a non-for profit foundation life nutrition, dietary supplements, IV solutions; infusion systems of applications, ranging from bakery committed to advancing scientific pharmaceuticals as well as functional and devices; parenteral nutrition; and confectionery to culinary and cooperation and fostering research on and medical nutrition. With our surgery products and anesthetics; infant nutrition. Over 30 years ago maternal and infant health. longstanding expertise offering a and pharmacy automation, software in the Netherlands, Loders Croklaan comprehensive product and service and services. The company’s global invented the process to accurately We aim to stimulate science and portfolio, BASF is well-positioned footprint and the critical nature of its rearrange fatty acids on triglycerides research in Europe and to empower to offer nutritional solutions such products and services play a key role without using chemicals. This process parents with information on the crucial as Human Milk Oligosaccharide in expanding access to healthcare in led to the development of Betapol® early years of their child‘s life. 2’-Fucosyllactose (HMO 2’-FL), emerging and developed countries. which mimics the unique Sn-2 fat BINC focuses on 5 research areas of omega-3 and omega-6 fatty acids, Baxter’s employees worldwide are structure found in breast milk. With it, expertise: lutein, vitamins to support future building upon the company’s rich we created the OPO category of infant innovations for the early life nutrition heritage of medical breakthroughs milk formula and revolutionized the Microbiota, allergies, infant brain market. to advance the next generation of IMF market. development, nutrition and child healthcare innovations that enable obesity, maternal health patient care. BINC Geneva and BINC China is part of health and Happiness Group: a world global premium nutrition and lifetime wellness provider. Industry & 180 ESPGHAN 52nd Annual Meeting www.espghancongress.org 181 General Information Exhibitor Directory Listing Exhibitor Directory Listing

Booth No. Booth No. Booth No. Booth No. 17 7 18 38

Country Country Country Country France Sweden Switzerland United Kingdom

More information More information More information More information www.biocodex.com www.biogaia.com www.buhlmannlabs.ch www.childliverdisease.org

Since the discovery of Saccharomyces BioGaia is an innovative Swedish Calprotectin is the best marker for Children’s Liver Disease Foundation boulardii CNCM I-745 in 1953, Biocodex healthcare company and a world IBD/IBS diagnosis and IBD therapy (CLDF) is a charity based in the UK. has become an international key player in leader in probiotics with 28 years follow up. With the new and easy We take action against the effects the microbiota realm. In order to rein­­ force­ experience of developing, marketing to use IBDoc® calprotectin home of childhood liver disease, providing its leadership in this field, Biocodex­ chose and selling probiotic products. Over test, invasive procedures can be information, emotional support, to devote its expertise to an innovative the years we have created networks of avoided and the child and its parents family and young people’s services and strategy: the Microbiota Mission. leading, independent researchers and are empowered for their disease projects, research funds and a voice The microbiota mission consists of the specialists, manufacturing experts and management. BÜHLMANN has for all affected. At least two children following: local distribution partners worldwide. developed into THE CALPROTECTIN are diagnosed with a liver disease Advance scientific discovery in Micro­ Our products are recommended by COMPANY with highest quality every day in the UK. CLDF is the only biota by funding academic research pediatricians and other healthcare standards and its determination UK charity dedicated to fighting all with Biocodex Microbiota Foundation professionals in more than 100 to increase the knowledge and forms of childhood liver disease. and early stage investment in start-up countries. application of calprotectin in pediatrics. BÜHLMANN’s new companies All BioGaia’s products contain Quantum Blue® Infliximab and Educate general public and health care Lactobacillus reuteri, a probiotic Adalimumab trough level rapid assays, professionals on growing importance bacteria that helps good are the first point of care tests that of microbiota on healthcare and well- microorganisms restore a natural allow determination of biologics levels being with our Biocodex Microbiota balance in the gut. To date L. reuteri within 15 minutes. Institute has been tested in more than 200 Provide solutions improving microbiota clinical trials (February 2019) and health with our unique probiotic drug proven effective and safe in children S. boulardii CNCM I-745 and innovative and adults. product range, Symbiosys. Because every patient deserves the best, Biocodex is committed to make a positive difference and enhance patient’s life worldwide. Industry & 182 ESPGHAN 52nd Annual Meeting www.espghancongress.org 183 General Information Your Health – Our Science Exhibitor Directory Listing

Booth No. Booth No. 9 8

Country Country Denmark New Zealand

More information More information www.chr-hansen.com/probiotics www.dgc.co.nz

Chr. Hansen is a global bioscience Dairy Goat Co-operative (DGC) is the company aiming at improving food world’s market leader for nutritional and health. Probiotics are a key focus products for infants and children area for us. We have been working based on goat milk. DGC pioneered with clinically documented probiotics the world’s first commercialised infant for more than 25 years and offer a formula from goat milk, and continues premium range of probiotic strains to provide high quality branded goat under the Probio-Tec® brand – milk nutritional powders to more than including the two best documented 30 countries around the world and probiotic strains in the world named continues to drive the category into LGG® and BB-12®. Together with the 21st century. DGC uses the most our partners we bring documented recent nutritional science (including probiotics to market in convenient two randomised double-blind clinical formats for infants and children, e.g. trials) combined with state of the art drops. At Chr. Hansen we engage in processing using whole goats’ milk to New clinical scientific partnerships with universities deliver the natural benefits of goat and research institutions and are milk to infants and young children. ™ represented in several international results for BB-12 scientific associations. within infant colic Visit us at booth #9 – and get the exciting results of a new clinical study on Bifidobacterium, BB-12™

Industry & 184 ESPGHAN 52nd Annual Meeting www.espghancongress.org 185 General Information Exhibitor Directory Listing Exhibitor Directory Listing

Booth No. Booth No. Booth No. Booth No. 43 27 39 41

european foundation for the care of newborn infants

Country Country Country Country The Netherlands/USA Italy Germany Belgium

More information More information More information More information www.dekasvitamins.com www.dicofarm.com www.efcni.org www.efcca.org

DEKAsvitamins.com develops and Dicofarm is a nutraceutical and The European Foundation for the The European Federation of Crohn‘s commercializes DEKAs. DEKAs pharmaceutical group based in Italy. Care of Newborn Infants (EFCNI) is the & Ulcerative Colitis Associations fat-soluble vitamins are based on a The group was founded in 1977 and first pan-European organisation and (EFCCA) is an umbrella organisation clinically tested delivery technology since then has established a strong network to represent the interests of representing 36 national Crohn’s and that enhances their absorption. DEKAs experience in developing of high preterm and newborn infants and their Ulcerative Colitis (collectively known Essential and DEKAs Aqua-E are for quality products. Our daily obligation families. It brings together parents, as Inflammatory Bowel Disease or patients with Cholestatic Liver Disease. is to realize products and solutions healthcare experts from different IBD) patient associations. We are an DEKAs Bariatric is given after Bariatric capable of improving people’s quality disciplines, and scientists with the organisation of people united in our Surgery. DEKAs Plus are all-in-one of life. Our portfolio embodies our common goal of improving long- commitment to improve the life of the multivitamin and mineral supplements profound commitment to innovation term health of preterm and newborn over 10 million people living with IBD for patients with Cystic Fibrosis. DEKAs and include OTX medications, Food children. EFCNI’s vision is to ensure the worldwide (3.4 million in Europe alone) is made in the USA by Callion Pharma Supplements and Medical Devices in best start in life for every baby. and to give them a louder voice and (www.callionpharma.com). DEKAs is key therapeutic areas that cover many more visibility. For more information: www.efcni.org widely available in the Americas and Pediatric fields such as Neonatology Europe. DEKAs is a Food for Special and Gastroenterology. Medical Purposes and must be taken under medical supervision. Contact us via [email protected]. Industry & 186 ESPGHAN 52nd Annual Meeting www.espghancongress.org 187 General Information Exhibitor Directory Listing

Booth No. Booth No. 31 10

Country Country Italy The Netherlands

More information More information www.eurospital.com www.frieslandcampina.com/en

Eurospital, an Italian IVD Company Royal FrieslandCampina provides with 70 years of history, focuses its millions of consumers all over the activities in specific sectors such as in world with dairy products containing vitro diagnosis of Coeliac Disease, IBD, valuable nutrients from milk. We detection of genetic predisposition to supply consumer products such Coeliac, Type 1 Diabetes and Lactose as dairy-based beverages, infant Intolerance. nutrition, cheese and desserts in more Visit us at than 100 countries, while we also Actively present worldwide, booth 4 produce ingredients and semi-finished Eurospital’s aim is to provide products for infant nutrition, the food Paediatricians, Gastroenterologists industry and the pharmaceutical sector and Laboratory Immunologists with for manufacturers around the world. highly innovative diagnostic tests such as Calprest family products for The company is fully owned by calprotectin determination, Eu-tTG and Zuivelcoöporatie FrieslandCampina Essential ingredients α-Endomysium for the identification B.V., with 18.645 member farmers and base powders for of the coeliac patient, as well as in the Netherlands, Germany XeliGen, DiabeGen and LactoGen and Belgium and is one of the infant formula. for the determination of genetic world’s largest dairy cooperatives. predisposition to CD, T1D and lactose FrieslandCampina has branch offices • The experts in infant nutrition intolerance. in 33 countries. The Company’s central office is based in Amersfoort, the • A commitment to pure Netherlands. and traceable • When nourishment matters most

The inside matters. MONT 12 HS - T M O O R + F 1 2 HMO’s – Galacto-oligosaccharides — Micro- Y

encapsulated LC-PUFA oils – Milk Fat – Nutritional E

A

Oil Powders – Hydrolysates – Lactoferrin - R

(Demineralised) Whey proteins – Lactose S

www.frieslandcampinaingredients.com Industry & 188 ESPGHAN 52nd Annual Meeting www.espghancongress.org 189 General Information Exhibitor Directory Listing Exhibitor Directory Listing

Booth No. Booth No. Booth No. Booth No. 4 15 32 46

Country Country Country Country The Netherlands Germany Germany Belgium

More information More information More information More information www.frieslandcampinaingredients.com www.hipp.com/hcp www.immundiagnostik.com www.inbiose.com

FrieslandCampina Ingredients is HiPP GmbH & Co. Vertrieb KG is Immundiagnotik AG, founded in Inbiose has made its mark as a a leading producer of essential Germany’s leading manufacturer of 1986 by Dr. F. P. Armbruster (CEO), leader in the development of human ingredients and base powders for baby food with a strong focus on is specialised on the development, milk oligosaccharides, which are of the global infant formula market. We organic premium quality. It offers production, and world-wide paramount importance for the health are the experts in infant nutrition infant, follow-on and growing- distribution of innovative parameters of newborns and developing infants. solutions and strongly focus on up formula, a huge range of and detection methods for laboratory Inbiose develops and produces optimising microbiome in four areas: complementary feeding, a product diagnostics and medical research. specialty carbohydrate ingredients brain, growth, immunity and digestion. range for pregnant and breastfeeding Focused on the development of that are addressing needs in markets With over 75 years of experience, our women and also provides baby care immunological tools, of HPLC including human nutrition, dietary deep understanding of ingredients cosmetics. The company is a family-run and molecular biology methods, supplements, medical nutrition and and applications enables us to develop business which was founded in 1932 and of new applications for mass beyond. The company develops cost- next generation infant nutrition and is based in Pfaffenhofen, Bavaria, spectrometry (LC-MS/MS), IDK effective processes for the production ingredients such as HMO’s and Germany. HiPP products are exported concentrates on the development and of specialty carbohydrates using its optimised proteins. in 60 countries all over the world. production of laboratory diagnostics( proprietary GlycoActives® high- from screening to monitoring). IDK productivity platform. The company holds a strong portfolio in markers of develops partnerships with global cardio-reno-vascular system, skeletal industry segment leaders to develop system, oxidative stress/anti-aging, and commercialize new specialty gastroenterology and nutrition. The carbohydrate ingredients. company owns more than 35 patents More information can be found at worldwide. www.inbiose.com. Industry & 190 ESPGHAN 52nd Annual Meeting www.espghancongress.org 191 General Information Exhibitor Directory Listing Exhibitor Directory Listing

Booth No. Booth No. Booth No. Booth No. 1 33 22 24

Biotechnologie GmbH

Country Country Country Country Germany Switzerland United Kingdom France

More information More information More information More information www.jennewein-biotech.de www.karger.com www.KendalNutricare.com www.ctrs.fr/?lang=en

Jennewein Biotechnologie GmbH Karger Publishers – Connecting the “Kendal Nutricare Ltd specialises in the Laboratoires CTRS was founded is a leading company specializing in World of Biomedical Science production of formulated full-cream in 2002 to develop, register and the production of rare functional infant formulas and infant cereals market innovative therapies targeted Karger Publishers is a globally active monosaccharides.and oligosaccharides marketed under the brand “Kendamil”, at orphan diseases. The company medical and scientific publishing for nutritional, pharmaceutical, and adult nutrition products marketed commercialises a therapy for two ultra- company. Independent, Swiss- cosmetic and medical applications. under the brand “Kendalife”. rare bile acid synthesis defects and a based and family-run in the fourth The company produces rare product for the treatment of multiple generation, the company is dedicated We are the only British manufacturer monosaccharides such as L-Fucose myeloma. CTRS is fully committed to serving the information needs of infant formulas in the UK and use and Sialic Acid. It also manufactures to bring new treatments and satisfy of the scientific community with British whole milk, sourced from the an extensive portfolio of HMO’s such unmet medical needs for extremely publications of high-quality content, Lake District UNESCO World Heritage as 2‘-Fucosyllactose, 3‘-Fucosyllactose, small patient population with a special covering all fields of medical science. Site. Lacto-N-tetraose, Lacto-N-neotetraose focus on liver disorders. It partners and acidic HMO’s like 3‘-Sialyllactose The Karger publishing program Since 1962 we have been with the healthcare community to and 6‘-Sialyllactose. Jennewein’s comprises some 50 new book releases manufacturing in Kendal, in a BRC provide services aimed at improving human milk oligosaccharides every year as well as 105 peer- grade AA certified factory where patients’ standard of care. CTRS has are produced using the latest reviewed journals. In line with the we employ 135 experienced staff been awarded the prestigious 2014 fermentation technology. This process company‘s commitment to the global including engineers, operative Prix Galien France and 2016 Prix is based on research and ensures a transfer of knowledge, Karger content technicians, laboratory microbiologists Galien International for its product high quality and safety of the product. is published predominantly in English, and research scientists. Orphacol® (cholic acid). with a strong focus on basic and These HMO’s are approved for kosher Kendal Nutricare have recently won clinical research. and halal.2‘-Fucosyllactose is also the ‘Federation of Small Businesses, approved fort he US and EU market. International Business of the Year Award 2019’ and the ‘Northern Powerhouse, High Growth Markets Exporter of the Year Award 2019’. Industry & 192 ESPGHAN 52nd Annual Meeting www.espghancongress.org 193 General Information This material is for healthcare professionals only. Exhibitor Directory Listing Exhibitor Directory Listing DO MORE THAN JUST MANAGE COW’S MILK Booth No. Booth No. ALLERGY: HELP GIVE HER 45 11 THE ABILITY TO PROTECT HERSELF FROM FUTURE ALLERGIC 1† MANIFESTATIONS Country Country Switzerland USA

ONLY NUTRAMIGEN More information More information WITH LGG ® CAN www.mdpi.com www.meadjohnson.com

A pioneer in scholarly open access For over 110 years, Mead Johnson publishing, MDPI has supported has been a global leader in pediatric academic communities since 1996. nutrition. We develop, manufacture, Based in Basel, Switzerland, MDPI has market and distribute more than the mission to foster open scientific 70 products in over 50 countries. exchange in all forms, across all Our mission is to nourish the world’s disciplines. Our 202 diverse, peer- children for the best start in life. The reviewed, open access journals are Mead Johnson Pediatric Nutrition supported by over 35,500 academic Institute (MJPNI) pioneers new editors. We serve scholars from around discoveries that improve the health the world to ensure the latest research and well-being of children. is freely available and all content is distributed under a Creative Commons Our team of experts focus on Attribution License (CC BY). advancing scientific understanding, engaging with global experts and enabling innovation to inform the TRANSFORMING THE LIVES OF BABIES development of nutrition solutions. Since June of 2017, MJN has been WITH COW’S MILK ALLERGY part of RB (Reckitt Benckiser), a global health and hygiene company Visit us at booth 11 seeking to become the global leader in consumer healthcare. Mead Johnson’s

†Versus Nutramigen without LGG®. science, innovation, product portfolio Reference: 1. Canani RB et al. J Allergy Clin Immunol 2017;139:1906–1913. and mission are vital, foundational Nutramigen without LGG® is a food for special medical purposes for the dietary management of cow’s milk allergy and must be used under medical supervision. Nutramigen with LGG® is not recommended for premature and immunocompromised infants unless directed and supervised by a healthcare professional. elements of the new company’s largest IMPORTANT NOTICE: Breastfeeding is best for babies. The decision to discontinue breastfeeding may be diffi cult to reverse and the introduction of partial bottle-feeding global business unit – RB Health. may reduce breast milk supply. The fi nancial benefi ts of breastfeeding should be considered before bottle-feeding is initiated. Failure to follow preparation instructions carefully may be harmful to your baby’s health. Parents should always be advised by an independent healthcare professional regarding infant feeding. Products of Mead Johnson must be used under medical supervision. *Trademark of Mead Johnson & Company, LLC. © 2018 Mead Johnson & Company, LLC. All rights reserved. LGG® is a registered trademark of Chr. Hansen A/S. Industry & 194 ESPGHAN 52nd Annual Meeting www.espghancongress.org 195 General Information Exhibitor Directory Listing Presenting ModuLife, a complete dietaryExhibitor management Directory Listing solution based on the proven novel dietary therapy, The Crohn’s Disease Exclusion Diet (CDED). Booth No. Booth No. 23 13

Country Country Sweden Switzerland

More information More information www.mirissolutions.com www.nestle.com

Miris AB is the manufacturer of the Nestlé helps the next generation Miris Human Milk Analyzer. Miris of children to develop their full Human Milk Analyzer provides a potential and live healthier lives by fast and simple way to measure the providing high quality, innovative, macronutrients in human milk enabling science-proven nutrition solutions and targeted fortification in your NICU. education for mothers and infants in Miris has over 12 years of experience the crucial first 1000 Days’ of life. in human milk analysis in clinical care Nestlé Health Science is a science- and the Miris Human Milk Analyzer driven nutritional health business is approved as a medical device in focusing on medical nutrition and Europe and FDA approved for clinical consumer health products to change use in US. the course of health for consumers, patients and its partners in healthcare. CDED combines a whole food diet with ModuLife offers medical education The Nestlé Nutrition Institute (NNI), partial enteral nutrition (Modulen® IBD). as well as a virtual patient support as a non for profit association in platform designed to support healthcare It is designed to reduce the exposure to dietary Switzerland, shares leading science components hypothesized to negatively affect professionals and patients throughout based information and education the microbiome, intestinal barrier and innate the dietary therapy journey. immunity without sacrificing the possibility of Healthcare professionals can learn more about with practicing health professionals enjoying whole foods, which makes it highly the CDED therapy and become ModuLife worldwide. NNI is committed to acceptable for patients. Recent data from a experts thanks to dedicated e-learning randomised controlled trial demonstrate the foster the highest levels of discussion modules. Patients can locate ModuLife experts benefits of the CDED therapy on remission rates, in their area, access a large selection of CDED- within scientific community and build gut microbiota and tolerance, paralleled to the friendly recipes & meal plans, track their food exclusive enteral nutrition (EEN), a proven dietary nutrition knowledge globally. All NNI intake, diet adherence and well-being. intervention and standard treatment for CD*,1-4 exclusive resources are available at www.nestlenutrition-institute.org

THERE’S NO OTHER CD TREATMENT LIKE IT *Crohn’s Disease 1. Van Limbergen J et al. OP05, presented at the 14th Congress of ECCO; March 6-9, 2019, Visit www.mymodulife.com Copenhagen/Denmark. 2. Sigall Boneh R et al. DOP42, presented at the 14th Congress to get more information of ECCO; March 6-9, 2019, Copenhagen/Denmark. 3. Dunn KA et al. P832, presented at

the 14th Congress of ECCO; March 6-9, 2019, Copenhagen/Denmark. 4. Wine E et al. and register for our freeIndustry & nd P346, presented at the 14th Congress of ECCO; March 6-9, 2019, Copenhagen/Denmark. online medical training. 196 ESPGHAN 52 Annual Meeting www.espghancongress.org 197 General Information Exhibitor Directory Listing

Booth No. Booth No. 2 25

Country Country France Spain

More information More information www.novalac.com www.noventure.com

The majority of infants experience at Noventure is an innovation-based least one dietary problem in the first enterprise, headquartered in months of life.1 Pioneer in pediatric Barcelona, specialized in licensing gastro-enterology and allergology, medical devices to partner companies. Novalac developed a comprehensive Noventure’s products are natural range of adapted infant formulas. polymers based on a proprietary Each specialty formula, whether it barrier technology that reinforces manages GI troubles, allergies, or the epithelia, thereby restoring its other problems, is backed by at least functionality. In Gastroenterology, one clinical trial, coordinated by our newest product is Gelsectan®, a internationally renowned experts. medical device intended to restore the Present in more than 60 countries intestinal function in those patients worldwide, Novalac (or Novamil) is suffering from alterations due to almost exclusively distributed through Irritable Bowel Syndrome (IBS), and pharmacies. to relief and prevent symptoms such as chronic or relapsing diarrhoea, 1 Prevalence and dietetic management of mild abdominal tension, pain, bloating and gastrointestinal disorders in milk-fed infants. Infante Pina D., World J Gastroenterol 2008 14(2): 248-254 flatulence.

MEET THE SEE OUR TALK TO PIONEERS GLOBAL BRANDS OUR TEAM

in Goat Milk that feed and nurture about the latest clinical paediatric nutrition families in over research in Goat Milk 30 countries paediatric nutrition

VISIT US AT BOOTH #8 Industry & 198 ESPGHAN 52nd Annual Meeting www.espghancongress.org 199 General Information Exhibitor Directory Listing Exhibitor Directory Listing

COMING Booth No. Booth No. SOON* 3 36 Our most advanced HMOs combination and more than 100 oligosaccharide structures, bringing us even closer to breast milk Country Country The Netherlands Japan

More information More information www.nutricia.com www.takeda.com

Nutricia pioneers nutritional solutions Takeda Pharmaceutical Company that help people live longer, more Limited (TSE:4502/NYSE:TAK) is a joyful and healthier lives. Building on global, values-based, R&D-driven bio­ more than a century of nutritional pharmaceutical leader head­quartered research and innovation, Nutricia in Japan, committed to bringing Better continues to transform lives through Health and a Brighter Future to patients the power of nutrition. by translating science into highly- innovative medicines. Takeda focuses Nutricia’s science-based products and its R&D efforts on four therapeutic services support healthy growth and areas: Oncology, Gastroenterology (GI), development during the first 1000 Neuroscience and Rare Diseases. We days. Nutricia also helps to address also make targeted R&D investments in some of the world’s biggest health Plasma-Derived Therapies and Vaccines. challenges including conditions in We are focusing on developing highly early life such as pre-term birth, innovative medicines that contribute faltering growth, food allergy and rare to making a difference in people‘s metabolic diseases, as well as age- lives by advancing the frontier of new related conditions and chronic disease, treatment options and leveraging our Visit the Nutricia booth such as frailty, cancer, stroke and early enhanced collaborative R&D engine and and get a chance to Alzheimer’s disease. win a special prize capabilities to create a robust, modality- As part of Danone, Nutricia fully diverse pipeline. Our employees are embraces the company’s “One Planet. committed to improving quality of life * Product availability and/or design varies by country. To find out more, One Health” vision reflecting that for patients and to working with our speak to one of our Nutricia representatives at booth no. 3 the health of people and the health partners in health care in approximately of the planet are interconnected and 80 countries and regions. therefore seeks to protect and nourish For more information, visit both. https://www.takeda.com

IMPORTANT INFORMATION: Breastfeeding is best for babies. Infant formula is suitable from birth when babies are not breastfed. It is recommended that all formula milks be used on the advice of a doctor, midwife, health visitor, public health nurse, dietitian, pharmacist, or other professional responsible for maternal and child care. For Healthcare Professionals use only – not for distribution to the general public. Industry & 200 ESPGHAN 52nd Annual Meeting www.espghancongress.org 201 General Information Exhibitor Directory Listing Exhibitor Directory Listing

Booth No. Booth No. 47 42 Please come and visit the Takeda Revestive® team Developed and funded by at stand 36 Takeda Pharmaceuticals

REVESTIVE®▼ (teduglutide) 1.25mg and 5mg powder and solvent in clinical trials. In case of a significant deterioration, the need for continued for solution for injection PRESCRIBING INFORMATION (Please refer treatment with Revestive should be reassessed. Management of fluids during treatment with Revestive: Parenteral support should be reduced to full Summary of Product Characteristics (SmPC) before prescribing) Country Country Presentation: 1.25mg strength: One vial of powder contains 1.25mg carefully and not be discontinued abruptly. The subject’s fluid status should of teduglutide (a glucagon-like peptide-2 (GLP-2) analogue). After be evaluated and adjusted as needed. Concomitant medication: Close The Netherlands United Kingdom reconstitution, each vial contains 1.25mg teduglutide in 0.5ml of solution, monitoring required in patients receiving oral medicines requiring titration corresponding to a concentration of 2.5mg/ml. 5mg strength: One vial of or with a narrow therapeutic index due to potential increased absorption. More information More information powder contains 5mg teduglutide. After reconstitution, each vial contains Special clinical conditions: Caution in patients with severe, clinically www.vaneeghen.com www.wisepress.com 5mg teduglutide in 0.5ml of solution, corresponding to a concentration of unstable concomitant diseases, or in patients with malignancies within the 10mg/ml. Indication: Revestive is indicated for the treatment of patients last five years. Discontinuation of treatment: Due to the risk of dehydration, aged 1 year and above with Short Bowel Syndrome (SBS). Patients should discontinuation of treatment with Revestive should be managed carefully. be stable following a period of intestinal adaptation after surgery. Dosage Excipients: Revestive contains less than 1mmol sodium (23mg) per and Administration: Adults and Paediatric Population (≥1 year): 0.05mg/ dose and is essentially ‘sodium-free’. Caution is needed in persons with vaneeghen is a family-owned Wisepress.com, Europe’s leading kg body weight once daily, by subcutaneous injection into the abdomen or a known hypersensitivity to tetracycline. Paediatric population: See also company with more than 350 years conference bookseller, has a complete thigh (in case of pain, scarring or tissue hardening). Treatment should be general precautions for adults. Colo-rectal polyps/Neoplasia: Faecal initiated under the supervision of a medical professional with experience in occult blood testing should be done for all children and adolescents at of experience in the production and range of books and journals relevant the treatment of SBS or paediatric SBS. A treatment period of 6 months is initiation and annually. Colonoscopy/sigmoidoscopy is required if there is distribution of food-related items. to the themes of the meeting. Books recommended after which treatment effect should be evaluated. In children evidence of unexplained blood in the stool. Colonoscopy/sigmoidoscopy below the the age of 2 years, treatment should be evaluated after 12 weeks. is recommended for all children and adolescents after one year of Over the years, we have evolved into can be purchased at the stand or, Some adult patients may take longer to respond to treatment (i.e., those treatment and every 5 years thereafter, and if they have new or unexplained a leading international distributor of if you would rather not carry them, who still have presence of colon-in-continuity or distal/terminal ileum); if no gastrointestinal bleeding Interactions: No clinical drug-drug interaction overall improvement is achieved after 12 months, the need for continued studies have been performed. There is a potential for increased absorption innovative products, vitamins, plant posted to you – Wisepress will deliver treatment should be reconsidered. If a dose is missed, that dose should of concomitant medicinal products. Pregnancy and Lactation: Avoid. extracts, minerals and other nutrients. worldwide. In addition to attending be taken as soon as possible on that day. Special Populations: Paediatric Effects on ability to drive and use machines: Only a minor influence 200 conferences per year, Wisepress population: For paediatric patients <20kg, use Revestive 1.25mg strength, on the ability to drive, although caution as syncope has been reported. Having been in business for centuries, otherwise use 5mg strength. There are no data available on treatment of Adverse Effects: Very common (≥ 1/10): Respiratory tract infection has a comprehensive medical and you can rely on our experience and paediatric patients for periods over 6 months. The safety and efficacy in (serious), headache, abdominal pain and distension, vomiting, nausea, scientific bookshop online with great children <1 year old has not been established. Elderly: No dose adjustment gastrointestinal stoma complication, injection site reaction. Common specific knowledge. Still as curious in patients > 65 years. Renal impairment: No dose adjustment in mild renal (≥1/100 to <1/10): Influenza- like illness, decreased appetite, fluid overload, offers. impairment. Reduce the daily dose by 50% in moderate and severe renal anxiety, insomnia, congestive heart failure, cough, dyspnoea, colorectal as if on day one. We’re adaptable to impairment (creatinine clearance < 50 ml/min) and end-stage renal disease. polyp, colonic stenosis, flatulence, intestinal obstruction (serious), change with a willingness to constantly Hepatic impairment: No dose adjustment in mild and moderate hepatic pancreatic duct stenosis (serious), pancreatitis (serious), small intestinal impairment. Revestive has not been studied in patients with severe hepatic stenosis (serious), cholecystitis (serious), cholecystitis acute (serious) and re-invent ourselves. impairment. Contraindications: Hypersensitivity to the active substance, oedema peripheral. Paediatric population: The type and frequency of any of the excipients or trace residues of tetracycline. Active or suspected adverse reactions in children and adolescents was similar to that in adults. Exactly what today’s world requires. malignancy or a history of malignancies in the gastrointestinal tract and Prescribers should consult the SmPC in relation to other adverse reactions. Big and experienced enough for your pancreas including the hepatobiliary system within the last five years. Package quantity and price for UK: Packs of 28 vials of powder, 28 Warnings and Precautions: It is strongly recommended that every time 0.5ml solvent in pre-filled syringes and 6 plungers, available as 1.25mg ambitions. Small and lean enough Revestive is administered to a patient, the name and lot number of the strength - £7,307.70 or 5mg strength- £14,615.39. Legal Category: for your resourceful and tailored product are recorded in order to maintain a link between the patient and POM. Date of Revision: February 2019. Marketing authorisation nutritious solution. vaneeghen. the lot of the product. Colo-rectal polyps: A colonoscopy with removal of number and holder: EU/1/12/787/001-003. Shire Pharmaceuticals polyps should be performed at the start of treatment, with yearly follow-up Ireland Limited, Block 2 & 3 Miesian Plaza, 50-58 Baggot Street Lower, Nutritious solutions. colonoscopies (or alternative imaging) during the first 2 years of treatment, Dublin 2, Ireland. Email: [email protected] Further information is then at a minimum of 5 year interval. Gastrointestinal neoplasia including available on request. Revestive is a registered trade name. hepatobiliary tract: If detected, should be removed. In case of malignancy, treatment should be discontinued. Gallbladder and bile ducts: In gallbladder This medicinal product is subject to additional monitoring. This will allow or bile duct-related symptoms, reassess the need for continued treatment. quick identification of new safety information. Adverse events should be Pancreatic diseases: Reassess the need for continued treatment in case reported. Reporting forms and information can be found at: of pancreatic adverse events. Monitoring of small bowel, gallbladder and UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in bile ducts, and pancreas: SBS patients should be closely monitored in the Google Play or Apple App Store Ireland: Adverse events should relation to short bowel function, gallbladder, bile ducts, and pancreas signs be reported to the Pharmacovigilance Unit at the Health Products and symptoms, and, if indicated, additional laboratory investigations and Regulatory Authority (HPRA) at: http://hpra.ie UK and Ireland: appropriate imaging techniques. Intestinal obstruction: Assess the need Adverse events should also be reported to Shire Pharmaceuticals Ltd. for continued treatment in case of recurrent intestinal obstructions. Fluid at: [email protected] Overload: Fluid overload has been observed in clinical trials and occurred most frequently during the first 4 weeks of therapy and decreased over Copyright © 2019 Takeda Pharmaceutical Company Limited. All rights reserved. time. Patients with cardiovascular disease should be monitored with All trademarks are the property of their respective owners. Shire Pharmaceuticals Ireland Limited now part regard to fluid overload, especially during initiation of therapy. In general, ® fluid overload can be prevented by appropriate and timely assessment of of Takeda, remains the MA holder for Revestive . parenteral nutrition needs; assessments conducted more frequently within Date of preparation: April 2019 Industry & the first months202 of treatment. ESPGHAN Congestive 52nd Annualheart failure Meeting has been observed C-APROM/UK//2918 www.espghancongress.org 203 General Information Exhibitor Directory Listing Exhibitor Directory Listing

Booth No. Booth No. 21 – For 100 years, Wyeth Nutrition has pioneered nutrition science with premium-quality products that meet the needs of infants, young children, and adults,

Country Country including mothers to be and lactating mothers. Switzerland China

More information More information www.wyethnutrition.com www.ymini.yili.com Parents and doctors can be confident that we use and will continue to use extensive clinical rigor, For the past 100 years, Wyeth Yili Maternal and Infant Nutrition Nutrition has pioneered innovative Institute (YMINI) is established to scientific research, world-class manufacturing, nutrition science with premium-quality conduct researches in advanced products that meet the needs of scientific areas, facilitate and product safety standards to provide optimal infants, young children and adults. communications among health care Through clinical rigor, scientific professionals, and promote scientific nutritional support for healthy outcomes. research, world-class manufacturing education. Aiming to improve and product safety standards, we women and children‘s nutrition and deliver scientifically sound solutions health status, YMINI is a non-profit This relentless commitment to excellence will that offer parents confidence to help organization based on Yili Group’s nourish children and support healthy years of maternal and infant nutrition drive us to create the most advanced nutrition futures, when breastfeeding is not an research. YMINI strives to discover the option. By partnering with mothers, best for the well-being of women and that will help ensure a bright and healthy future. doctors and scientists, we continue children through global scientific and to discover and learn what is needed technological collaborations. to ensure the best advancement for the health and well-being of future generations. In 2012 Wyeth Nutrition was acquired by Nestlé SA and operates as part of Nestlé Nutrition.

Come and visit Wyeth Nutrition at Booth #21

WYETH is a registered trademark of Wyeth LLC. Used under license. Industry & 204 ESPGHAN 52nd Annual Meeting www.espghancongress.org 205 General Information

13201 Wyeth Ad r4v1 FIN4.indd 1 4/23/19 10:41 AM Disclosure of Sponsorships Please find below the contribution from members of the Pharmaceutical Codes of Practice in accordance with the respective rules and transparency regulations. General N/N COMPANY Information 1 Avanos AMOUNT 13.840 € ITEM Sponsorship Package Bronze

2 DICOFARM AMOUNT 7.560 € ITEM Sponsorship Package Chrome

3 Noventure AMOUNT 9.450 € ITEM Sponsorship Package Chrome Industry & 206 ESPGHAN 52nd Annual Meeting www.espghancongress.org 207 General Information General Information General Information

Congress Venue Industry Exhibition Cloakroom Name Badge Wednesday, 05 June 2019 18:30 – 20:30 Scottish Event Campus (SEC) A cloakroom is provided for all delegates Upon registration onsite, all participants Glasgow, G3 8YW Thursday, 06 June 2019 08:00 – 18:00 during the official opening hours. The cloak­ will receive a name badge, which must Scotland – United Kingdom Friday, 07 June 2019 08:00 – 18:00 room will close 30 minutes after the end be worn visibly for the entire duration of the last session and is located in Hall 5. of the congress. The name badge acts Saturday, 08 June 2019 08:00 – 14:15 There you can also drop off your luggage. as entrance ticket for the congress. Congress Language Name badges will not be reprinted. For Abstracts Any items left here are the responsibility The complete scientific programme of the individual and ESPGHAN cannot be lost badges, a fee of 25% of the original including all courses will be held in English. All abstracts accepted for presentation held accountable for any loss of personal registration fee applies. A simultaneous translation will not be (oral or poster) will be published in the items. available. Journal of Paediatric Gastroenterology Nursing Room and Nutrition (JPGN). The abstracts will also be published in digital format in CME-CPD Credits (EACCME) A nursing room is accessible during the Congress Office the Congress App as well as on Congress For CME-CPD credits please see page 213. congress hours and is located at room The congress office and registration desk Talks & Speakers. Fyne on the ground level. Please follow the signs onsite. are located in Hall 5 of SEC. Coffee & Lunch Breaks Phone: +44 (0)141 576 34 56 ESPGHAN Abstracts on USB Key Snacks and refreshments during the Kindly sponsored by Nestlé Press official break times are included in the Congress Opening Hours Abstracts presented at the ESPGHAN 52nd registration fee. The catering areas are Registered members of the press are Annual Meeting are also available on a invited to use the Press Centre in Hall 5. Wednesday, 05 June 2019 08:00 – 20:30 located in the Industry Exhibition (Hall 4). USB Key and are being distributed from Please follow the signs onsite. The Clydebuilt Bar & Kitchen on the Thursday, 06 June 2019 07:15 – 19:30 the Nestlé stand no. 13 during exhibit concourse level serves as a cash bar. Friday, 07 June 2019 07:15 – 19:45 opening hours. Kindly note that gluten- and lactose- Public Transport & Saturday, 08 June 2019 08:30 – 14:15 Please visit the booth to meet with a free coffee and lunch breaks will also be Bike Rental Nestlé representative and present the served at the catering area in the Industry voucher found in your congress bag in All delegates receive a ScotRail Exhibition (Hall 4). Registration Desk exchange for your USB Key. Conference Rover ticket onsite. The ticket is valid from 05 – 08 June 2019. Wednesday, 05 June 2019 07:00 – 20:30 Thursday, 06 June 2019 06:30 – 19:30 Certificate of Attendance ESPGHAN AGM You can also use the free bike service ‘Nextbike’ to discover the city. Free Friday, 07 June 2019 06:45 – 19:45 Annual General Meeting Delegates are able to print their unlimited rentals for all delegates! Saturday, 08 June 2019 07:30 – 14:30 Certificate of Attendance (not the CME- Assembly of ESPGHAN members on Register on www.nextbike.co.uk, enter CPD Certificate) at the Self-Print-Counters Friday, 07 June 2019 from 17:30 – 19:45 your personal details and enter the code located in Hall 5 of the SEC by scanning the (Lomond Hall). 569856 under my account/vouchers. Speakers Ready Room barcode printed on their name badge. The information counter at the SEC is happy Wednesday, 05 June 2019 07:00 – 18:00 Internet Corner to assist you with your Nextbike rental. Thursday, 06 June 2019 06:30 – 18:30 The Certificate of Attendance will also The Internet Corner is located in the The bike docking station is located in front Friday, 07 June 2019 06:30 – 18:00 be available on the congress website after the congress. The delegates can Industry Exhibition (Hall 4). Printing of the SEC – enjoy the ride! Saturday, 08 June 2019 07:30 – 12:00 create their certificates and send it to facilities are available. their own email address by typing in their Silence Room Poster Exhibition registration number. Mobile Phones A place of tranquillity in the midst of a Wednesday, 05 June 2019 18:30 – 20:30 Charging Stations Delegates are kindly requested to keep lively conference area. The silence room Thursday, 06 June 2019 08:00 – 18:00 their mobile phones on silent mode in all is available to members of all religions Friday, 07 June 2019 08:00 – 18:00 Charging stations are available in the rooms where scientific and educational and all world views. It is accessible during exhibition hall and the registration area Saturday, 08 June 2019 08:00 – 14:15 sessions are being held, as well as in and the congress hours and is located at room during the official congress hours. around the poster and exhibition area. Etive on the ground level. Please follow Please feel free to recharge your mobile the signs onsite. device in a secure code locker. Industry & 208 ESPGHAN 52nd Annual Meeting www.espghancongress.org 209 General Information General Information General Information

For the most valuable in life. Sustainability ESPGHAN Office The following measures have been taken to European Society for Paediatric Gastro­ make the Annual Meeting more sustainable: enterology, Hepatology and Nutrition · Name badges made of FSC paper Rue De-Candolle 16 (‚FSC‘ stands for Forest Stewardship 1205 Genève, Switzerland Council, an organization that works to [email protected] promote the practice of sustainable www.espghan.org forestry worldwide) HiPP ORGANIC · Conference pencils made of Congress & Industry biodegradable plastic Organisation COMBIOTIC® · Notebooks made of recycled paper · Conference bags made from high quality, Important building blocks environmentally-friendly cotton in the fair trade program “Made in Africa” provide for a good start supporting women empowerment in EUROKONGRESS GmbH communities in Ethiopia Schleissheimer Str. 2 · Refillable water bottles made of glass 80333 Munich, Germany for every delegate Phone +49 89 210 98 60 · Usage of local products for catering to Fax +49 89 210 98 698 the most possible extent [email protected] · Free public transportation tickets for all www.eurokongress.de delegates during the conference dates within the ‘Conference Zone’ Programme Changes The new generation of milk formula low protein content Welcome Reception Should last minute changes due to Breast milk is the best nutrition for a baby, as it supplies functional, private or organisational needs The Welcome Reception will take place be necessary, they will be announced – important building blocks for baby’s healthy development. at the SEC in the Industry Exhibition when possible – on the congress website If breastfeeding is not possible, the baby should be given prebiotics (Hall 4) on Wednesday, 05 June 2019 (GOS from lactose) and the Congress App. The event organiser a milk formula, which is based on the natural model and starting 18:30 (free of charge for congress accepts no liability for any additional costs whose composition is based on current scientific findings. participants). Please note that your badge caused by a change of programme. serves as your entrance ticket. probiotics (L.. fermenttum)) Wi-Fi Disclaimer HiPP 1 ORGANIC COMBIOTIC® fulfils these criteria, is well tolerated and contains functional building blocks with Delegates may connect to the free Neither ESPGHAN nor EUROKONGRESS Wi-Fi network “SEC Wi-Fi”. You will be GmbH shall be liable for accidents, bodily proven benefits: omega 3 & 6 forwarded to the SEC splash page. Please injury, and theft as well as for additional • Low protein content: LCP click “Connect” to finalize the access. costs due to the change of event date, for healthy weight gain1 location, and programme or similar. • Prebiotics and probiotics: Liability for additional costs due to delays, nutrients The conference is kindly significant reduction in gastrointestinal infections2,3 supported by changes or cancellations of flights, trains according or other means of transport as well as • LCP (DHA/ARA): due to strike action, illness, weather or promote cognitive development4 environmental disasters is also excluded. It is the responsibility of each participant In addition, in reliable HiPP organic quality, to arrange appropriate theft-, accident-, controlled according to the highest standards. health- as well as travel-cancellation Important note: Breast milk is the best nutrition for an infant. Infant formula should only be used insurance. Participants take part at their following advice from a paediatrician, midwife or other independent experts.

own responsibility and risk. 1 Fleddermann M et al. Clin Nutr 2014; 33:588-595 2 Gil-Campos M et al. Pharm Res 2012; 65:231-238 3 Maldonado J et al. JPGN 2012; 54:55-61 4 Koletzko B et al. J Perinat Med 2008; 36:5-14 hipp.com/hcp Industry & 210 ESPGHAN 52nd Annual Meeting www.espghancongress.org 211 General Information General Information General Information

Registration Fees The congress registration fees include: • a name badge Annual Meeting, 06 – 08 June 2019 Congress Ticket Day Ticket • access to all sessions ESPGHAN Member 1 550 € 300 € • access to the poster and exhibition area ESPGHAN Non-Member 865 € 365 € • all personal congress documents Emeritus Member 1 200 € N/A • the coffee breaks and lunches Allied Health Professionals – ESPGHAN Member 1,2 355 € 180 € • a ScotRail Conference Rover ticket • invitation to the Welcome Reception (subject of availability) Allied Health Professionals – Non Member 2 450 € 200 € NASPGHAN Member 3 752 € N/A Congress Cancellation Policy Trainee ESPGHAN Member 355 € 180 € Cancellations had to be submitted in writing. Young Investigator 4 450 € 200 € Cancellations received up until Sunday, 31 March 2019 incurred a cancellation 5 Student 355 € 200 € fee of 50 € for the Annual Meeting and of 25 € for the courses. From this date onwards or in case of a no-show, registration fee reimbursements Postgraduate Courses, 05 June 2019 Additional Course were no longer possible unless the organisers were provided with a named Clinical Course in PGHaN 205 € replacement who took on the registration. AHP Course 180 € The Members Evening registration fee is non-refundable. IBD Course 205 €

Endoscopy Learning Zone, 07 – 08 June 2019 CME-CPD Credits (EACCME) Endoscopy Learning Zone (per session) 50 € The congress has been approved for CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME). The number Social Programme of CME credits granted, and how to claim them, are available on the congress website and in the congress app. Welcome Reception, 05 June 2019 Free of charge

6 ESPGHAN Members Evening , 07 June 2019 50 € In accordance with EACCME rules & regulations, CME-CPD Credits may only be All scientific registration fees are exempt from VAT. granted once attendance onsite has been confirmed and the online evaluation form completed after the conference has ended. Hostesses will be available by each session hall entrance to scan attendance. It is the responsibility of 1 Please note that in order to qualify for the member 4 A Young Investigator is defined as someone working in rate all members need an active membership status. Paediatric Gastroenterology, Hepatology or Nutrition participants to ensure their attendance is scanned on all conference days to The organisers reserve the right to change the for less than 10 years. They should ensure that they registration status if membership fees are not paid. have a confirming letter from a sponsoring member accrue the maximum possible credits. Only participants who have had their 2 Allied Health Professionals include Nurses and of ESPGHAN to be presented at the registration desk attendance scanned will be emailed the evaluation form. Dieticians and must provide proof of their AHP onsite. certification at the registration desk onsite in order 5 The student discount is limited to students until the age to qualify at the stated rate. of 35 and a valid student ID must be presented onsite. 3 Only applicable for NASPGHAN members 6 Encashment in the name and for the account of EUROKONGRESS GmbH Industry & 212 ESPGHAN 52nd Annual Meeting www.espghancongress.org 213 General Information Hillhead

Kelvinbridge Station

Glasgow Map SPT Subway St Georges Cross Kelvinhall Public Transport (on own expense only) Suburban Rail (incl. Scot Rail Conference Rover ticket) Cowcaddens Kelvingrove Art Gallery and Museum

Charing Cross Partick

Buchanan Street Glasgow Queen Street Exhibition Centre Scottish Event Campus (SEC)

Argyle Street High Street Anderston Arches

Central Station St Enoch Argyle Street

Cessnock Bridge Street

Kinning Park

Shields Road Industry & 214 West Street 215 General Information www.fispghan.org www.espghancongress.org sharing the future of digestive health

Barcelona, Spain October 19–23, 2019 Venue: Fira Gran Via

We bring together the best in gastroenterology. Join us!

Find out more, visit www.ueg.eu/week

218 ESPGHAN 52nd Annual Meeting www.espghancongress.org 219

19_04_Inserat_UEGWeek2019_A5_RZ.indd 1 15.04.19 14:07 DISCOVER THE BEST FROM NATURE AND SCIENCE!

Nils den Besten Dr. Corina Ponne 3rd generation farmer Lead Dairy Scientist

Check out the latest insights on the benefi ts of Friso’s LockNutri technology at FrieslandCampina booth nr. 10.

220 ESPGHAN 52nd Annual Meeting

5147_FCE-ESPGHAN19_ads.indd 2 28-03-19 10:34